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Preliminary Comments  IV 
Preliminary Comments 
 
I would like to use to opportunity to comment on a couple of formal aspects of this work.  
The first chapter contains an introduction to the theoretical background of the concept, 
epidemiological aspects, aetiology and treatment of social phobia. Because the emphasise of 
this work is placed on the evaluation of treatment for social phobia, the theoretical part also 
focuses largely on the description of aetiological models and the treatment concepts derived 
from them as well as on the current state of treatment research. 
The second chapter gives a short introduction to the intention, methods and results of the three 
conducted studies. The chapters 3, 4, and 5 are the original versions of the publication-based 
manuscripts. The second study „Effectiveness of an Empirically Supported Treatment for 
Social Phobia in the Field” is now in press in the Journal “Behaviour Research and Therapy”. 
In the appendix the interested reader will find a table of the studies analysed in STUDY I, a 
more detailed description of the complete patient sample underlying STUDY III, a detailed 
description of the therapeutic procedure as well as a copy of all assessment measures and 
formulas used.  
Because the publication based manuscripts were submitted in English language it seemed 
appropriate, for reasons of standardization, to write the complete doctoral dissertation in 
English. The sole exceptions to this are the German summary as well as the German original 
questionnaires and formulas depicted in the appendix.   
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1. Theoretical Background  1 
1. Theoretical Background  
1.1. Social Phobia: Concept and Classification 
Anxiety in social situations is neither uncommon nor particularly dysfunctional. About 80% 
of the general population report having suffered from shyness at some point in their life and 
about 40% even describe themselves as shy persons (Pilkonis & Zimbardo, 1979). Many 
well-known artists suffer from stage fright. Pop-idol Robbie Williams even admitted being so 
shy that he was on medication during the TV-show „Wetten Dass...“. Presumably all of us 
have experienced a certain degree of exam nerves or feeling nervous in expectation of an 
important date. However, while low levels of anxiety or nervousness can even boost 
performance, higher levels are extremely interfering.  
The term social phobia is used in the case of marked and persistent fear in one or more social 
or performance situations, in which the person is exposed to unfamiliar people or to possible 
scrutiny by others. Individuals with social phobia fear to act in a way that will be 
embarrassing or degrading and thus be subject to negative evaluation. In many cases an 
individual may fear that other people could notice physical symptoms of anxiety and be 
scornful or humiliating towards them (Criterion A, Diagnostic and Statistical Manual of 
Mental Disorders, DSM-IV, American Psychiatric Association, APA, 1994). Even the 
expectation of being confronted with the fear situation provokes anxiety, which may be 
accompanied by a series of somatic anxiety symptoms (Criterion B). Even though the fear is 
recognized as excessive (Criterion C) a socially phobic individual will try and avoid the 
feared situations whenever possible. When this is not possible he or she endures them with 
intense anxiety (Criterion D). The social fear causes marked distress and can interfere 
significantly with occupational functioning, social activities or relationships (Criterion E). In 
individuals younger than 18 years the symptoms must have persisted for at least six months 
(Criterion F). The fear and avoidance is not due to direct physiological effects of a substance 
or a general medical condition and is not better accounted for by another mental disorder 
(Criterion G). 
Social phobic fear is associated with performance situations, such as public speaking, and 
everyday social interactions, such as attending a party or speaking to an employer. The fear of 
public speaking has been found to be the most typical fear, followed by situations such as 
entering a room, which is already occupied by others, being addressed in front of others and 
meetings with strangers (Faravelli et al., 2000; Furmark, Tillfors, Stattin, Ekselius, & 
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Fredrikson, 2000; Stein, Torgrud, & Walker, 2000). Typical worries involve being 
embarrassed or judged anxious, weak, crazy, inadequate or stupid. People diagnosed with 
social phobia are also often hypersensitive to criticism and negative evaluation and find it 
difficult to be assertive. Additionally, many social phobics suffer from feelings of inferiority 
(Clark & Wells, 1995). The anxiety provoked in a social situation is often accompanied by a 
series of physical anxiety symptoms, which are likely to be visible, such as blushing, 
sweating, or trembling. In severe cases these symptoms may meet criteria for a panic attack 
(DSM-IV, 1994, fourth edition). 
The criteria for social phobia have evolved considerably over the years. The first definition of 
social phobia in DSM-III (American Psychiatric Association, 1980, third edition) classified it 
as a simple phobia limited to the experience in a situation in which the individual is exposed 
to possible scrutiny by others. In the accompanying text, it was suggested that “generally an 
individual has only one social phobia” (p. 227). Individuals who experience anxiety in a broad 
range of social situations were considered as suffering from avoidant personality disorder. In 
DSM-III-R (American Psychiatric Association, 1987, third edition revised) the definition of 
the concept of social phobia broadened and included individuals with fears in a range of social 
situations. Customary classification systems, the tenth edition of the ICD-10 Classification of 
Mental and Behavioural Disorders (World Health Organization, 1992) and DSM-IV (1994, 
fourth edition) have moved closer together in the course of their development and now use 
relatively similar criteria to describe the degree of distress experienced by people suffering 
from social phobia. DSM-IV describes more generally an immediate anxiety reaction 
(criterion B) whereas ICD-10 emphasizes specific physical reactions (blushing or trembling, 
nausea or urge to urinate). The DSM-III-R and DSM-V also offer the possibility of specifying 
a generalized subtype if the fear involves almost all social situations as opposed to a 
nongeneralized subtype, when the fear only involves one or a few social situations. 
Individuals with generalized social phobia and non-generalized social phobia have been 
significantly differentiated according to a number of demographic and clinical features. 
Individuals with generalized social phobia have been found to be younger, less educated and 
more likely to be unemployed (Heimberg, Hope, Dodge, & Becker, 1990). Also, generalized 
social phobics endorse higher levels of depression, social anxiety, avoidance and fear of 
negative evaluation on a row of self-report measures (Brown, Heimberg, & Juster, 1995; 
Turner, Beidel, & Townsley, 1992), are more often single, have an earlier age at onset and 
higher rates of alcoholism (Mannuzza et al., 1995). In spite of these differences the subtyping 
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scheme is a subject of controversial debate. The main controversy seems to focus on the 
question of whether the subtypes differ qualitatively or only quantitatively (Boone et al., 
1999; Chambless, Tran, & Glass, 1997; Holt, Heimberg, & Hope, 1992; Heimberg, Hope, et 
al., 1990; Stein, Torgrud, & Walker, 2000). It is also unclear how the criteria fear in “most 
situations” can be operationalized. In answer to the introduction of the subtyping scheme in 
DSM-III-R some researchers have suggested other subtyping schemes (Eng, Heimberg, 
Coles, Schneier, & Liebowitz, 2000; Heimberg, Holt, Schneier, Spitzer, & Liebowitz, 1993). 
However, the dichotomous subtyping system was retained in DSM-IV. The lack of an 
operational definition for the subtypes allows for a variety of interpretations, thereby 
hindering comparisons across studies (Hazen & Stein, 1995). As a consequence, STUDY II 
adopted an attempt used in a study by Gerlach, Wilhelm, Gruber, and Roth (2001) to 
categorize subtypes according to the number of feared situations listed in a reliable and valid 
structured clinical interview for DSM-III-R (Diagnostisches Interview bei Psychischen 
Störungen [Diagnostic Interview for Psychological Disorders], Margraf, Schneider, & Ehlers, 
1991). 
1.2. Differential Diagnosis 
The similarity of symptoms within the anxiety and mood disorders may provide a difficulty in 
arriving at a reliable diagnosis of social phobia. The anxiety disorders share some overlapping 
features (e.g. fear and avoidance), whereas social phobia and depression have the aspect of 
social withdrawal in common. These similarities make a thorough diagnostic assessment of 
social phobia in terms of a diagnostic interview (see STUDY II and STUDY III) absolutely 
necessary, if one is to arrive at a reliable diagnosis. 
1.2.1. Panic Disorder 
Even though individuals suffering from panic disorder with agoraphobia may avoid social and 
performance situations, they do so for fear of having a panic attack and being unable to obtain 
help in that situation, and not specifically for fear of negative evaluation, humiliation and 
embarrassment (Ball, Otto, Pollack, Uccello, & Rosenbaum, 1995; Mannuzza, Fyer, 
Liebowitz, & Klein, 1990). Hazen and Stein (1995) point out that although both groups may 
suffer from panic attacks, in social phobia these attacks are situation bound and occur when 
entering or anticipating a social situation. In contrast, for the diagnosis of panic disorder there 
must be a history of at least one unexpected attack and subsequent attacks which do not occur 
exclusively in social situations. Also, in social phobia the content of automatic thoughts 
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revolves around fear of embarrassment and negative evaluation, whereas in panic disorder, 
the thoughts revolve around catastrophic consequences, such as heart attack, death or loss of 
control. Both social phobics as well as individuals diagnosed with panic disorder suffer from 
somatic anxiety symptoms. However, and not surprisingly, it has been found that social 
phobics are more likely to endorse symptoms that can be observed by others, such as 
blushing, muscle twitching, dry mouth, trembling or sweating in comparison to individuals 
with panic disorder, who tend to experience dizziness, palpitations, chest pain, breathing 
problems, feeling faint and numbness (Amies, Gelder, & Shaw, 1983; Gorman & Gorman, 
1987; Reich, Noyes, & Yates, 1988; Hazen & Stein, 1995). 
1.2.2. Generalized Anxiety Disorder 
Generalized anxiety disorder and social phobia share some clinical features that complicate 
differential diagnosis. Mennin, Heimberg, and MacAndrew (2000) found 24% of their large 
sample of social phobic patients to receive an additional diagnosis of generalized anxiety 
disorder. Rapee, Sanderson, and Barlow (1988) discovered that although social anxiety is also 
common among people diagnosed with generalized anxiety disorder, the impairment 
associated with it is much higher for social phobia. The number of social situations that 
produce fear was considerably greater than the one reported by subjects with any other 
anxiety disorder and social phobics spend more time worrying about social situations. Turk, 
Fresco, and Heimberg (1999) point out that the uncontrollable worry that individuals with 
generalized anxiety disorder experience is not exclusive to social situations. They emphasize 
that a hallmark feature of generalized anxiety disorder is the heightened focus on possible 
catastrophic consequences across several domains of life. Also, like with panic disorder 
somatic symptoms tend to differ, with individuals with generalized anxiety disorder reporting 
more frequent occurrences of headaches and fear of dying (Reich et al., 1988; Cameron, 
Thyer, Feckner, Nesse, & Curtis, 1986). It may be questioned though, whether these 
distinctions are sufficient to reliably differentiate social phobia from generalized anxiety 
disorder in a clinical setting (Turk et al, 1999). 
1.2.3. Depression  
To differentiate social phobia from depression, a clinician must be able to determine whether 
social withdrawal occurs because of low energy or because of fear of negative evaluation 
(Turk et al., 1999). Another common feature is the hypersensitivity to rejection or criticism 
and a negative self-concept, which has lead Brunello et al. (2000) to speculate that social 
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phobia and depression may arise from a common vulnerability. They also see support for this 
idea in the fact that both disorders respond well to monoamine oxidase inhibitors. Clark and 
Wells (1995) argue that the negative self-schemata of depressed patients are relatively stable 
and persist throughout depressive episodes. In contrast, social phobics can have a positive 
view of themselves when they are alone or in situations they do not find threatening. 
1.2.4. Avoidant Personality Disorder 
The new criteria for the classification of a generalized subtype have brought about some 
confusion concerning the distinction to avoidant personality disorder. Apart from the fact that 
the criteria for avoidant personality disorder have become more similar to those of social 
phobia, the rules in DSM-III-R (1987, third edition revised) were changed so that both 
diagnoses can be given to the same person. Turk et al. (1999) raise the question of whether the 
two diagnostic entities represent distinct disorders or the same disorder differing only in 
degree. Most researchers have come to the conclusion that the distinction tends to be a 
quantitative one and that the co-occurrence of generalized social phobia and avoidant 
personality disorder describes individuals with the most severe social phobias and the poorest 
global and social functioning (Heimberg et al., 1993; Herbert, Hope, & Bellack, 1992; Holt, 
Heimberg, & Hope, 1992; Feske, Perry, Chambless, Renneberg, & Goldstein, 1996; Rettew, 
2000; Turner et al., 1992).  
1.3. Epidemiology 
1.3.1. Prevalence  
Estimates of prevalence of social phobia fluctuate considerably. One reason for this can be 
seen in different interpretations of the criterion of interference with a person’s life in DSM-IV 
(1994, fourth edition) and ICD-10 (World Health Organization, 1992). Stein, Walker, and 
Forde (1994) investigated the effects of different thresholds in the categorization and found 
fluctuations in rates of prevalence between 1.9% and 18.7%. Further reasons can be assumed 
in the differences in the classification criteria between DSM-III and DSM-III-R as well as in 
non-uniform interview systems. The establishment of DSM-III-R and DSM-IV criteria that do 
not differ much and the development of widespread interview systems based on these criteria 
has led to more uniform as well as higher rates of prevalence. In the National Comorbidity 
Survey (Magee, Eaton, Wittchen, McGonagle, & Kessler, 1996) in the USA a rate of 
prevalence of 13.3% was found. In Basel, Switzerland, this rate was 16.1% (Wacker, 
Müllejans, Klein, & Battegay, 1992), in Sweden 15.6% (Furmark et al., 1999), in France 
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7.3% (Pélissolo, André, Moutard-Martin, Wittchen, & Lépine, 2000), in Italy 6.6% (Faravelli 
et al., 2000) and in a German sample of men and women aged between 14-24 in Munich 4.9% 
and 9.5% respectively (Wittchen, Stein, & Kessler, 1999), indicating social phobia to be one 
of the most frequent chronic psychological disorders.  
1.3.2. Developmental Aspects 
Social phobia most often has its onset during adolescence, follows a chronic course and tends 
not to remit spontaneously (Burke, Burke, Regier, & Rae, 1990; Hazen & Stein, 1995; 
Schneier, Johnson, Hornig, Liebowitz, & Weissman, 1992; Wittchen, Stein, et al., 1999). 
Research of developmental aspects of social phobia is still in its early stage. Based on the 
research reviewed by Hudson and Rapee (2000) it seems that the ability to experience self-
consciousness or to anticipate negative evaluation is unlikely to occur below the age of eight 
years. The beginning of adolescence accompanies the onset of increased self-consciousness. 
Changes in the individual’s social situation in which an individual may have to regain his or 
her place in a social group open up the possibility of increased social concerns. It appears that 
the family may be involved in modelling the childs attitude. Child-rearing styles of 
overprotection or control, rejection and a lack of warmth as well as restricted exposure to 
social stimuli and parental modelling of socially related concerns might play an important 
role. Other environmental factors that could be involved are peer rejection, childhood illness, 
social isolation and birth order. However, most of the reviewed studies used retrospective data 
and many did not measure actual social phobia, but related constructs, such as shyness, self-
consciousness, social anxiety, and audience sensitivity.  Thus, further research is necessary to 
clarify the processes underlying the development of social phobia  
1.3.3. Risk Factors and Socio-demographic Correlates 
Epidemiological studies are concurrent in coming to the conclusion that women are affected 
by social phobia more frequently than men (Magee et al., 1996, Faravelli et al., 2000, 
Schneier et al., 1992; Wittchen, Stein, et al., 1999), nevertheless there are also contradicting 
findings (Bourdon et al., 1988). Younger persons as well as persons with a lower socio-
economic status and unmarried persons tend to be more often affected than older, married or 
better educated people (Magee et al., 1996; Schneier et al., 1992; Schneier et al., 1994), 
although these factors are likely to be significantly inter-correlated. Studies have found 
proportions of over 50% of individuals who fulfil the criteria for social phobia to be 
unmarried, or to be divorced or separated (Furmark et al., 1999, Schneier et al., 1992; see also 
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Appendix C). Social phobia also seems to be a risk factor for weak school performance, 
truancy, premature termination of school, weak work performance and alcohol misuse 
(Mullaney & Trippett, 1979; Liebowitz, Gorman, Fyer, & Klein, 1985; Schneier et al., 1994; 
Schneier, Martin, Liebowitz, Gorman, & Fyer, 1989; Stein & Kean, 2000) as well as smoking 
and nicotine dependence (Sonntag, Wittchen, Höfler, Kessler, & Stein, 2000). Apart from 
showing reduced productivity at work, social phobic individuals spend more days out of work 
because of emotional problems (Stein, McQuaid, Laffaye, & McCahill, 1999; Wittchen, 
Stein, et al., 1999). A series of studies have shown individuals with social phobia to suffer 
from a reduced quality of life in various domains (Bech & Angst, 1996; Schneier et al., 1994; 
Mendlowicz & Stein, 2000; Stein & Kean, 2000; Wittchen, Fuetsch, Sonntag, Müller, & 
Liebowitz, 1999). In spite of this impairment, social phobia is poorly recognized and rarely 
treated by the mental health system (Katzelnick & Greist, 2001; Magee et al., 1996; Ross, 
1993; Schneier et al., 1992; Wittchen, Fuetsch, et al., 1999; Wittchen, Stein, et al., 1999). 
1.3.4. Comorbidity 
The clinical picture of social phobia is complicated by the fact that it is often connected to 
other psychological disorders. In fact, comorbidity seems to be the rule rather than the 
exception. Den Boer (2000) analysed data from four US epidemiological studies, 
investigating a total of 361 persons, who fulfilled the diagnostic criteria for social phobia. On 
average, 80% of these individuals were diagnosed with a further lifetime diagnosis. Other 
anxiety disorders were found to be the largest category of comorbid disorders, followed by 
depression (20%) and alcohol misuse (15%). The tendency of social phobia to be related to a 
row of other psychological disorders is reported in many other clinical (Barlow, 1994; 
Gelernter et al, 1991; Otto et al., 2000; Turner, Beidel, Borden, Stanley, & Jacob, 1991) and 
epidemiological studies (Brown & Barlow, 1992; Perugi et al., 1999; Schneier et al., 1992).  
1.4. The Biological Basis of Social Phobia 
1.4.1. Genetic Factors 
There is considerable evidence suggesting that genetic factors play an important role in the 
development of social phobia (Hudson & Rapee, 2000). The issue of genetics has been 
studied in a series of adoption, twin, and family studies. Several family studies have shown 
higher prevalence of social phobia in relatives of probands with social phobia than in relatives 
of probands with other anxiety disorders or no psychological disorders (Fyer, Mannuzza, 
Chapman, Liebowitz, & Klein, 1993; Reich & Yates, 1988; Stein et al., 1998). One of these 
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family studies (Stein et al, 1998) found an increased risk for generalized social phobia in first-
degree relatives of individuals with generalized social phobia, but not in relatives with non-
generalized social phobia, which fits in well with the fact that other authors (Boone et al., 
1999; Heimberg et al., 1990; Levin et al., 1993) found differences in biological reactions to 
social situations between generalized and non-generalized social phobics, suggesting 
differences in the biological basis of the two groups (Bell, Malizia, & Nutt, 1999). The 
findings of family studies are supported by twin-studies suggesting moderate heritability of 
social fears (Kendler, Neale, Kessler, Heath, & Eaves, 1992; Skre, Onstad, Torgersen, 
Lygren, & Kringlen, 2000).  
1.4.2. Neurobiological Factors 
Various models have been used to study neurobiological features of social phobia, including 
assessments of neurotransmitter function, response to chemical challenge, and neuroimaging. 
However den Boer (2000) points out that most studies involved limited numbers of patients 
and that there is still no clearly defined biological dysfunction in patients with social phobia.  
Several findings in studies using different approaches underline the potential role of the 
dopaminergic system. First, a high comorbidity between Parkinson’s disease and social 
phobia has been found, generating the idea that dopamine depletion is a possible cause of 
social phobia (Lauterbach & Duvoisin, 1991; Richard, Schiffer, & Kurlan, 1996; Stein, 
Heuser, Juncos, & Uhde, 1990). Second, misuse of amphetamines seems to be capable of 
causing social phobia through dopamine depletion (Williams, Argyropoulos, & Nutt, 2000). 
Third, clinical observations of the effects of MAOIs (Liebowitz et al., 1992) also suggest a 
contribution of the domaninergic system in social phobia. Finally, studies using single photon 
emission computed tomography (SPECT) in patients with social phobia found striatal 
dopamine reuptake site densities to be markedly lower in social phobics than in matched 
comparison groups without a mental disorder (Schneier et al., 2000; Tiihonen et al., 1997). 
However, Bell et al. (1999) argue that in view of the clinical findings on dopamine it is 
unlikely that this observation is related to an increase in synaptic dopamine but to a decrease 
in the number of sites. Nevertheless, Stein (1998) concludes that a role for dysfunction within 
dopaminergic circuits in social phobia seems probable and further efforts in this direction are 
likely to be fruitful. However, the controversial interpretations (see also Coupland, 2001; den 
Boer, 2000) underline the necessity of further clarification of the exact role of dopamine.  
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A number of further findings point to other neurobiological factors that might be promising. 
Research on neurotransmitter abnormalities suggests that patients with social phobia may 
exhibit selective hypersensitivity of serotonergic systems (Tancer et al., 1995). Neuro-
imaging research has demonstrated that the amygdala is involved in the processing of neutral 
faces in individuals with generalized social phobia. Slides of neutral faces enhanced amygdala 
activation in social phobics, but not in the healthy controls, who only responded to emotional 
facial expressions with amygdala activation (Birbaumer et al., 1998). Finally, in experiments 
on chemical challenges social phobics have been found to react with an increase of anxiety to 
CO2 and to caffeine, similar to patients with panic disorder (compare Bell et al., 1999; den 
Boer, 2000).  
On the other hand, it must also be pointed out that a number of studies have failed to find 
significant abnormalities in social phobics. For example, in a study using magnetic resonance 
imaging no difference could be demonstrated between patients with social phobia and normal 
control participants with respect to total, caudate, putamen, and thalamic volumes (Potts, 
Davidson, Krishnan, & Doraiswamy, 1994). Also, in a SPECT-study social phobics revealed 
no differences in cerebral blood flow in comparison to healthy comparison subjects (Stein & 
Leslie, 1996).  
1.4.3. Evolutionary Factors 
It has been suggested that social anxiety occurs as a result of social conflict and acts as a 
gesture of submissiveness to ward off attack from more dominant members of the same 
species thus avoiding fights and potential damage. As such, the socially anxious behaviour of 
some individuals is favourable for group cohesiveness and functioning as a social unit. This 
idea has led ethological theorists to state that social phobia has its onset in adolescence 
because that is the time when the individual is searching for his or her place within the social 
system (Öhman, 1986). In line with this evolutionary view is the assumption of a biological 
preparedness (Öst & Hugdahl, 1981; Öhman, 1986). The authors found that Pavlovian 
contingencies involving evolutionary fear relevant unconditioned and conditioned social 
stimuli (e.g. angry facial expressions) were much more effective in prompting conditioned 
fear than contingencies of evolutionary arbitrary stimuli. They concluded that there is a basic 
preparedness to react fearfully to such stimuli. 
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1.5. Cognitive and Behavioural Models of Explanation 
1.5.1. Early Theories 
1.5.1.1. Classic Conditioning 
Early models focused on classic conditioning and postulated that a traumatic experience, an 
embarrassing moment in a social situation is responsible for the onset of the phobia (Öst & 
Hugdahl, 1981; Öhman, 1986). An example of such an experience could be failing at the 
blackboard in front of the entire school-class and being laughed at, or beginning a flirt and 
being mocked or pitied. However, Hofmann, Ehlers, and Roth (1995) found that although 
traumatic experiences have been reported by individuals with public speaking anxiety, in 
almost all cases these occurred long after the onset of their social phobia. 
1.5.1.2. Deficits in Social Skills 
Another theory was put forward suggesting that social phobia is the result of a principally 
reasonable, but exaggerated fear that has become contra productive in the course of time (Öst, 
Jerremalm, & Johansson, 1981; Trower, Bryant, & Argyle, 1978). This theory states that 
individuals with social phobia suffer from a lack of social skills, such as not knowing how to 
give a good speech (how to prepare, how to pronounce, how to dress), how to begin a 
conversation with a stranger or how to decline an offer etc.. Social skill deficiencies can also 
reveal themselves in rapid and breathy speech, tensed posture and jerky and poorly controlled 
gestures that increase the risk of embarrassment. Instead of training and optimising their 
skills, these individuals react with an increase of avoidance of social situations, which causes 
existent social competences to degenerate. Lack of social skill, in the sense of emitting fewer 
actions followed by less respondence, has been found to characterize depressed patients (Libet 
& Lewinsohn, 1973) and can possibly explain the onset and maintenance of social phobia for 
a subgroup of social phobics, but the empirical validation as a general model for social phobia 
has not been successful. Studies examining the social skills of socially anxious individuals 
have come to different conclusions, with some finding evidence for behavioural deficiencies 
(Stopa & Clark, 1993; Halford & Foddy, 1982) and others not (Clark & Arkowitz, 1975; 
Rapee & Lim, 1992). In fact, Trower et al. (1978) state themselves that many outpatient 
studies have failed to find clear evidence for the behavioural effect of social skills training in 
comparison to desensitisation. Furthermore, Heimberg (2001) points out that even if 
behavioural deficits are observed, it is unclear whether they are due to a lack of social 
knowledge or skill or to behavioural inhibition and avoidance produced by anxiety. 
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1.5.1.3. Irrational Beliefs 
Ellis (1962) formulated irrational beliefs as an explanation of neurotic disorders. He argues 
that social anxiety can be explained by the irrational belief that one must always make a good 
impression in order to be loved and accepted by everybody one is in contact with. Another 
aspect can be that people get hooked to the idea that they must always achieve perfect 
performances in order to be regarded as valuable, leading to fear of risk and failure. As a 
consequence, these people tend to be more occupied with themselves than with the task, 
which results in less enjoyment or actual failure. Even if people managed to achieve this 
perfectionist and actually unreachable goal, they would have to continuously worry about how 
much they are loved or whether they are still loved. According to Lazarus (1979) an 
overgeneralization of the self takes place when people see their whole ego questioned because 
of an imperfect performance in a social situation. This overgeneralization goes together with 
an absolutistic way of thinking and a low feeling of self-worth and thus is mainly responsible 
for anxiety, feelings of guilt and depressive reactions.  
The model of self-representation by Schlenker and Leary (1982; Leary & Kowalski, 1995) 
takes a similar approach by postulating that the socially anxious person is particularly 
motivated to present a good, socially desired impression, while simultaneously suffering from 
a low feeling of self-esteem. A person will feel socially anxious to the degree that they doubt 
whether they are able to make such an impression. 
1.5.1.4. Vulnerability 
Beck, Emery, and Greenberg (1985) also stress the role of cognitions in their proposal of a 
model of  vulnerability. They state that persons will feel vulnerable in a given situation if they 
believe they are lacking important skills necessary to cope with it. The perception of 
insufficient coping skills makes the situation appear dangerous and triggers the “vulnerability 
mode”. Once this mode is activated, incoming data are processed in terms of the individual’s 
weaknesses rather than in terms of his or her resources (e.g. What if I can’t remember my next 
line?). The person will tend to downgrade his own abilities, since the immediate theme is 
weakness rather than strength. Incongruent, positive or functional information about the self 
or the situation are suppressed or distorted, because they have to go against the stream of 
negative ideation. The socially anxious person may determine his or her degree of 
vulnerability in an evaluative situation by the answers to a network of implicit questions “To 
what degree is this a test of my competence or acceptability?”, “How much do I have to prove 
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myself to me or others?”, or “What is my status relative to that of my evaluators?” (Beck et 
al., 1985, p. 147). 
1.5.1.5. Public Self-Consciousness 
In the centre of a further model is the concept of self-awareness and public self-
consciousness. Buss (1980) argued that although everybody is apt to feel more self-aware in a 
public situation, this applies even more to socially anxious individuals, who tend to be high 
on the trait of public self-consciousness. Self-consciousness describes the process of 
observing and evaluating one’s own perception, thoughts, evaluations and somatic and motor 
processes and continuously checking these self-observations against a standard of social 
expectations. Drawing on evidence from experiments on self-esteem, Buss comes to the 
conclusion that public self-consciousness is likely to lead to inhibition of social responsivity 
and liveliness, as well as to discomfort, embarrassment or anxiety. Also, the perception of a 
discrepancy between what you are and what you think the social ideal is can diminish self-
esteem. Nevertheless, he emphasises that apart from being self-conscious, several other 
factors may also serve to heighten a person’s motivation to manage impression, such as the 
characteristics of the other persons involved and the value of the goals in the interaction.  
1.5.1.6. Metacognition  
According to Hartman (1983), the socially anxious person engages in too much self-focused 
meta-cognition, which refers to a self-monitoring of one’s thoughts and “involves the direct 
awareness of one’s behavioural intentions and inputs to motor systems and thus allows the 
person to edit the production of his or her behavior” (1983, p.440). The person is pre-
occupied with thoughts about his or her physiological arousal, ongoing performance and other 
people’s perception of him- or herself as socially incompetent, nervous or inadequate. 
Excessive focusing of attention on these normally automatic processes leads to a withdrawal 
of attention from the situation or the other person, resulting in a loss of efficiency and 
impairment in interpersonal performance. Hartman suggested that a negative sense of self 
combines with self-monitoring in producing anxiety. The perceptual and processing 
mechanism involves a feedback system, which results in an escalating anxiety cycle. Hartman 
(1983) proposes a combination of his model with the assumptions put forward by Schlenker 
and Leary (1982). However, Hartman assumes that the desire to make a good impression is an 
important consideration in the development stages of social anxiety. In later stages the self-
conceptualisation as being socially anxious and the fear of embarrassment play a more 
important role than the desire to make a good impression.  
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In a review of numerous studies, Hope, Gansler, and Heimberg (1989) found self-
consciousness, and particularly self-focused attention to be linked to social anxiety, but only 
when the subject is vulnerable due to another factor such as social evaluation or lack of 
confidence to perform well. They also come to the conclusion that physiological arousal or 
awareness of it leads to self-focused attention. They conclude that excessive self-focused 
attention may be most problematic for social phobics who experience more intense 
physiological reactions. Social phobics vary in the degree of their arousal (Öst, Jerremalm, & 
Johansson, 1981), however, with some exceptions (Jerremalm, Jansson, & Öst, 1986; 
Scholing & Emmelkamp, 1993a), little attention has been directed to differential response to 
treatment. STUDY III is to our knowledge the first study examining physiological arousal as 
a predictor for treatment response. 
1.5.2. Integrative Models 
1.5.2.1. A Cognitive Behavioural Model of Social Phobia 
The cognitive behavioural model by Heimberg, Juster, Hope, and Mattia (1995) does not 
actually present a new attempt at explanation, but aims at integrating various results from 
research and existing models. The model is based on the assumption of a predisposition to 
develop social phobia, which may be inherited or produced by factors in the childhood or 
adolescent environment, which have sensitised the person to threatening aspects of social 
encounters. Such factors can include a socially anxious parent, perfectionist standards, or 
overprotection and isolation from social contacts. Negative peer group or heterosexual 
experiences may also sensitise the child or adolescent to the potential consequences of social 
situations. This hypothesis is supported by some retrospective and child research (for a review 
see Hudson & Rapee, 2000). Heimberg et al. (1995) state that these experiences result in a set 
of beliefs that increase the probability that the person will approach social situations 
apprehensively or try and avoid them. These beliefs include the assumption that social 
encounters are dangerous to one’s self-esteem, that the only way to avoid negative outcomes 
is to perform perfectly, and that he or she does not have what it takes to perform perfectly. As 
a consequence the person will anticipate humiliation, embarrassment and rejection and 
experience increased arousal before and during the social situation. The increased arousal then 
provides the person with further evidence of danger and may lead him or her to feel anxious 
that the anxiety will become visible to others. The authors provide a feed-back-model, in 
which the various processes feed into each other and contribute to the escalation of a person’s 
anxiety and possibly even result in a disruption of behavioural performance. However, even if 
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performance does not objectively suffer, the authors state that the person is likely to decide 
that it was inadequate, because he or she compares it to a perfectionist standard and expects 
that others will evaluate it in the same way. In the end the sequence serves to affirm the 
negative beliefs and predictions and to increase the probability that the next social incidence 
will be experienced similarly.  
1.5.2.2. A Cognitive Model of Social Phobia  
Wells & Clark (1997) argue that although Hartman (1983) and others have underlined the 
pivotal role of self-focused attention in the maintenance of social phobia, the mechanisms 
they describe linking self-focus to social phobia are likely to operate in other disorders and it 
is necessary to specify social phobic specific mechanisms. Drawing on the given theories and 
extensive clinical work, Clark and Wells (1995) advanced a cognitive model of social phobia. 
In the model, the social phobic is motivated to present a favourable impression but is insecure 
in his ability to do so in particular situations. This insecurity is explained as a manifestation of 
negative self-focused processing. It is linked to safety behaviours that are intended to protect 
self-esteem and prevent negative judgements from others. Safety behaviours differ from 
simple avoidance of the complete social situation. For example, someone can merely be 
avoiding eye contact. The avoidance of revealing blushing by wearing a thick layer of makeup 
or sweating by wearing particularly cool clothes or using deodorant several times a day are 
also considered safety behaviours. The authors state that some of these safety behaviours can 
paradoxically inflame problematic symptoms and increase the likelihood of poor 
performance. They propose that safety behaviours can maintain distorted thinking in social 
phobia by exacerbation of symptoms, by prevention of disconfirmation, by maintenance of 
self-attention, or by contamination of the social situation. The negative consequences of 
safety behaviours as well as somatic symptoms and cognitive interpretations feed back to the 
self-consciousness and reinforce distorted impressions of the self. The authors distinguish 
three phases of distorted processing. Dysfunctional processing can occur in the phobic 
situation itself, in advance of the situation as apprehension and rumination or, finally, after 
leaving the situation it is likely to continue as a “post mortem”, in which the social phobic 
goes over the situation, contemplating how it was, how it should have been and what the 
possible consequences are. However, the authors emphasize that the most important of these 
phases with regard to problem maintenance is the phase in the actual social situation. Similar 
to Beck et al. (1985) they state that the social situation activates dysfunctional conditional 
assumptions (e.g. If I am quiet people will think I’m boring), self-beliefs (e.g. I’m different) 
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or rigid rules for social situations (e.g. I must always sound fluent and intelligent). Schemas of 
this type make the individual vulnerable to perceiving social situations as potentially 
dangerous, leading to somatic and cognitive symptoms and inadequate safety behaviours. 
Also, when the socially anxious individual enters the social situation, there is a shift in his or 
her focus of attention towards an intensified negative self-processing. This self-focused 
attention, which is experienced as an increase in self-consciousness, reduces the attention 
available for processing external information and increases anxiety. The basic components of 
the model interact with each other in the maintenance of fear through four key feedback 
cycles. The self-processing can serve to increase danger appraisals. Safety behaviours 
maintain negative self-beliefs as well as negatively bias the appraisals of others. Finally, 
anxiety symptoms offer subjective support to distorted self-appraisals. 
1.6. Treatment of Social Phobia  
So far, research has focused on cognitive behavioural treatment strategies as well as 
pharmacological treatment. The major classes of cognitive behavioural therapies that have 
been applied to social phobia include exposure, cognitive restructuring, relaxation training 
techniques and social skills training (Heimberg, 2001). Many of the strategies have been 
derived from the biological and psychological models described above. The usefulness of 
relaxation strategies was concluded from the knowledge of physiological arousal and its 
possible impact on self-focused attention. Social skills training is delineated from the model 
of social skill deficits. Cognitive interventions, such as restructuring beliefs and 
interpretations as well as re-shifting attention are derived from the cognitive theories (Beck et 
al., 1985; Buss, 1980; Clark and Wells, 1995; Ellis, 1962; Hartman, 1983; Schlenker & Leary, 
1982). The expectancy of a positive effect of exposure was rendered from the good results 
achieved with patients suffering from simple phobia and panic and agoraphobia (Butler, 
Cullington, Munby, Amies, & Gelder, 1984), who share a number of common features with 
social phobic individuals. Similarly, many of the psychopharmacologic therapies were tested 
because of the good results achieved with patients suffering from major depression.  
1.6.1. Cognitive Behavioural Interventions 
1.6.1.1. Relaxation Techniques 
Relaxation techniques aim at helping the patient to learn to attend to and control the degree of 
physiological arousal experienced during or in anticipation of feared events. Most of the 
relaxation techniques, including systematic desensitization are derived from the pioneering 
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work of Wolpe (1969). However, research on systematic desensitisation for social anxiety is 
meagre, yielding contradicting results. Marzillier, Lambert, and Kellett (1976) tested 
systematic desensitisation in a sample of psychiatric out-patients with social or interpersonal 
difficulties and found it not to be superior to an untreated control group. Florin and Gurk 
(1978) developed a program for the treatment of exam anxiety, in which relaxation techniques 
took up a large part. Of the participants in the program 50% stated that it had helped them 
very much in overcoming anxiety. Jerremalm et al. (1986) suggested that relaxation 
techniques might be specifically effective for patients with fear of physical reactions, but 
could not support this hypothesis in their treatment outcome study. 
1.6.1.2. Social Skills Training 
The most commonly used techniques in social skills training are therapist modelling, 
behavioural rehearsal, corrective feedback, social reinforcement and homework assignments 
(Trower et al., 1978). Studies investigating the effects of social skill training have yielded 
non-uniform results. Mersch, Emmelkamp, Bögels, and Van der Sleen (1989) compared it to 
rational emotive therapy and found it to be equally effective. However they did not find it to 
be more effective for patients who performed weakly in a social interaction test, thus lending 
no support to the hypothesis that it might be particularly helpful for this subgroup of patients. 
Wlazlo, Schroeder-Hartwig, Hand, Kaiser, and Münchau (1990) found no significant 
difference in treatment efficacy between social skills training and exposure. Also, Stravynski, 
Marks, and Yule (1982) found no superior effect, when social skills training was combined 
with cognitive modification. On the other hand, Marzillier et al. (1976) found a waiting-list 
control group to make a comparable progress to a group of patients treated with social skills 
training over a period of three to four months. Also, Trower et al. (1978) point out themselves 
that many outpatient studies have failed to find clear evidence for the behavioural effect of 
social skills training in comparison to desensitisation. As the effectiveness of social skills 
training alone for social phobia is questionable it is often combined with exposure (Hofmann 
et al., 1995; Turner, Beidel, Cooley, Woody, & Messer, 1994) yielding satisfying results. 
1.6.1.3. Exposure 
Exposure requires the patient to imagine (in sensu exposure) or actually confront (in vivo 
exposure) the feared stimuli. In most cases, the first step is to generate a list of problematic 
situations with the patient. Such situations frequently concern giving a speech to an audience, 
serving drinks, being interviewed, asking for a date. The situations are rank-ordered and 
(mostly) the patient will begin exposure to a moderately feared situation to gain confidence 
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and experience success before addressing more feared situations (Fresco & Heimberg, 2001). 
In the early stages of the treatment, situations are entered in company of the therapist and the 
patient is asked to remain in the situation until he or she has experienced a certain degree of 
habituation to it. After repeated and prolonged exposure and when the situation  no longer 
elicits a distressing level of fear, exposure is continued in the next situation. This process 
continues until the patient can master all the feared situations with a significantly reduced 
amount of anxiety. 
Several studies have demonstrated a clear efficacy of exposure for social phobia (Alden, 
1989; Butler et al, 1984; Fava, Grandi, & Canestrari, 1989; Newman, Hofmann, Trabert, 
Roth, & Taylor, 1994; Turner, Beidel, & Jacob, 1994; Mattick & Peters, 1988; Mattick, 
Peters, & Clarke, 1989; Mersch, 1995). Nevertheless, a number of problems arise when 
treating social phobia with pure exposure, which have led some authors (e.g. Fresco & 
Heimberg, 2001) to question its sufficiency for social phobia. Butler (1985) has listed these 
difficulties, which include the problem of clearly specifying tasks in advance, because social 
situations are variable and unpredictable, the time limit of many social situations, and the 
central role of thoughts and attitudes that are difficult to control in the situation. The post-
mortem processing problem described by Clark and Wells (1995) can be added. Fresco and 
Heimberg (2001) point out that exposure is maximally effective when patients fully engage in 
all aspects of the situation in contrast to distracting themselves and focusing on negative 
evaluations and predictions or applying safety behaviours.  
1.6.1.4. Cognitive Restructuring 
Cognitive restructuring consists of a set of interventions originating from the cognitive theory 
and therapies of Beck et al. (1985) and Ellis (1962). Individuals are taught to identify 
irrational or negative thoughts that occur during the anxiety-provoking situation. Next, they 
are taught to evaluate the accuracy of those thoughts as compared with objective information, 
which is derived by repeated questioning or, as an alternative, by behavioural experiments, 
such as observing others in a social situation or testing the effect of safety behaviours (Ellis, 
1962; Clark and Wells, 1995). When dysfunctional thoughts are triggered by general beliefs, 
the therapist will question these beliefs (Ellis, 1962). Finally, the patient is motivated to 
develop rational alternative thoughts based on the acquired information.  
Recent research on cognitive interventions focuses on a treatment based on the model of 
Clark and Wells (1995). Treatment consists of deriving an idiosyncratic version of the model, 
which is used as a point of reference during treatment, identifying safety behaviours and 
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demonstrating their adverse effects via experimental exercises, training patients to shift their 
attention away from the self to the external situation (as already suggested by Hartman, 1983), 
video-feedback to modify distorted self-imagery, behavioural experiments and identifying and 
modifying problematic anticipatory and post-event processing.  
Behavioural experiments contain exposure elements, although exposure is not applied as 
systematically as described above. In the cognitive approach, exposure is less about 
habituation but more about the opportunity for patients to collect information that will enable 
them to revise their judgement about the degree of risk in a given situation (Heimberg, 2001). 
Although most studies have investigated the combined effect of exposure and cognitive 
restructuring, studies that only evaluated cognitive interventions supply strong evidence for 
their efficacy, particularly for the rational emotive therapy (Kanter & Goldfried, 1979; 
Schelver & Gutsch, 1983) but also for the treatment developed by Clark and Wells (1995) 
(Stangier, Heidenreich, Peitz, Lauterbach, & Clark, 2002). Additionally, Hofmann (2000) 
found changes in self-focused attention to be highly correlated with pre-post differences in 
social phobic anxiety. 
1.6.1.5. Combination of Exposure and Cognitive Restructuring 
Heimberg et al. (1995) have presented a specific cognitive-behavioural group treatment 
(CBGT) for social phobia. The treatment is conducted in 12 weekly sessions that last for 
approximately 2.5 hours and is typically administered to groups of six patients and conducted 
by two co-therapists (Fresco & Heimberg, 2001). Treatment consists of developing a 
cognitive-behavioural explanation of social phobia, training patients in the skill of identifying, 
analysing, and disputing problematic cognitions, exposure to simulations of feared situations, 
cognitive restructuring, in vivo exposure as homework assignments and teaching patients to 
self-administer cognitive restructuring in combination with homework assignments. CBGT 
has received the most empirical attention and support (Cox, Ross, Swinson, & Direnfeld, 
1998; Gruber, Moran, Roth, & Taylor, 2001; Heimberg, Becker, Goldfinger, & Vermilyea, 
1985; Heimberg, Dodge, et al., 1990; Heimberg et al., 1998; Hope, Heimberg, & Bruch, 
1995; Hope, Herbert, & White, 1995; Otto et al., 2000). STUDY I describes an individualized 
approach to the combination of exposure and cognitive interventions (see Appendix D). 
1.6.2. Pharmacological Treatment 
The goals of pharmacotherapy for social phobia aim at ameliorating the target symptoms, 
such as anticipatory anxiety, socially cued panic, avoidance behaviour and dysphonic 
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ruminations, to address comorbid conditions as well as to achieve remission and recovery. To 
achieve this, clinicians have been using various chemical agents (Marshall, 1993; Miner & 
Davidson, 1995; Scott & Heimberg, 2000; Walker & Kjernistedt, 2000). Irreversible, non-
specific monoamine oxidase inhibitors (MAOIs) have been shown to achieve a positive 
response rate in studies using phenelzine (Gelernter et al., 1991; Liebowitz et al., 1992), but a 
lower response for atenolol (Turner, Beidel, & Jacob, 1994). However, despite the well-
established efficacy, clinicians rarely chose MAOIs as first-line treatment for social phobia, 
because of the need for a low tyramine diet and diverse side effects. Other studies have 
supported the efficacy of clonazepan (Davidson et al., 1993; Munjack, Baltazar, Bohn, Cabe, 
& Appleton, 1990; Otto et al., 2000) as well as aprazolan (Gelernter et al., 1991). However, 
the use of benzodiazepines must be questioned, as many social phobic patients suffer from 
comorbid alcohol dependence, which is a contraindication for the use of benzodiazepines. All 
existing selective serotonin reuptake inhibitors (SSRIs) have been studied in the treatment of 
social anxiety and the evidence from controlled studies supports their efficacy, specifically the 
efficacy of sertraline (Blomhoff et al., 2001), fluvoxamine (Stein, Fyer, Davidson, Pollack, & 
Wiita, 1999), and paroxetine (Baldwin, Bobes, Stein, Scharwächter, & Faure, 1999). The 
SSRIs seem to be emerging as first line pharmacological treatment for social phobia. They are 
well tolerated in the short- and long term, safe and also effective in treating frequent comorbid 
disorders, such as depression (Walker & Kjernisted, 2000). In spite of their efficacy in the 
treatment of major depression, beta-blockers have been proved less effective in the treatment 
of social phobia (Liebowitz et al., 1992; Turner, Beidel, & Jacob, 1994). 
1.6.3. Present State of Treatment Research  
In the area of social phobia a series of meta-analyses have found a high efficacy of cognitive 
behavioural treatments in the reduction of social phobic anxiety, with mean effect sizes 
ranging from 0.8 to 1.1 (Fedoroff & Taylor, 2001; Gould, Buckminster, Pollack, Otto, & Yap, 
1997; Feske & Chambless, 1995; Ruhmland & Margraf, 2001; Taylor, 1996). However, it 
should be pointed out that the meta-analyses were based on similar pools of studies for 
cognitive-behavioural treatments as the amount of studies is limited. Table 1.1. shows the 
mean pre-post and pre-follow-up effect sizes for the different treatment conditions from the 
given meta-analyses.  
Fedoroff and Taylor (2001) found treatment with benzodiazepines to be significantly more 
effective than all other strategies with exception of SSRIs. However, they report follow-up 
studies only for psychotherapy with effect sizes in the range of attention placebo. The studies 
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they analysed used varying follow-up periods (up to six months), but there was no significant 
effect when the authors controlled for length. 
Table 1.1.  
Mean Effect Sizes and Number of Trials for Psychological and Pharmacological 
Interventions in Meta-Analyses. 
 Fedoroff & 
Taylor 
(2001) 
Gould et al. 
(1997) 
Feske & 
Chambless 
(1995) 
Ruhmland 
& Margraf 
(2001) 
Taylor 
(1996) 
Wait-list control 
Post 
FU (1-6 months) 
 
0.03 (9) 
   
0.03 (5) 
 
-0.13 (5) 
 
Attention placebo 
Post 
FU (1-6 months) 
 
0.45 (4) 
0.42 (1) 
   
 
 
 
0.48 (5) 
Exposure  
Post 
FU (1-6 months) 
 
1.08 (7) 
1.31 (7) 
 
0.89 (9) 1 
 
0.99 (9) 
1.04 (7) 
 
1.76 (7) 
1.06 (6) 
 
0.82 (8) 
0.93 (8) 
Cognitive Therapy  
Post 
FU (1-6 months) 
 
0.72 (7) 
0.78 (5) 
 
0.60 (4) 1 
  
1.13 (3) 
 
 
0.63 (5) 
0.96 (5) 
EX and CT 
Post 
FU (1-6 months) 
 
0.84 (21) 
0.95 (10) 
 
0.80 (8) 1 
 
0.90 (12) 
1.10 (10) 
 
1.07 (17) 
1.39 (13) 
 
1.06 (11) 
1.08 (9) 
Social Skill 
Training 
Post 
FU (1-6 months) 
 
0.64 (7) 
0.86 (4) 
 
0.60 (3) 1 
  
0.85 (2) 
 
0.65 (4) 
0.99 (3) 
Relaxation 
Post 
0.51 (4)   0.44 (2)  
Benzodiazepines 
Post 
 
2.10 (5) 
 
0.72 (2) 1 
   
SSRI 
Post 
 
1.70 (12) 
 
1.89 (2) 1 
   
MAOIs 
Post 
 
1.08 (15) 
 
0.64 (5) 1 
   
ß-blockers 
Post 
  
-0.08 (3) 1 
   
Numbers in parenthesis reflect the number of trials. Post = post-assessment after treatment, FU = follow-up (1-6 
months), EX = exposure, CT = cognitive therapy, SSRI = selective serotonin reuptake inhibitors, MAOIs = 
monoamine oxidase inhibitors. 1 = controlled pre-post and follow-up effect sizes. 
 
In the meta-analysis by Ruhmland and Margraf (2001) studies investigating social skills 
training and relaxation strategies achieved significantly lower effect sizes than exposure, 
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cognitive therapy or a combination of both. Nonetheless, all treatment strategies were better 
than the waiting list control groups. In order to have a better comparison with the other meta-
analyses, the 1-6 months follow-up period is reported in table 1. However, follow-up data 
over longer periods of time for exposure and cognitive behavioural treatment were reported 
for five studies, yielding effect sizes comparable to those at post-assessment. 
In the meta-analysis by Gould et al. (1997) a more conservative approach was chosen, 
including only controlled studies and excluding open trial pharmacological studies. Follow-
up-data (3-6 months) are only reported for single studies. They found studies reporting 
follow-up-data to have a mean follow-up effect size .21, suggesting that subjects continued to 
make modest improvement, with the exception of the only follow-up study investigating 
pharmacotherapy, which indicated no further treatment gains. Gould et al. also examined the 
costs of treatments in relation to their efficacy. Cognitive behavioural group treatment was 
found to be clearly the least costly intervention, and clonazepan the least costly 
pharmacological intervention, especially by the end of the second year. Individual cognitive 
behavioural therapy combined with clonazepan and phenelzine totalled about twice the charge 
of group treatment and treatments with fluvoxamine were clearly the most expensive 
interventions.  
The meta-analysis by Feske and Chambless (1995) concentrated on the comparison of studies 
testing cognitive behaviour therapy and studies testing exposure treatment. Their results 
indicated that treatment modalities are equally effective. 
Taylor (1996) compared waiting-list control, placebo, exposure, cognitive therapy, a 
combination of exposure and cognitive restructuring and social skills training. He found all 
treatment conditions including placebo to differ significantly from the waiting-list-control 
group and only the combination of exposure and cognitive restructuring to yield a 
significantly larger effect than placebo. He also found a tendency for the effects of treatment 
to increase by a 3-month follow-up. 
In sum, it seems that cognitive behavioural treatment is an effective and relatively 
inexpensive treatment that provides stable long-term effects. Although medical treatment 
(particularly SSRI) tends to be more effective on a short-term basis, long-term effectiveness is 
questionable and evidence for it has yet to be delivered. The doubt whether medical treatment 
is capable of producing stable effects is supported by the results of a large comparison study 
of CBGT and phenelzine (Heimberg et al., 1998; Liebowitz et al., 1999). At post-test both 
groups had improved comparably, although phenelzine patients had improved more on a 
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subset of measures. Also, many of the phenelzine patients who were classified as responders 
at post (after 12 weeks) had already achieved gains by the six-week assessment and this was 
less common among the patients treated with CBGT. However, after a follow-up period of six 
months, 50% of the previously responding phenelzine patients relapsed, compared to 17% of 
the CBGT patients.  
To date, there are no published studies that have examined the combined effectiveness of 
cognitive-behavioural-and pharmacological treatments, although there are some being 
conducted at present (Heimberg, 2001).  
Apart from the need for further investigation of long-term effects for medical treatment, I 
would like to emphasize two further issues arising from the current state of treatment research 
for the treatment of social phobia. 
First, in spite of the effective treatment, social phobia is an under-treated psychological 
disorder (Katzelnick & Greist, 2001; Magee et al., 1996; Ross, 1993; Schneier et al., 1992; 
Wittchen, Fuetsch, et al., 1999; Wittchen, Stein, et al., 1999). Ross (1993) lists a row of 
barriers for treatment, expressed by people who contacted the Anxiety Disorders Association 
of America. They include ignorance about social phobic fears on the part of health 
professionals and the public, trivialization of the problem by family and friends, under 
diagnosis, the stigma attached to mental disorders in general, the sense of secrecy, shame, and 
embarrassment that accompanies social phobia in particular and the lack of access to 
affordable and professional care. Even of those social phobic patients who overcome the first 
boundaries and are fortunate enough to receive an adequate treatment offer, not all take up 
that offer and not all profit from treatment or are able to maintain success over a longer period 
of time. Scott and Heimberg (2000) point out that clinicians should be aware of alternative 
strategies for the treatment of social phobia because no treatment has been shown effective for 
all individuals. Thus, further research should focus on the question of which patients might 
benefit from which treatment. The question of whether there are patient characteristics on the 
basis of which the clinician is able to predict treatment attrition and success is addressed in 
STUDY III.  
Second, the fact that treatment has been shown to be effective under research conditions does 
not necessarily mean that it will be equally effective in clinical practice. In fact, many 
practitioners doubt whether they will be as successful with their patients as researchers are 
with the patients they investigate and treat. There are numerous differences between research 
conditions and clinical practice, ranging from characteristics of the sample to the type of 
1. Theoretical Background  23 
building or the training of therapists. The question of whether these have any influence on the 
size of the effect is attended to in STUDY I. Finally, there is a need to demonstrate that 
cognitive behavioural treatment will work just as well in clinical practice, by comparing the 
effects achieved in clinical practice with those achieved in randomised controlled trials. This 
is done in STUDY II. 
In the following chapter, the conducted studies will be introduced at more length, giving a 
brief description of their purposes and methods as well as a summary of the results. The 
complete descriptions of the studies are depicted in the chapters 3, 4, and 5. 
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2. Purpose and Summary of the Studies 
2.1. Purpose and Summary of STUDY I 
Although the effectiveness of cognitive behavioural treatment for social phobia has been 
studied in a large number of outcome studies and re-analysed in a row of meta-analyses, the 
question of whether this treatment will work in clinical practice remains unanswered. Private 
practitioners and other psychotherapists working under no research conditions often argue that 
their patients obviously differ from the research samples and that they therefore do not obtain 
as good results as those reported in the given literature. Yet very little attention has been given 
to the question of the generalization of these results to clinical practice. Juster, Heimberg, and 
Engelberg (1995) investigated self-selection and sample selection in a treatment study of 
social phobia. They found that although acceptors were found to score higher on only one of 
25 pretreatment measures of clinical functioning, they improved significantly more on 3 of 5 
posttreatment measures (global improvement, social anxiety and avoidance) than refusers or 
excluded patients. Weisz, Weiss, and Donenberg found for child and adolescent therapies that 
“research focusing on more representative treatment of referred clients in clinics has shown 
more modest effects, in fact, most clinic studies have not shown significant effects” (1992, 
p.1578). Shadish et al. (1997) conducted a secondary analysis of meta-analytic data and found 
very few studies that were even remotely clinically representative. However, studies that 
fulfilled a certain number of the criteria revealed effect sizes that were about 10% smaller 
than those of the complete sample of therapy studies.  
These findings are in line with “a growing recognition that controlled clinical trials may not 
capture the full richness and variability of actual clinical practice and a concern on the part of 
some that the very process of randomisation may undermine the representativeness of clinical 
encounter” (Chambless & Hollon, 1998, p. 14) and underline the importance of more research 
to answer the question of generalization of treatment effects. It is possible that the selection 
criteria generally applied in efficacy studies lead to homogenous samples with low standard 
deviations in the applied measures. A small denominator in the fraction calculating the effect 
size could result in an overestimation of treatment effects in comparison to typical clinical 
samples. Thus, the aim of STUDY I was to direct further attention to the possibility that 
higher effect sizes in the treatment of social phobia are achieved in typical research conditions 
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and that these are not due to the quality of treatment but to sample selection and study 
characteristics.  
To do this, we re-examined the current research on social phobia treatment and selected 
studies for which pre-post effect sizes could be calculated with the provided means and 
standard deviations for the outcome measures across treatment. Thirty studies1 (see Appendix 
A) on cognitive and/or behavioural treatment of social phobia or severe interpersonal anxiety 
met our criteria for inclusion and were selected for our review. We categorized the studies 
according to common exclusion criteria, the heterogeneity of the sample and laboratory study 
characteristics according to the criteria listed by Shadish et al. (1997) and compared the mean 
effect size (ES) and standard deviation (SD) for each group of studies according to the applied 
sample and study criteria. We also calculated a laboratory and a restriction score according to 
the amount of applied typical research criteria a study fulfilled and analysed the correlation of 
these scores with the effect sizes. 
Generally, the results of STUDY I did not offer convincing evidence for the assumption that 
effect sizes might be explained by the failure to gain typical samples. Two of the direct group 
comparisons even revealed the opposite effect. Patient samples that included patients with 
comorbid avoidant personality disorder and patients with prior treatment experience revealed 
higher effect sizes than samples without. Also, the results indicate that even the accumulation 
of sample restriction does not have predictive value for the pre-post effect sizes of treatment. 
However, there were some results in support of the observations made by private 
practitioners. Samples excluding patients with comorbid psychosis, substance misuse and 
bipolar disorder were shown to reach higher effects than those including these patients. The 
same applied for studies that were conducted following a treatment manual. We also found 
studies working with participants who were homogeneous in the length of their disorder to 
produce higher treatment effects than the other studies. There was strong evidence for the 
hypothesis that this relation is moderated by the size of the standard deviations in the applied 
measures. Finally, and most importantly we found evidence for an influence of accumulated 
laboratory criteria for research studies on the effect size. There was a significant tendency for 
studies applying laboratory treatment conditions, such as recruiting patients by adverts, 
applying treatment in university settings, using specifically trained therapists and following 
and monitoring treatment manuals to achieve higher effect sizes.  
                                                 
1 The analyzed studies are numbered 1-30 in the reference list. 
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In summary, the results in STUDY I are in line with Shadish et al. (1997) in finding a 
tendency for studies applying a row of research criteria to reveal slightly lower effect sizes. 
However, we found that this is not due to sample restriction in typical research studies. It 
seems that the laboratory characteristics, such as recruiting patients, the place of the study, the 
training of therapists or the implementation of a treatment manual have more influence on the 
difference.  
2.2. Purpose and Summary of STUDY II 
STUDY II also addressed the potential gap between clinical research and practice, by 
following the recently popular distinction between the efficacy of psychotherapy and its 
effectiveness (Weisz, Donenberg, Han, & Weiss, 1995). Efficacy (or research therapy) refers 
to the effects of psychotherapy in randomised, controlled trials, usually conducted in 
university settings involving recruited patient clients, using a highly structured treatment 
manual for a narrow problem focus and trying to establish a high degree of internal validity. 
Effectiveness (or clinical therapy) refers to the effects of natural clinical psychotherapy 
conducted in the field, which means in private practice or in mental health centres, using 
quasi-experimental designs and trying to establish a high degree of external validity or 
generalization of results to various settings. All of the treatment studies carried out so far can 
be classified as efficacy studies with varying amounts of sample restriction and laboratory 
study conditions. So far, no study has tested the hypothesis whether treatment for social 
phobia can be delivered with the same effectiveness in a clinical setting, in which patients are 
not recruited by adverts, not randomised to treatment groups or preselected in a way typical of 
research but are part of the usual referral system and medical routine. STUDY II was an 
attempt to investigate the generalization of an empirically supported treatment for social 
phobia to a clinical setting. STUDY II also investigated the possibility that the effect-size 
could be enhanced by restricting the sample of patients according to the criteria employed in 
research settings.  
The effectiveness of exposure combined with cognitive restructuring was examined in four 
outpatient clinics in the community and a large number of experienced and inexperienced 
therapists. Participants were 217 patients diagnosed with social phobia as the primary disorder 
who agreed to undergo treatment in one of four outpatient clinics run by the Christoph-
Dornier-Foundation for Clinical Psychology (CDS). The patients were treated with high 
density in vivo exposure, supplemented by cognitive interventions (Appendix D). Patients 
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were assessed before treatment and six weeks after treatment (Appendix B) with a large 
battery of disorder specific and related self-report measures (Appendix E). 
The results of STUDY II provided support for the clinical effectiveness of exposure 
combined with cognitive interventions for patients with social phobia. Fifty-six percent of the 
patients had reliably improved on social phobic fears and 57% were more likely to be drawn 
from a healthy population sample six weeks after the end of therapy. The rate of patients who 
felt impaired in important areas of their life dropped significantly, indicating that patients 
succeeded in transferring the effects of therapy into their every-day-life. The mean effect size 
for the measures of social phobia was 0.82, thus being within, but at the bottom range of the 
effect sizes reported in the meta-analyses for cognitive behavioural therapy (Fedoroff & 
Taylor, 2001; Gould et al., 1997; Feske & Chambless, 1995; Ruhmland & Margraf, 2001; 
Taylor, 1996). No higher effect size was attained when the sample was restricted, applying 
frequently used selection criteria. Even the comparison of a subgroup of patients, for which a 
row of restriction criteria was applied (low depression, no prior treatment, a medium age of 
20–50 and homogenous in the severity of disorder) did not reveal a higher effect size than the 
remaining sample. The finding that the effect size was in the bottom range of those found in 
meta-analyses might be due to the fact that the questionnaire measures applied were less 
sensitive to change than those in the comparison studies that have been analysed in the meta-
analyses. A direct comparison with studies using the same measures provides a different 
picture, as effect-sizes in these studies tended to be lower.  
One shortcoming of STUDY II was that 11% of the patients could not be motivated to 
complete the follow-up questionnaires at post assessment. Although no significant differences 
were found between these patients and the ones who completed the follow-up questionnaires, 
there was a tendency for them to occupy an intermediate position between the completers and 
the dropouts, who differed significantly from one another on some of the measures. The 
higher depression scores and comorbidity found for patients who dropped out of therapy also 
underline the necessity of giving further attention to this group of patients. Nevertheless, an 
intent-to-treat-analysis also produced highly significant pre-post differences. 
Taken together, STUDY II provided convincing evidence that empirically validated treatment 
for social phobia, the combination of exposure and cognitive restructuring, can be transported 
into natural field settings. However, it is most likely that these results require not only a 
thorough diagnostic procedure to assess social phobia as the primary problem but also 
frequent and maintained supervision of the therapists. 
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2.3. Purpose and Summary of STUDY III 
Today, the social phobic health service user is in the fortunate position of having a range of 
treatments from which to choose. However, not all patients benefit from the tested treatment 
approaches. Turner, Beidel, Wolff, Spaulding, and Jacob (1996) calculated treatment success, 
taking into consideration not only patients who completed treatment but also those who were 
offered treatment, but refused or dropped out of it. This resulted in an alarmingly low rate of 
52% of the patients seeking treatment for social phobia who actually profited from it. Also, 
there is little information available to indicate which patient with social phobia is more likely 
to benefit from which treatment (Walker & Kjernistedt, 2000). Awareness of prognostic 
features can be helpful in indicating treatments of choice, since a variety of effective 
treatment variations are available. Knowing about factors that are responsible for attrition as 
well as for failure to benefit from treatment may help to understand the processes underlying 
treatment and enable the therapist to adapt treatment procedures, delivery and planning 
accordingly to improve a specific patient’s prognosis (van Minnen, Arntz, & Keijsers, 2002). 
A series of studies have investigated predictors for treatment response in social phobia (e.g. 
Chambless et al., 1997; Mersch, Emmelkamp, & Lips, 1991; Salabería & Echeburúa, 1996; 
Scholing & Emmelkamp, 1999; Turner et al., 1996). Most studies have concentrated on 
predicting change caused by treatment and end state functioning, focusing on 
sociodemographic and biographical variables, impairment, severity, subtypes, and 
comorbidity as potential predictors for change or end state functioning. Little attention has 
been directed to the questions of treatment dropout, refusal or relapse after treatment. Also, a 
number of promising variables has not been examined as predictors. Finally, the available 
studies are limited by the fact that predictors were studied in the context of controlled 
outcome studies whose inclusion criteria are likely to limit the variability of the factors 
studied as predictors. Specifically in the case of treatment refusal the question must be raised 
whether refusal of participating in a study with random assignment can be compared to the 
refusal to take up a (individualized) treatment offer as such. The aim of STUDY III was 
therefore to search for predictors of treatment acceptance, attrition, effectiveness, and relapses 
after treatment in a field treatment outcome study for social phobia and to compare these to 
variables identified as predictors in the context of controlled efficacy studies. 
Patients diagnosed with social phobia seeking treatment in a naturalistic setting (N = 287, for 
a detailed description of this sample see Appendix C) were classified as refusers prior to 
treatment (16%), refusers after cognitive preparation (8%), dropouts (6%), and completers 
2. Purpose and Summary of the Studies                         29 
(69%). Outcome was assessed by residual gain scores and patient improvement ratings six 
weeks and one year after the end of treatment. Patients who completed the one-year follow-up 
were categorized as stable (87%) or deteriorated (13%). Demographic and disorder-related as 
well as therapist and treatment variables were used as predictors for each classification.  
The results of STUDY III indicate that approximately only 43% of the patients seeking 
treatment actually completed and benefited from it in the end. The only predictor for 
treatment attrition was comorbidity. Treatment gain was best predicted by satisfaction with 
health. Also, patients characterized by more generalized social phobia improved less by 1-
year-follow-up. Pretreatment depression had no effect on change as assessed by the self-report 
measures, although more depressed patients reported having improved less. Patients who were 
more severely impaired at pretreatment found it harder to maintain treatment gain. Three 
important clinical implications were derived from the results of STUDY III. (1) Treatment 
refusers are as severely impaired by social phobic symptoms as patients who undergo 
treatment and additional efforts are needed to motivate these patients to take up treatment. (2) 
Cognitive preparation and the beginning of treatment should be even more adapted to 
pretreatment feelings of impairment and comorbid disorders, by restructuring hampering 
cognitions or conducting specific treatment for comorbid disorders. (3) It seems important to 
arrange for additional sessions over a specific period of time when patients are more severely 
impaired or suffer from more generalized social phobia, to enable them to integrate the 
treatment effects into their everyday life. 
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3. STUDY I 
How much do Sample Characteristics Affect the Effect 
Sizes? - An Investigation of Studies Testing the 
Treatment Effects for Social Phobia. 2 
3.1. Introduction 
Private practitioners and other psychotherapists working under no research conditions often 
argue that their patients obviously differ from the research samples and that they therefore do 
not obtain as good results as those reported in the given literature. Possibly as a reply to this, 
writers have recently begun to distinguish between the efficacy of psychotherapy and its 
effectiveness (Weisz, Donenberg, Han, & Weiss, 1995). Efficacy (or research therapy) refers 
to the effects of psychotherapy in randomised, controlled trials trying to establish a high 
degree of internal validity. These are usually conducted in university settings, involving 
recruited patient clients, selected according to inclusion criteria and using a highly structured 
treatment manual for a narrow problem focus. Effectiveness (or clinic therapy) refers to the 
effects of natural clinical psychotherapy conducted in the field, which means in private 
practice or in mental health centres, using quasi-experimental designs and trying to establish a 
high degree of external validity. While the efficacy of psychotherapy is generally well 
established, the generalization of efficacy findings can be challenged. Weisz, Weiss, and 
Donenberg found for child and adolescent therapies that “research focusing on more 
representative treatment of referred clients in clinics has shown more modest effects, in fact, 
most clinic studies have not shown significant effects” (1992, p.1578). Shadish, Matt, 
Navarro, Siegle, Crits-Christoph, Hazelrigg, et al. (1997) conducted a secondary analysis of 
meta-analytic data and found very few studies that were even remotely clinically 
representative. For a study to pass as clinical it had to be carried out in non-university 
settings, involve patients that were referred through usual clinical routes, involve experienced, 
professional therapists with regular caseloads and free to use a wide variety of procedures in 
                                                 
2 Reprinted in part from Journal of Anxiety Disorders (in press). Lincoln, T.M.., & Rief, W., How much do 
sample characteristics affect the effect sizes? An investigation of studies testing the treatment effects for social 
phobia. Copyright 2003 with permission from Elsevier. 
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treatment rather than therapists in training or trained specifically for the purpose. The 
therapists were also not to have used a treatment manual and the implementation of the 
treatment should not have been monitored. Finally, the studies were to have used clients who 
were heterogeneous in personal characteristics as well as in focal presenting problems. Only 
one study fulfilled the authors’ complete set of criteria for clinic therapy. However, studies 
that fulfilled a certain number of the criteria revealed effect sizes that were about 10% smaller 
than those of the complete sample of therapy studies.  
In the area of social phobia a series of meta-analyses have found a high efficacy of cognitive 
behavioural treatments in the reduction of social phobic anxiety, with mean effect sizes 
ranging from 0.8 to 1.1 (Fedoroff & Taylor, 2001; Gould, Buckminster, Pollack, Otto, & Yap, 
1997; Feske & Chambless, 1995; Ruhmland & Margraf, 2001; Taylor, 1996). Yet very little 
attention has been given to the question of generalization of these results to clinical practice. 
Juster, Heimberg, and Engelberg (1995) investigated self-selection and sample selection in a 
treatment study of social phobia. They found that although acceptors were found to score 
higher on only one of 25 pretreatment measures of clinical functioning, they improved 
significantly more on 3 of 5 posttreatment measures (global improvement, social anxiety and 
avoidance) than refusers or excluded patients. In a large clinical practice study (Lincoln, Rief, 
Hahlweg, Frank, von Witzleben, et al. 2002) we found the effect size for treatment of social 
phobia to be at the bottom range of those reported in meta-analyses. These findings are in line 
with “a growing recognition that controlled clinical trials may not capture the full richness 
and variability of actual clinical practice and a concern on the part of some that the very 
process of randomisation may undermine the representativeness of clinical encounter” 
(Chambless & Hollon, 1998, p. 14) and underline the importance of more research to answer 
the question of generalization of treatment effects. It is possible that the selection criteria 
generally applied in efficacy studies leads to homogenous samples with low standard 
deviations in the applied measures. A small denominator in the fraction calculating the effect 
size could result in an overestimation of treatment effects in comparison to typical clinical 
samples. In this case, private practitioners would be well advised to reduce their expectations 
concerning the effects of treatment that has been proved to be successful in the literature. 
Thus, further attention must be directed to the possibility that higher effect sizes are achieved 
in typical research conditions and that these are not due to the quality of treatment but to 
sample selection and study characteristics. In the present study we will re-examine the current 
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research on social phobia treatment to investigate whether sample restriction and laboratory 
conditions affect the effect sizes.  
3.2. Method 
3.2.1. Retrieval of Studies  
In a first step, we searched for studies investigating exposure or cognitive behavioural 
treatment effects for patients with social phobia as primary axis I diagnosis. For this purpose 
we selected studies for which pre-post effect sizes could be calculated with the provided 
means and standard deviations for the outcome measures across treatment. We located studies 
by searching through the reference lists of available studies as well as by using the computer 
based retrieval system PsycLIT (American Psychological Association, 1994). We used the 
search terms “social phobia treatment” and “social phobia therapy” to search for journal, book 
and chapter citations from 1996 to the present 2001. Further studies were located on the basis 
of the meta-analyses cited above that investigated therapy outcome effects for social phobia. 
Unpublished studies were retrieved through correspondence with contributers in the field of 
research on social phobia in Germany.  
3.2.2. Study Sample 
Thirty studies on cognitive and/or behavioural treatment of social phobia or severe 
interpersonal anxiety met our criteria for inclusion and were selected for our review. Twenty-
two of the studies were listed in one of the meta-analyses referred to above. They were 
supplemented by six further published and two unpublished studies. Most of these studies 
investigated treatment effects, many of them comparing different treatments or different 
orders of treatment components to each other. One study investigated the sensitivity of 
different questionnaires (Cox, Ross, Swinson, & Direnfeld, 1998) and three studies 
investigated differences in treatment outcome for different subgroups of patients (Jerremalm, 
Jansson, & Öst, 1986; Hope, Herbert, & White, 1995; Hofmann, Newman, Becker, Taylor, & 
Roth, 1995).  
Only patient-samples treated with cognitive behaviour therapy that included some form of 
cognitive restructuring or exposure to feared situations were used to calculate the effect sizes. 
The treatments applied in the studies included cognitive behavioural group therapy (CBGT) 
developed by Heimberg, Juster, Hope and Mattia (1995) (Cox et al., 1998; Gruber, Moran, 
Roth, & Taylor, 2001; Heimberg, Becker, Goldfinger, & Vermilyea, 1985; Heimberg, Dodge, 
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Hope, Kennedy, Zollo, et al., 1990; Heimberg, Liebowitz, Hope, Schneier, Holt, et al., 1998; 
Hope, Heimberg, & Bruch, 1995; Hope, Herbert, et al., 1995; Otto, Pollack, Gould, 
Worthington, McArdle, & Rosenbaum, 2000), a combination of exposure and cognitive 
restructuring (Butler, Cullington, Munby, Amies, & Gelder, 1984; Clark & Agras, 1991; 
Gelernter, Uhde, Cimbolic, Arnkoff, Vittone, et al., 1991; Lincoln, et al., 2002; Mattick & 
Peters, 1988; Mattick, Peters & Clarke, 1989; Mersch, 1995; Scholing & Emmelkamp, 1993a; 
Scholing & Emmelkamp, 1993b; Taylor, Woody, Koch, McLean, Paterson, & Anderson, 
1997) pure exposure (Alden, 1989; Fava, Grandi, & Canestrari, 1989; Newman, Hofmann, 
Trabert, Roth, & Taylor, 1994; Turner, Beidel, & Jacob, 1994), exposure and social skills 
training (Hofmann et al., 1995), personal effectiveness therapy and exposure (Wlazlo, 
Schroeder-Hartwig, Hand, Kaiser, & Münchau, 1990), social effectiveness therapy (Turner, 
Beidel, Cooley, Woody, & Messer, 1994), self-instructional training (Jerremalm et al., 1986), 
social skills training combined with cognitive modification (Stravynski, Marks, & Yule, 
1982), rational emotive therapy (Kanter & Goldfried, 1979; Schelver & Gutsch, 1983), and 
cognitive therapy (Stangier, Heidenreich, Peitz, Lauterbach, & Clark, 2002). 
3.2.3. Data Analysis Plan 
3.2.3.1. Calculation of effect sizes 
As it was our intention to investigate effects of the sample characteristics and not the effects 
of treatment, subsamples of patients treated with different cognitive or behavioural 
interventions or different formats (group versus individual) within one study were combined 
into a single sample. This meant that the effect sizes for different treatment conditions as well 
as for group and individual therapy within the same study were averaged. We justified this by 
the fact that meta-analyses (Feske & Chambless, 1995; Ruhmland & Margraf, 2001; Taylor, 
1996) failed to find significant differences between cognitive behaviour therapy and exposure 
or between group and individual therapy. In contrast, subsamples of patients with different 
characteristics within one study were left as distinct subgroups, thus going into the 
calculations as separate samples.  
We applied the criteria chosen by Feske and Chambless (1995) for the calculation of effect 
sizes. They were calculated using the formula (Mpretest – posttest / SDpretest) and averaged 
in the case of more than one measure to assess social anxiety. Effect sizes were based on 
questionnaire self-evaluation measures because clinical ratings have shown to result in larger 
effects and could lead to an overestimation of the effects in studies using them. The following 
measures of social anxiety were included: the Fear of Negative Evaluation Scale (FNES, 
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Watson & Friend, 1969), the Personal Report of Confidence as a Speaker (PRCS, Paul, 1966) 
the Social Avoidance and Distress Scale (SADS, Watson & Friend, 1969) the Social Phobia 
and Anxiety Inventory (SPAI, Turner, Beidel, Dancu, & Stanley, 1989), the Social Phobia 
Subscale of the Fear Questionnaire (Marks & Mathews, 1979), the Social Situations 
Questionnaire (SSQ, Bryant & Trower, 1974), the Social Phobia and Social Interaction 
Anxiety Scale (SPS/SIAS, Mattick & Clarke, 1998), the Fear Survey Schedule (FSS, Hallam 
& Hafner, 1978) and the Unsicherheits-Fragebogen [Uncertainty-questionnaire] (Ullrich de 
Muynck & Ullrich, 1977), a commonly used and well validated scale in Germany. 
3.2.3.2. Categorization of studies 
In a second step, we categorized all studies that had provided the necessary information 
following the guidelines set up by Shadish et al. (1997). We operationalized these criteria by 
categorizing the studies according to their exclusion criteria, the heterogeneity of their sample 
and their laboratory study characteristics (see Appendix A). 
3.2.3.2.1. Exclusion criteria.  
Exclusion of participants with (a) past or present comorbid substance misuse, past psychosis 
or bipolar disorder, (b) comorbid depression, (c) comorbid further Axis I disorders, (d) 
comorbid avoidant personality disorder (APD), (e) a low degree of severity (defined by 
participants having to reach a certain score in one of the questionnaires or on a rating of 
severity scale) or (f) prior treatment for social phobia. 
3.2.3.2.2. Heterogeneity of the sample.  
(g) Were the majority (more than 60%) of the participants students or academics? (h) Were 
the participants of the sample heterogeneous in the duration of their disorder (defined by the 
standard deviation of the mean duration of disorder)? (i) Were they heterogeneous in the 
severity of their disorder on the questionnaire measures (defined by the standard deviation of 
the Social Phobia subscale of the FQ [Marks & Mathews, 1979], the FNES and the SADS 
[Watson & Friend, 1969] as these were the most frequently used measures)? (j) Was the age 
range limited? (k) Were there qualitative sample restrictions (e.g. investigating only 
musicians, only patients with comorbid avoidant personality disorder, only generalized or 
only specific subtypes)?  
3.2.3.2.3. Laboratory characteristics.  
(l) Was a large part of the sample recruited by adverts made explicitly for the study? (m) Was 
the study carried out in a university setting? Because 11 studies had not provided explicit 
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information on this aspect, we decided to categorize these studies according to their reference 
address. We judged 9 of these studies to have been carried out in a university and 2 to have 
been carried out in a clinic setting. (n) Were the therapists specifically trained doctoral 
students or researchers or were they therapists working with normal caseloads? (o) Was a 
treatment manual used? (p) Was the implementation of the manual strictly monitored? This 
was assumed if it had been pointed out explicitly in the study.  
3.3. Results 
3.3.1. Comparison of Studies According to Sample and Laboratory 
Characteristics  
Table 1 shows the mean effect size (ES) and standard deviation (SD) for each group of studies 
according to the applied sample and study criteria. Because of a number of very small sizes 
and the assumption that they may be more prone to sample error, studies were weighted with 
the root of n. The effect-sizes were then compared using t-tests with Bonferoni-adjustment for 
each comparison separately (p = 0.05/13 = .004). A significant difference in mean effect sizes 
was found for four of the comparisons. In contrast to expectations, two of these comparisons 
revealed higher effects for studies fulfilling the criteria for clinical therapy. Samples in which 
comorbid APD had been included as well as samples including patients with prior treatment 
experience reached higher effect sizes. However, studies that had excluded patients with 
comorbid psychosis, substance misuse and bipolar disorder or had been carried through 
following a treatment manual reached higher effect sizes than those who had not.  
To test a possible negative relation of the heterogeneity in age as well as duration and severity 
of disorder with the effect size, a correlation analysis was carried out. The results are 
presented in table 2. Studies working with patient samples that were more homogenous in the 
duration of disorder tended to achieve higher effect sizes and the heterogeneity of the sample 
concerning the severity of disorder was also negatively related to the effect size. The 
correlations between the age range and the standard deviation of the mean age and mean 
effect sizes were lower, with only the age range reaching significance. 
3.3.2. Effects of Accumulative Research Characteristics 
In order to estimate the accumulative effect of typical research characteristics on the effect 
size, we calculated a “general research score” for each study. To clarify whether a significant 
effect can be better explained by sample or by laboratory characteristics, we devided the 
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general score into a “sample restriction score” as well as a “laboratory score”. One point was 
given for each of the sample selection and laboratory criteria listed in table 1 and these points 
were then added up. The scores were only calculated for studies that had given information on 
the variables of interest, because too many missing values could possibly have resulted in an 
underestimation of restriction criteria applied in the study. For this reason, four of the studies 
(Cox et al., 1998; Fava et al., 1989; Kanter & Goldfried, 1979; Schelver & Gutsch, 1983) 
were omitted from the calculation. As information on the amount of students had not been 
specifically mentioned in many of the studies, this variable was also neglected in the 
calculation. For the 30 remaining samples the analysis of the general research score with the 
effect sizes revealed a correlation of r = .27 (two-tailed p ≤= .01, weighted n = 134). The 
correlation of the sample restriction score with the effect sizes revealed a correlation of r = 
.09 (two-tailed p = .28). The correlation of the laboratory score with the mean effect sizes was 
r = .32 (two-tailed p < .01).  
3.3.3. Effect of Sample Selection on the Standard Deviations  
To test the hypothesis that sample selection results in a lower standard deviation in the 
questionnaires, we tested the correlation between the sample restriction score, the age range, 
the standard deviation of age and of duration of disorder with the standard deviation of the 
Social Phobia subscale of the FQ (Marks & Mathews, 1979), the FNES and the SADS 
(Watson & Friend, 1969). Table 3 shows this analysis, revealing only the standard deviation 
of the duration of disorder to be correlated with the standard deviations of the applied 
measures. The sample restriction score was not related to a lower standard deviation in the 
questionnaires and only one of the six correlations of sample variety in age and the standard 
deviations reached significance, whereas the others did not even reveal a definite tendency.  
3.4. Discussion 
The main aim of this study was to test the hypothesis that sample selection and laboratory 
study conditions lead to higher treatment effects in comparison to clinical conditions. We 
hypothesized that sample restriction would produce homogeneous samples and that this 
would affect the effect size. We did find the standard deviations of the questionnaire measures 
at pre-treatment to be positively related to the effect sizes. However, with the exception of the 
standard deviation of the duration of disorder, our sample restriction criteria were not related 
to these standard deviations. Generally, there was not much evidence for the assumption that 
effect sizes might be explained by the failure to gain typical samples. Two of the direct group 
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comparisons even revealed the opposite effect. Patient samples that included patients with 
comorbid avoidant personality disorder and patients with prior treatment experience revealed 
higher effect sizes than samples without. Also, the results indicate that even the accumulation 
of sample restriction does not have any predictive value for the pre-post effect sizes of 
treatment. On the other hand, we found some results to be in support of the observations made 
by private practitioners and other psychotherapists working under no research conditions. 
Firstly, samples excluding patients with comorbid psychosis, substance misuse and bipolar 
disorder were shown to reach higher effects than those including these patients. The same 
applied for studies that were conducted following a treatment manual. Secondly, we found 
studies working with participants who were homogeneous in the length of their disorder to 
produce higher treatment effects than the other studies. There was strong evidence for the 
hypothesis that this relation is moderated by the size of the standard deviations in the applied 
measures, which, in turn revealed moderate to high correlations with the standard deviation of 
the duration of disorder and moderate correlations with the effect size. Thirdly, and more 
important than these single findings, is the influence of accumulated laboratory criteria for 
research studies on the effect size. We found a significant tendency for studies applying 
laboratory treatment conditions, such as recruiting patients by adverts, applying treatment in 
university settings, using specifically trained therapists and following and monitoring 
treatment manuals to achieve higher effect sizes.  
It must be noted, though, that the current study is characterized by certain difficulties 
complicating the interpretation of results. One very small study sample (Fava et al., 1989) 
revealed a mean effect size of 4.75 thus being far out of the range of the other effect sizes, 
ranging from 0.3 to 1.8 (see Appendix). However, we considered the size of the effect an 
insufficient reason for omitting a study. Also, we were interested in securing a large 
variability of studies. By weighting the studies with the root of n we tried to prevent effect 
sizes from very small samples from having too much influence on the results. The study by 
Fava et al., which fulfils most of the criteria for a clinical study, still remains responsible for 
some of the rather large standard deviations of the mean effect sizes in the group comparisons 
(see table 1). Without it, more of the comparisons would have had a stronger tendency 
towards significantly higher effect sizes for the studies applying research characteristics, two 
more (qualitative sample restrictions and recruiting by adverts) even reaching significance.  
The interpretation of the single group differences is complicated by the inter-correlations of 
the laboratory or sample characteristics. For example the laboratory characteristics are all 
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positive ranging from .25 to .65, suggesting the possibility that some of them might be more 
relevant than others or that they might cancel each others effects. However, a linear regression 
analysis of these characteristics with the effect size as dependent variable supported the 
finding that the use of a treatment manual is the most important predictor of the effect sizes. 
Generally, significance testing in this study has to be interpreted with caution as the case 
numbers were artificially raised by the weighting procedure. As an alternative, the size of the 
differences can be considered, ranging between 20 and 35% for the significant findings. 
It could also be argued that sample restriction factors could be confounded with other study 
factors, that affect pre-post effect size, e.g. treatment effectiveness, amount of treatment, type 
of outcome measure and that we cannot necessarily assume that these are equally distributed 
across all the comparisons made. However, the amount of treatment was fairly similar across 
studies and the majority of studies had used more than two outcome measures. Also, by 
choosing studies with similar treatment approaches we tried to rule out large differences in 
treatment effectiveness.  
Another limitation could be seen in the fact that most of the studies were controlled efficacy 
studies carried out under typical research conditions. Only a minority of the studies fulfilled 
many of the criteria listed by Shadish et al. (1997) for being clinically representative. None of 
the samples were heterogeneous in their focal presenting problems, which was one of the 
criteria Shadish et al. had set up for clinic therapy. All patients suffered from social phobia or 
severe social inhibition as primary problem. On the other hand, there is no compelling reason 
hindering practitioners from treating patients according to their primary diagnosis.  
Finally the number of study samples was very small and not all authors had given precise or 
sufficient information on the variables of interest. This resulted in very low case numbers for 
some of the comparisons. It may also have resulted in some failures to classify studies 
correctly (e.g. concerning the place in which the treatment was carried out or the monitoring 
of the treatment manual).  
The optimal conditions in testing the hypothesis would obviously have been a set of about 60 
studies all applying the same treatment with varying sample selection and study conditions 
and noting precise information on these conditions. As this was not the case, we had to make 
the best of the available studies. 
In summary, the data are in line with Shadish et al. (1997), in finding a tendency for studies 
applying a row of research criteria to reveal slightly lower effect sizes. However, it does not 
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seem to be the impossibility of restricting their samples that could hinder private practitioners 
from achieving equal effects. It is the accumulation of laboratory characteristics, such as 
recruiting patients, the place of the study, the training of therapists or the implementation of a 
treatment manual that correlate positively with treatment effects. These findings give reason 
to hope, because they imply that researchers as well as practitioners can add to bridging the 
(small) gap between research and clinical practice. Researchers could try and conduct their 
treatment research under more natural conditions with health service users. On the other hand, 
therapists working in clinical practice would be well advised to follow treatment manuals and 
attend regular disorder specific training or supervision.  
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Table 3.1. 
Mean pre– post effect sizes for social phobia treatment according to sample and laboratory 
characteristics  
 applies does not apply  
 ES    (SD) n    (N) ES    (SD) n    (N) p 
Sample Restriction Criteria      
(a) exclusion of comorbid psychosis, 
substance misuse or bipolar disorder  
0.94 (.34) 25 (112) 0.77 (.22)   4 (23) * 
(b) exclusion of comorbid depression  0.91 (.33) 17 (71) 0.92 (.32) 12 (63)  
(c) exclusion of comorbid axis I 
disorder  
0.93 (.32) 11 (46) 0.91 (.33) 18 (88)  
(d) exclusion of comorbid APD 0.75 (24)   6 (25) 0.95 (.33) 23 (109) * 
(e) exclusion of low severity 1.03 (.38) 12 (49) 1.00 (.70) 21 (103)  
(f) exclusion of prior treatment  0.71 (.39)   6 (32) 1.10 (.63) 26 (116) * 
(g) majority of sample are students  1.05 (.40) 11 (47) 1.21 (.99)   7 (42)  
(k) qualitative sample restrictions 1.17 (.39) 10 (40) 0.96 (.67) 23 (112)  
Laboratory Characteristics      
(l) patients recruited by adverts 1.03 (.40) 19 (89) 0.98 (.83) 14 (63)  
(m) carried out in a university setting 1.02 (.74) 17 (74) 1.00 (.75) 16 (77)  
(n) using specially trained therapists  1.03 (.31) 19 (91) 1.10 (.95) 11 (49)  
(o) following a treatment manual 1.05 (.65) 31 (132) 0.79 (.04)   2 (20)  * 
(p) monitoring treatment manual 1.01 (.36) 16 (72) 1.02 (.77) 17 (79)  
* = p ≤  .004; ES = mean effect size, n = number of samples, N = n weighted by the root of the sample size. 
3. How much do Sample Characteristics Affect the Effect Sizes?   41 
Table 3.2. 
Intercorrelations Between Effect Sizes and the Heterogeneity of the Sample Concerning Age, 
Duration of Disorder and Severity  
  Age range SD Age SD Duration SD FNES SD FQ, SP SD SADS 
ES -.20* 
(N = 98)* 
-.19  
(N = 102) 
-.33** 
(N = 71) 
-.42** 
(N = 61) 
-.45** 
(N = 76) 
-.43** 
(N = 47) 
* = p ≤  .05, **; p ≤  .01; N = number of samples weighted by the root of the sample size; FNES = Fear of 
Negative Evaluation Scale; FQ, SP = Social Phobia subscale of the Fear Questionnaire; SADS = Social 
Avoidance and Distress Scale. 
 
Table 3.3. 
Intercorrelations Between Sample Restriction, Sample Variance and the Standard Deviations 
of the Social Phobia Questionnaires  
 Restriction Score Age range SD Age SD Duration 
SD FNES -.15 (N= 47) -.22 (N= 31) -.04 (N= 32) .61 (N= 24)** 
SD FQ, SP .19 (N=68) -.19 (N= 46) .29 (N= 60)* .47 (N= 51)** 
SD SADS .18 (N= 37) .22 (N= 32) .15 (N= 24) .94 (N= 13)** 
* = p ≤  .05, **; p ≤  .01; N = number of samples weighted by sample size; FNES = Fear of Negative Evaluation 
Scale; FQ, SP = Social Phobia subscale of the Fear Questionnaire; SADS = Social Avoidance and Distress Scale. 
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4. STUDY II 
Effectiveness of an Empirically Supported Treatment for 
Social Phobia in the Field3 
4.1. Introduction 
How well do the results of empirically supported treatments hold up in actual clinical practice 
(Wade, Treat, & Stuart, 1998)? It is often argued on behalf of private practitioners and other 
psychotherapists working under no research conditions that their patients obviously differ 
from the research samples and that they therefore do not obtain as good results as those 
reported in the given literature. Chambless & Hollon (1998) point out “a growing recognition 
that controlled clinical trials may not capture the full richness and variability of actual clinical 
practice” (p. 14). Writers have recently begun to distinguish between the efficacy of 
psychotherapy and its effectiveness (Weisz, Donenberg, Han, & Weiss, 1995). Efficacy (or 
research therapy) refers to the effects of psychotherapy in randomised, controlled trials, 
usually conducted in university settings involving recruited patient clients, using a highly 
structured treatment manual for a narrow problem focus and trying to establish a high degree 
of internal validity. Effectiveness (or clinical therapy) refers to the effects of natural clinical 
psychotherapy conducted in the field, which means in private practice or in mental health 
centres, using quasi-experimental designs and trying to establish a high degree of external 
validity or generalization of results to various settings.  
While the efficacy of psychotherapy is generally well established, the generalization of 
efficacy findings can be challenged. Weisz, Weiss, and Donenberg (1992) found for child and 
adolescent therapies that “research focused on more representative treatment of referred 
clients in clinics has shown more modest effects. In fact, most clinic studies have not shown 
significant effects” (p. 1578). Recently, Shadish, Matt, Navarro, Siegle, Crits-Christoph, 
Hazelrigg, et al. (1997) conducted a secondary analysis of past meta-analytic data and found 
very few studies, which were even remotely clinically representative. For a study to pass as 
                                                 
3 Reprinted from Behaviour Research and Therapy (in press). Lincoln, T.M., Rief, W., Hahlweg, K., Frank, M., 
von Witzleben, I., Schröder, B., Fiegenbaum, W., Effectiveness of an empirically supported treatment for social 
phobia in the field. Copyright 2003 with permission from Elsevier. 
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clinical, it had to be carried out in non-university settings, involve patients that were referred 
through usual clinical routes, involve experienced, professional therapists with regular 
caseloads and free to use a wide variety of procedures in treatment rather than therapists in 
training or trained specifically for the purpose. The therapists were also not to have used a 
treatment manual and the implementation of the treatment was not to have been monitored. 
Finally, the studies were to have involved clients who were heterogeneous in personal 
characteristics as well as in focal presenting problems. Only one study fulfilled the authors’ 
complete set of criteria for clinical therapy. However, studies that fulfilled a certain degree of 
the criteria revealed effect sizes that were about 10% smaller than those of the complete set of 
therapy studies. This finding seems to support the doubts of practitioners concerning the 
transferral of research findings and underlines the necessity of further investigation.  
In the area of social phobia there is a large body of support for cognitive behavioural therapy. 
Four meta-analyses have found average uncontrolled pretest-posttest effect sizes for the 
reduction of social phobic anxiety ranging from 0.80 (Fedoroff & Taylor, 2001), 0.90 (Feske 
& Chambless, 1995), 1.06 (Taylor, 1996) to 1.07 (Ruhmland & Margraf, 2001). The mean 
controlled effect size was found to be 0.84 (Gould, Buckminster, Pollack, Otto, & Yap, 1997). 
Effect sizes were also high for general anxiety (Ruhmland & Margraf, 2001) but slightly 
lower for the reduction of depressive symptoms (Feske & Chambless, 1995) after treatment 
for social phobia.  
However, most of the reported studies are characterized by sample selection criteria and thus 
do not reflect usual patient samples in clinical settings. Typically, the researchers had 
excluded patients with comorbid major depression, patients with prior treatment, patients 
outside a certain age range (e.g. 20-50 years), and patients with light to moderate impairment, 
with many studies even excluding patients with further Axis I disorders. Furthermore, several 
studies only investigated specific subsamples of patients with social phobia, such as physical 
reactors, specific subtypes, only musicians or only patients without a partner. All studies were 
conducted following a treatment manual and most of them involved specifically trained 
doctoral students and monitored the use of a treatment manual. Also, most of the studies 
involved patients recruited by newspaper advertisements, often offering free treatment in 
return for agreeing to take part in the study. Many of the studies were carried through in a 
university setting, involving mainly student participants. However, in a previous study 
(Lincoln & Rief, 2002), we found that none of the applied sample restriction criteria resulted 
in higher effect sizes. The data indicated that involving recruited patients and restricting the 
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variety of the sample in order to achieve a high degree of internal validity did not lead to an 
overestimation of effects in comparison to more clinically oriented studies. A limitation of the 
study was that the investigated samples were not clinical in the way defined by Shadish et al. 
(1997). With exception of the study we are going to present in this article, all of the studies 
were to be classified as efficacy studies with varying amounts of sample restriction and 
laboratory study conditions. Thus, generalization studies are needed to explore the 
transportability of empirically supported treatments to the field of outpatient psychotherapy 
(Wilson, 1996).  
Three recent generalization studies were conducted in Germany. Wetzel, Bents, and Florin 
(1999) examined exposure therapy with response prevention for obsessive-compulsive 
disorder and found results to be comparable with those in controlled studies. Tuschen-Caffier, 
Pook, and Frank (2001) evaluated the effectiveness of cognitive behavioural therapy for 
bulimia nervosa. The effect sizes were in the range of those found in controlled research. 
Similarly Hahlweg, Fiegenbaum, Frank, Schroeder, and von Witzleben (2001) evaluated the 
effectiveness of individual high-density exposure for panic disorder with agoraphobia and 
also found the effect sizes to be comparable with the average effect sizes reported by meta-
analytic studies of controlled efficacy research. 
The only study on social phobia partly studying generalization to clinical practice was a study 
investigating exposure therapy in general practice (Haug, HellstrØm, Blomhoff, Humble, 
Madsbu, & Wold, 2000). Although this study qualified as being clinical in the sense that it 
was carried out in and adapted to clinical conditions, a number of laboratory research aspects 
remained. More than a third of the participants were recruited by newspaper advertising, all 
comorbid Axis I diagnoses were excluded as well as treatment for social phobia within the 
previous six months. Finally, it can be assumed that having to give consent to a randomisation 
to one of the four treatment groups, which also included medical treatment, could have 
resulted in further sample selection as reported by Juster, Heimberg, and Engelberg (1995), 
who found differences between patients who agreed to random assignment to treatment 
conditions and those who did not. However, the groups responded similarly to cognitive 
behavioural treatment. So far, no study has tested the hypothesis whether treatment for social 
phobia can be delivered with the same effectiveness in a clinical setting, in which patients are 
not recruited by adverts, not randomised to treatment groups or preselected in a way typical 
for research but are part of the usual referral system and medical routine. The current study is 
an attempt to investigate the generalization of an empirically supported treatment for social 
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phobia to a clinical setting. The effectiveness of exposure combined with cognitive 
restructuring will be examined in four outpatient clinics in the community and a large number 
of experienced and inexperienced therapists and will address the following question: Does an 
effectiveness study of social phobia treatment deliver results comparable to those of efficacy 
studies?  
The study also investigates the possibility that the effect-size could be enhanced by restricting 
the sample of patients according to the criteria employed in research settings, by addressing a 
second question: Which effect does sample selection have on the effect sizes in the current 
sample?  
4.2. Method 
4.2.1. Setting 
The Christoph-Dornier Foundation for Clinical Psychology (CDS) was founded in 1989 with 
the aim of promoting research and clinical practice in clinical psychology. The CDS runs 
seven outpatient clinics in Germany, in which patients with a variety of disorders are treated, 
in particular patients with anxiety disorders. Patients are referred from different sources; for 
example, general practitioners, psychotherapists, psychiatric hospitals or they come because 
they have heard about the CDS. In most cases the patient’s health insurance company paid 
treatment or part of treatment, but patients had to take the trouble of applying for the 
reimbursement of expenses.  
4.2.2. Participants 
Participants were 217 patients who agreed to undergo treatment in one of four CDS outpatient 
clinics in the cities of Marburg (MB; founded in 1989), Dresden (DD, founded in 1994), 
Braunschweig, (BS, founded in 1995) and Münster (MS, founded in 1993). All patients were 
diagnosed with social phobia as the primary disorder with a structured interview (see below) 
according to the criteria listed in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-III-R, 3rd ed., revised, American Psychiatric Association, 1987), meaning that social 
phobia was judged by the patients to be the most severe disorder and the one for which they 
wished treatment. Patients were not preselected in any way, with the exception of medical 
conditions not allowing for high-density exposure treatment. The institute in Marburg 
contributed 45%, Dresden 26%, Braunschweig 16% and Münster 13% of the participants.  
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The mean age of the sample was 33.7 years (SD = 10.3, range 12 – 65). Fifty-seven percent of 
the patients were male, 3% had not completed school, 34% completed secondary school, 
which compromises the two lower schools in the German school system, 32% completed high 
school and 31% had a university degree. Sixty percent of the patients were employed, 13% 
were unemployed, housewives or in retirement and 27% were students or in apprenticeship. 
Forty-eight percent were married or lived together with a partner, 63% were childless.  
The mean age at onset of the disorder was 19.8 years (SD = 9.6). Eighteen percent report the 
disorder having begun before the age of 13, whereas another 32% report the beginning of the 
disorder having been during adolescence (13-18 years). The mean duration of disorder was 
13.6 years (SD = 11.1, range 0-57). Patients were diagnosed with generalized social phobia if 
they reported anxiety to be at least moderate in three or more from a list of twelve social 
situations in the clinical interview and if at least two different situational domains (formal 
speaking and interaction, informal speaking and interaction, observation of behaviour, and 
assertive interaction) were represented. Each interview protocol was checked by two raters, 
who agreed in 88% of the cases and came to a joint decision in unclear cases. Ninety percent 
were classified as generalized subtype, 10% as specific subtype. The ratings of severity were 
low (1-3) for 3% of the patients, moderate (4-6) for 64% and high (7-8) for 33% of the 
patients.   
Eighty percent had already undergone therapy: sixty-six percent had undergone some form of 
psychotherapy, 38% had received professional medical treatment for social phobia and 23% 
had already been hospitalised in an institution for mental health. Sixty-eight percent were 
using anxiolytic, antidepressive, neuroleptic or another kind of medication for their anxiety. 
Forty-four percent had at least one comorbid Axis I disorder. Assessment of Axis II 
comorbidity was not integrated as a regular part of the diagnostic interview. This limitation is 
due to financial restrictions set by the insurance companies and a different emphasis at the 
beginning of data collection.  
4.2.3. Treatment 
Typically, the patients were treated with high density in vivo exposure supplemented by 
cognitive interventions. The highly individualized treatment consists of three main phases:  
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4.2.3.1. Psychological and medical assessment  
Psychological assessment (4-6 sessions) is described in detail below. A medical check-up is 
particularly important in the context of exposure since this can be physiologically stressful 
and may be contraindicated (e.g. for patients with coronary heart disease). 
4.2.3.2. Diagnostic feedback and cognitive preparation  
Cognitive preparation for therapy takes place about one week later and is necessary to 
enhance the patient’s motivation for treatment. The patient’s core assumptions about the 
aetiology of social phobia are integrated into a model that is able to explain the way in which 
specific patterns engender and maintain social anxiety. Implications for therapy are then 
delineated on the basis of this model. Detailed information on the strategies of high-density 
exposure is provided and in this context the precondition of discontinuation of medication is 
explained. The patient is given 5-10 days to decide whether to participate in the treatment. 
The preparation phase is described in detail by Tuschen and Fiegenbaum (1997). It is not 
considered as actual treatment, but as a preparation for treatment. For this reason, patients (n 
= 24) who discontinued after this stage are considered as refusers rather than dropouts.  
4.2.3.3. High-density exposure combined with cognitive interventions 
When the patient decides to participate, exposure and cognitive intervention begin. The 
program is characterized by short treatment duration, usually lasting about five to seven days. 
The therapist is in close contact with the patient during the first days, during which it is not 
unusual for treatment to last for six to eight hours. The intensive treatment phase is followed 
by a self-control phase of six weeks, in which patients are instructed to continue exposing 
themselves to the feared situations in their everyday life. The self-control-phase is extensively 
prepared with the patient and additional support in the form of regular telephone contacts or 
additional treatment sessions is given when necessary. At the end of the self-control phase, 
the therapist and patient analyse the progress and the patient is motivated to integrate the 
interventions more and more into everyday life. 
Exposure to the feared situations plays a central role in the therapy as it serves several 
purposes. It is used to experience a certain degree of habituation to the situation. It also serves 
to assess and correct core amplifying cognitions as well as safety behaviours and failure 
focused attention. If possible, an audience used for the exposure situation can also function as 
giving feedback in order to correct dysfunctional self-perception. The exposure situations are 
chosen depending on the patients’ individual fears and starting with those feared most.  
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For example, if one of the most feared items is serving drinks while being observed by other 
people, the therapist will invite an audience in order to confront the patient with this situation. 
The exposure is extensively prepared with the patient. Expectations about the way the patient 
feels he or she is going to be perceived are noted and criteria for success are defined. The 
patient also decides on which aspects he or she would like to have feedback from the 
audience. The degree of perceived fear is rated on a scale from 0 (no fear) to 10 (maximum 
fear). The therapist interrupts the performance to assess the amount of perceived anxiety and 
instructs the patient to continue until habituation has taken place. A co-therapist videotapes 
the exercise. The audience is then asked to give the specific feedback defined before the 
exposure. Finally, the exposure situation and the feedback is discussed with the patient, using 
it as a natural segue into restructuring interventions in which the patient is taught to identify 
and challenge specific negative thoughts and general cognitive errors (e.g. because I feel bad, 
I must be performing badly) and perfectionist thinking (e.g. a less-than-perfect performance is 
a failed performance). The video feedback is used as an objective feedback and helps to detect 
safety behaviours.  
Generally therapists are free to vary the amount of exposure and cognitive therapy as well as 
the length of the intervention according to the needs of the individual patient. They are also 
free to use additional specific interventions for the treatment of comorbid disorders. 
4.2.4. Therapists 
Treatment was conducted by 57 diploma psychologists (roughly equivalent to a master’s 
degree; 57% were female, 43% were male) with training in behaviour therapy, who are 
doctoral students of the CDS. The directors of the respective CDS outpatient clinic supervise 
treatment extensively. Training in high-density exposure was not delivered in a standardized 
way and was comparable with procedures described by Wade, Treat and Stuart (1998). 
Training of novice therapists consisted in reading the relevant literature, viewing videotapes 
of treatment sessions, attending the supervision sessions and participating as a co-therapist to 
more experienced therapists or the clinic director in the treatment of at least two patients. 
Therapists differed in experience: inexperienced therapists (total number of patients treated 
with any disorder 1-10) treated 22% of the patients, therapists with medium experience (11-
20) treated 43% and experienced therapists (≥  21, range 21- 60) treated 35% of the patients.   
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4.2.5. Measures 
Patients were assessed before therapy (pre) with aid of a diagnostic interview as well as an 
extensive self-report assessment battery, which was also completed 6 weeks after the end of 
treatment (post). 
4.2.5.1. Diagnostic Interview 
The diagnosis was determined by a reliable and valid structured clinical interview for DSM-
III-R. The Diagnostisches Interview bei Psychischen Störungen (DIPS) [Diagnostic Interview 
for Psychological Disorders] (Margraf, Schneider, & Ehlers, 1991) is the German version of 
the Anxiety Disorders Interview Schedule – Revised (ADIS-R, DiNardo, Barlow, Cerney, 
Vermilyea, Vermilyea, Himadi, et al., 1986). The ADIS-R/DIPS is a semi-structured 
interview with well-established psychometric properties. The therapists, all of whom had 
received intensive training in the use and scoring of the instrument, conducted the interviews. 
The clinical director of the respective outpatient clinic reviewed each case. In difficult cases, a 
consensus diagnosis was derived jointly. 
4.2.5.2. General impairment 
4.2.5.2.1. Symptom Checklist-90-Revised (SCL-90-R, Derogatis, 1994; German version: 
Franke, 1995). The SCL-90-R is a 90-item questionnaire assessing nine primary symptom 
dimensions and a Global Severity Index (GSI), based on all 90 items. The GSI is used to 
measure the intensity of the perceived distress. Internal consistency for the German version of 
the SCL-90-R is .97. It is frequently used as part of psychotherapy evaluation.  
4.2.5.2.2. Questions on Life Satisfaction (FLZ M, Henrich & Herschbach, 2000; German 
Version: Henrich & Herschbach, 1996). The FLZ M is a short questionnaire for assessing 
general and health related quality of life. The questionnaire consists of two eight-item 
modules, “General Life Satisfaction” and “Satisfaction with Health”. The respondent rates 
each item twice, once for the subjective importance of the aspects of life or health addressed 
and once for the degree of satisfaction in that area. The two ratings are combined to a 
weighted satisfaction score. Internal consistency for the German version is .82 for General 
Life Satisfaction and .89 for Satisfaction with Health. As the FLZ M was not given to patients 
from the beginning, calculations can only be made for a smaller sample of n = 65 (FLZ-GA) 
and n = 73 (FLZ-GG). 
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4.2.5.3. Social phobia measures 
2.5.3.1. The subscale Interpersonal Sensitivity of the SCL-90-R. This scale assesses feelings 
of social uncertainty as well as fears of being observed or judged negatively. Internal 
consistency for the German version of the subscale is .86. 
2.5.3.2. Social Phobia Scale and Social Interaction Anxiety Scale (SPS/SIAS, Mattick & 
Clarke, 1998; German Version: Stangier, Heidenreich, Berardi, Golbs, & Hoyer, 1999). The 
SPS/SIAS is a 40-item self-report questionnaire, consisting of two scales assessing the fear of 
being observed and evaluated by others as well as interaction anxiety. Internal consistency for 
the German version is .94 for SIAS and .94 for SPS and sufficient validity data are provided. 
As the SPS/SIAS was not given to patients from the beginning, calculations can only be made 
for a smaller sample of n = 117 (SPS) and n = 116 (SIAS).  
2.5.3.3. Self-rating of impairment due to social phobia. Patients rated on a 5-point rating scale 
to what extent they felt impaired by their social anxiety in their work, their free time and 
social activities, and in their family life (0 = not at all, 1 = a little, 2 = moderately, 3 = 
severely, 4 = extremely).  
4.2.5.4. Related fears and avoidance 
4.2.5.4.1. Body Sensation Questionnaire (BSQ, Chambless, Caputo, Bright, & Gallagher, 
1984; German version: Ehlers, Margraf, & Chambless, 1993). The BSQ is a 17-item 
questionnaire to assess anxiety with regard to bodily symptoms, such as sweating or 
palpitations, which is common in patients with social phobic fears. This is shown by 
significant correlations (r =.39) with the SPS (Heinrichs, Hahlweg, Fiegenbaum, Frank, 
Schroeder, & von Witzleben, 2002). The German version has an internal consistency of 0.85.  
4.2.5.4.2. Agoraphobic Cognition Questionnaire (ACQ), Loss of Control subscale 
(Chambless, et al., 1984; German version: Ehlers et al., 1993). The ACQ is a 14-item 
questionnaire to assess anxiety/agoraphobic cognitions. The Loss of Control scale contains 
some items reflecting typical social phobic fears (e.g. I am going to act foolish). Internal 
consistency for the German version is .75. 
4.2.5.4.3. The subscale Anxiety of the SCL-90-R. This scale describes physical symptoms of 
anxiety as well as nervousness, tension and worries. Internal consistency for the German 
version is .88. 
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4.2.5.5. Depression 
4.2.5.5.1. Beck Depression Inventory (BDI, Beck & Steer, 1987, German version: Hautzinger, 
Bailer, Worall, & Keller, 1995). The BDI is a 21-item self-report questionnaire used to assess 
the severity of depression and common cognitive, affective and somatic symptoms of 
depression. Internal consistency for the German version is .88 and sufficient validity data are 
provided. Furthermore, the reliability and validity of the BDI have been specifically affirmed 
in patients with social phobia (Coles, Gibb, & Heimberg, 2001). 
4.2.5.5.2. The subscale Depression of the SCL-90-R. This scale includes feelings of slight 
depressiveness as well as symptoms of severe depression. Internal consistency for the German 
version is .89. 
4.2.5.6. Rating of improvement 
We used a 7-point rating scale (1 = very much better, 2 = much better, 3 = better, 4 = no 
change, 5 = worse, 6 = much worse, and 7 = very much worse) to assess the subjective 
improvement due to the therapy. Patients and therapists rated the degree of improvement six 
weeks after therapy (post). 
4.3. Results 
Data analysis was performed in a series of steps. First, treatment completers were compared 
with patients who dropped out during treatment or those who failed to complete the post-
assessment. Second, in a preliminary analysis, differences between the four outpatient clinics 
and between inexperienced and experienced therapists were analysed. In a third step, patients 
who had completed SPS (n = 85), SIAS (n = 84), FLZ-GG (n = 73) and FLZ-GA (n = 65) at 
pre and post were compared with the rest of the sample to test the possibility of generalizing 
their results to the complete sample and pre-post comparisons and consumer satisfaction were 
calculated. Fourthly, we considered effect sizes and the percentages of reliably and clinically 
significantly improved patients (Jacobson, Follette, & Revenstorf, 1984). Finally, in order to 
answer the question of whether the effect size is influenced by sample restriction, we 
compared subgroups characterized by the different exclusion criteria or specific sample 
characteristics as found in the efficacy studies to the remaining sample.  
4.3.1. Comparison of Treatment Completers and Dropouts 
Of the 217 patients who agreed to undergo treatment after the cognitive preparation phase, 18 
(8%) dropped out during treatment. The following reasons were given for dropping out during 
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treatment: The therapy seemed to hard to endure, the patient was transferred to another 
institution, the insurance refused to cover the costs, there were organizational difficulties or 
doubts regarding the rational for the treatment. Another 24 patients (11%) completed the 
treatment but did not send back the follow-up-questionnaires at post-assessment. Table 1 
shows a comparison of pretreatment variables for dropouts, treatment completers with 
missing follow-ups and treatment completers who participated in follow-ups. Univariate 
analysis of variance (ANOVA) with Tukey-HSD post hoc tests for continuous variables were 
used to examine differences between the groups. Post-hoc tests revealed no significant 
differences between treatment completers and patients with missing follow-ups on continuous 
variables. However, a comparison of treatment completers with dropouts during therapy 
revealed two significant differences: First, dropouts scored higher on the SCL-GSI. A more 
detailed analysis found significant post-hoc differences on the subscales depression (p ≤  .05), 
phobic anxiety (p≤  .01) and obsessive compulsive (p ≤  .05). Second, dropouts scored highly 
on the BDI, with a mean score of 22.7 (SD = 11.7), which indicates a severe level of 
depression (Hautzinger et al., 1995), compared to patients with missing follow-ups (18.3, SD 
= 11.6) and treatment completers (14.8, SD = 10.1). 
Chi-square-tests were used to examine differences between the groups on categorical 
variables. Dropouts from therapy were diagnosed significantly (Pearson’s Chi-square = 10.8, 
df = 2, two-tailed, p ≤  .01) more often with at least one comorbid Axis I disorder than 
treatment completers or patients with missing follow-ups.  
No differences were found between the groups concerning the scores in the questionnaires 
assessing social phobic fears, marital and educational status, gender, age, severity and 
duration of disorder, or the amount of prior treatment.  
4.3.2. Preliminary Analyses 
Analysis of covariance testing for differences between the four outpatient clinics with pre-
scores on the SPS/SIAS and the subscale Interpersonal Sensitivity of the SCL-90-R as 
covariates yielded nonsignificant results for the post-scores on these measures, indicating that 
treatment was delivered with the same effectiveness despite the differences in setting, 
therapists, and supervision. There was also no difference in the duration of treatment between 
the four clinics, with the mean duration for the complete sample being 35 sessions (each 
lasting for 50 minutes), including the session for the first contact and 6 sessions for the 
psychological assessment.  
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Correlation of the amount of therapist experience with the average effect sizes for the social 
phobia measures showed no significant effect of experience on therapy outcome (r = .01, p = 
.873, n = 157).  
4.3.3. Treatment Outcome and Consumer Satisfaction 
The sub-sample of patients who completed the SPS/SIAS and the FLZ did not differ from the 
rest of the sample who were not given these questionnaires on the SCL-GSI or any of the 
SCL-subscales in their response to treatment, so we found it reasonable to generalize the SPS 
results to the complete sample. Pre-post-comparisons on the questionnaire-measures were 
calculated for 175 patients who completed therapy and took part in the post assessment using 
paired sample t-tests with Bonferoni-adjustment for each time comparison separately (p = 
.05/11 =.005). In table 2 the means, standard deviations with the specific t-value, degrees of 
freedom and level of significance are presented. Patient scores on all variables decreased 
highly significantly from pre to post. The same results were achieved for an intent-to-treat-
analysis with pre-post comparisons including the complete sample and assuming there had 
been no change in patients who dropped out of treatment or did not complete the post 
assessment (see table 2). The questionnaires revealed some overlap, with pretreatment 
correlations ranging from r = -.15 (FLZ-GA and SCL-AN) to r = .81 (SCL-GSI and SCL-IS). 
The SCL-GSI revealed the highest correlations with other measures. At postassessment inter-
correlations were generally higher, but revealed a similar pattern.  
After treatment the patient and the therapist rated improvement on a 7-point rating-scale. At 
post 51% of the patients rated themselves as being much better or very much better, whereas 
70% of the therapists rated their patients to be better or very much better. Forty percent of the 
patients (25% of the therapists) rated being somewhat better. Six percent of the patients (4% 
of the therapists) rated being unchanged. Finally, 3% of the patients (1% of the therapists) 
rated being somewhat worse or much worse. The inter-correlation between ratings by 
therapists and patients was r = .67.  
4.3.4. Intra Group Effect Sizes, Reliable Change, and Clinical 
Significance  
We calculated effect-sizes using the formula (Mpretest-Mposttest)/SDpretest. According to 
Cohen (1988), effect sizes for t-tests are categorized as follows: low d >.2, medium d > .5, 
and high d > .8. Jacobson et al. (1984) propose two necessary conditions a patient has to 
fulfill for being classified as improved: a) he or she must have moved from a dysfunctional 
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range to the functional range during the course of therapy. This criteria was operationalized 
using the formular (MDYSF٭ SDFUNC + MFUNC٭SDDYSF)/SDDYSF + SDFUNC), defining the cut-off 
as the point from which it is more likely that a patient has ended up in the functional 
population than in the dysfunctional population. Means for functional populations were 
looked up in the test-manuals. For the SPS/SIAS, we used the data from a normal population 
of n = 80 that had been collected in the Christoph-Dornier-Foundation from control-groups in 
other studies. This comparison group reached a mean of M = 10.69 (SD = 9.01) in the SPS 
and M = 18.36 (SD = 8.56) in the SIAS. b) there must have been change during the course of 
therapy. Here, the Reliable Change Index (RCI) was applied, with RCI = (MPRETEST – 
MPOSTTEST)/SE, with SE = SDPRETEST '1 rxx− , where 'rxx  is the reliability of the measure. 
According to Jacobson et al. (1984) a patient is categorized as improved if the RCI is higher 
than 1.96 and as detoriated if the RCI is lower than - 1.96.  
Table 3 shows the results for the outcome variables according to the different criteria. At post 
assessment effect sizes ranged from .71 to .88. on the social phobic measures (SCL-
Interpersonal Sensitivity, SPS/SIAS). They ranged from 0.39 to .89 for general impairment 
(SCL-GSI, FLZ-GA, FLZ-GG). The effect sizes ranged from 0.70 to 0.78 for related fears 
(SCL-Anxiety, BSQ, ACQ-Loss of Control) and from 0.58 to 0.68 for depression (SCL-
Depression, BDI).  
Next, using each outcome measure, the percentage of persons demonstrating reliable 
improvement or detoriation was calculated. On average 56% of the patients were reliably 
improved on social phobic fears, 41% on related fears and avoidance, 48% on general 
impairment and 41% on depression. However, 2% of the patients deteriorated in their social 
phobic fears after the treatment.  
The percentage of patients more likely to be drawn from a functional population was 
calculated for each outcome measure before and after treatment for the sample of patients 
who completed post-assessment (n = 175). Considering social phobic fears 57% were now 
more likely to be drawn from a healthy sample, the percentages were 66% for depression, 
54% for general impairment and 64% for related fears respectively. 
The ratings of impairment in important areas of everyday life provide a final source to 
estimate clinical significance. Thirty percent still rated themselves as being severely or very 
severely impaired at work (in comparison to 87% before therapy). Twenty percent still felt 
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impaired during their free time (64% before therapy) and 5% remained feeling impaired in 
their family (33% before therapy).  
4.3.5. Effects of Sample Selection  
We calculated differences between the mean effect sizes of the social phobia outcome 
measures (SCL-Interpersonal Sensitivity, SPS and SIAS) of subgroups characterized by 
exclusion criteria or sample characteristics that had been applied in the investigated outcome 
studies in contrast to subgroups for which these criteria did not apply. Common criteria 
consisted of a) excluding comorbid depression, b) excluding patients with prior psychological 
treatment for social phobia, c) excluding patients with a severity of disorder below 4 in the 
DIPS 1-8 rating-scale, and d) excluding patients older than 50 or younger than 20. Further 
frequently found characteristics were e) excluding comorbid Axis I diagnosis, f) using 
samples consisting mainly of students, g) only treating specific subtypes of social phobia, or 
h) only cognitive reacting patients (in contrast to physical reactors). Table 4.4. shows the 
differences in mean effect sizes of subgroups according to the applied criteria. Using two-
tailed t-tests we found only one significant difference that was not, however, in support of the 
hypothesis that exclusion criteria lead to higher effect sizes. The group of patients with a BDI 
of 18 or above revealed a higher mean effect size than the rest of the sample. Also, the 
accumulated application of common exclusion criteria did not lead to higher effect sizes. A 
sample of patients characterized by a BDI-score below 18, no prior treatment experience for 
social phobia, a severity of at least 4 in the DIPS rating and aged 20 to 50 did not differ 
significantly from the remaining sample of patients (see table 5) in the way they responded to 
treatment. 
4.4. Discussion 
The questions addressed in this study were whether an effectiveness study of social phobia 
treatment delivers results comparable to those of efficacy studies and whether sample 
selection and study characteristics would have resulted in higher effect sizes.  
To test whether our sample differed from research samples on relevant pretreatment variables, 
we compared it to samples in 304 comparison studies testing cognitive behavioural and 
exposure therapy that we had investigated in a previous study (Lincoln & Rief, 2002). The 
                                                 
4 the comparison studies are numbered 1-30 in the reference list 
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mean age in our sample was 34 compared to 35 (SD = 4.3) as mean age of the comparison 
studies. Forty-three percent were married or with a partner compared to 43% (SD = 19.6) in 
the comparison studies. There were slightly more men (57%) than in the comparison studies 
(51%, SD = 13.5). The duration of disorder of 13.6 years is slightly lower than the mean of 17 
(SD = 6.4) in the comparison studies. About half of the patients suffered from comorbid 
disorders, which is characteristic of patients with social phobia (Magee, Eaton, Wittchen, 
McGonagle, & Kessler, 1996). A majority of patients (66%) had already received some kind 
of psychological treatment prior to the treatment in the CDS, which is comparably high in 
comparison to epidemiological findings (Magee et al., 1996). A direct comparison of 
comorbidity and prior treatment experience with the comparison studies was not possible 
because of imprecise description in many of the studies and the fact that comorbidity and 
prior treatment were frequent exclusion criteria.  
The mean pretreatment-score on the SPS (M = 38) was higher than the mean score of M = 31 
(SD = 4.9) in comparison studies using SPS or SIAS (Cox, Ross, Swinson, & Direnfeld, 1998; 
Gruber, Moran, Roth, & Taylor, 2001; Heimberg, Liebowitz, Hope, Schneier, Holt, 
Welkowitz et al., 1998; Mattick, Peters, & Clarke, 1989; Otto, Pollack, Gould, Worthington, 
McArdle, Rosenbaum et al., 2000; Stangier, Heidenreich, Peitz, Lauterbach, & Clark, in 
press). The score in the SIAS (M = 40) was comparable to the SIAS score in the comparison 
studies (M = 41, SD = 4.3). The same accounts for the mean BDI score (M = 15) compared to 
a mean of M = 14.5 (SD = 2.9) in comparison studies using the BDI (Cox et al, 1998; Gruber 
et al., 2001; Heimberg, Dodge, Hope, Kennedy, Zollo, & Becker, 1990; Jerremalm, Jansson, 
& Öst, 1986; Stangier et al., in press). A specific comparison with German outcome studies 
(Stangier et al., in press; Wlazlo, Schroeder-Hartwig, Hand, Kaiser & Münchau, 1990) also 
yielded no major differences.  
To summarize, the characteristics of the investigated, unselected group of social phobic 
patients were similar to treatment-groups reported in the literature, with the exception of a 
slightly higher percentage of men, a slightly higher score in the SPS, and possibly a higher 
ratio of patients with generalized social phobia, which might also be due to the rather liberal 
criteria applied for subtype discrimination. The duration of disorder for the patients in our 
study was shorter than the mean duration in the comparison studies, but longer than in the 
German comparison study (Wlazlo et al., 1990). Thus, it is possible that people suffering from 
social phobia in Germany do not wait as long before they seek help as patients in the United 
States, where most of the comparison studies were conducted. The average of 28 treatment 
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sessions was higher, but in the range of the average 22 sessions in the comparison studies (SD 
= 9). It must be noted though, that many of these are group treatments and individual 
treatments typically consisted of fewer sessions (M = 17, SD = 8), making the number of 
sessions in our study appear definitely higher. Possibly, additional treatment sessions were 
needed in our study to attend to comorbid disorders. However, it is important to keep in mind 
that some patients in controlled outcome studies with fixed numbers of sessions were offered 
additional treatment after post-assessment, which might have lead to further improvement not 
reflected in the pre-post effect sizes of these studies.  
The present study fulfils most of the criteria for a clinically representative study as defined by 
Shadish et al. (1997): (a) treatment was conducted in a non-university setting, (b) involved 
patients referred through usual clinical routes, (c) used patients heterogeneous in personal 
characteristics, (d) therapists did not use a treatment manual, (e) therapists were free to use a 
variety of procedures and were not restricted to a fixed number of sessions and (e) 
implementation of the treatment manual was not monitored. 
Two criteria were not met: (f) homogenous patients with regard to primary diagnosis (social 
phobia) were included instead of patients heterogeneous in focal presenting problems, and (g) 
only about 50% of the therapists can be regarded as experienced and the majority of therapists 
were still in their post-graduate 5-year psychotherapy training. Also, the therapists were 
doctoral students, which is more typical of efficacy studies. However, the therapists did work 
with regular caseloads and did not receive training specifically for the research study. On top 
of this, as Hahlweg et al. (2001) also pointed out, using experienced therapists only may not 
be a valid criteria for clinically representative studies, because there are varying levels of 
expertise among therapists working in institutions such as community mental health centres or 
psychiatric in-patient facilities. Therefore, from our point of view, the present study can be 
regarded as clinically representative. 
The outcome results six weeks after the end of treatment for patients completing the 
intervention provide support for the clinical effectiveness of exposure combined with 
cognitive interventions for patients with social phobia. Fifty-six percent of the patients were 
reliably improved on social phobic fears and 57% were more likely to be drawn from a 
healthy population sample six weeks after the end of therapy. The rate of patients who felt 
impaired in important areas of their life dropped significantly, indicating that patients 
succeeded in transferring the effects of therapy into their every-day-life. The mean effect size 
for the measures of social phobia was 0.82, thus being within, but at the bottom range of  the 
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effect sizes reported in the meta-analyses (Fedoroff & Taylor, 2001; Feske & Chambless, 
1995; Gould et al, 1997; Ruhmland & Margraf, 2001; Taylor, 1996).  
No higher effect sizes were attained when the sample was restricted, applying frequently used 
selection criteria. In the contrary, more depressed patients profited more. Even the 
accumulation of common restriction criteria did not result in a higher effect size. Thus, the 
absence of sample restriction in this study could not be made responsible for the slightly 
lower effect size in comparison to the meta-analyses. It also seems unlikely that the slight 
reduction of the effect size can be explained by sample differences. An explanation could be 
that most comparison studies are based on the Fear of Negative Evaluation Scale (Watson and 
Friend, 1969) or the Fear Questionnaire (Marks & Mathews, 1979) which have been reported 
to have larger treatment sensitivity, resulting in larger effect sizes than the SPS/SIAS (Cox et 
al. 1998). For a direct comparison with studies using the SPS/SIAS, we calculated the effect 
sizes based on SPS/SIAS using the formular Mpretest – Mposttest/SDpretest for the six other 
outcome studies mentioned above that had applied either SPS or SIAS or both measures at 
pre- and posttreatment. These studies achieved a mean of effect size 0.63 (SD = .35) for SPS 
and 0.51 (SD =.21) for SIAS which is lower than the ones achieved in the current study, being 
0.88 and 0.86 respectively. None of the 29 comparison studies used the Interpersonal 
Sensitivity scale of the German version of the SCL-90-R, so that a direct comparison was not 
possible here. However, five studies (Heimberg et al, 1998; Mersch, 1995; Scholing & 
Emmelkamp, 1993a and 1993b; Stangier et al., in press) did use some form of the SCL-90-R 
or specific subscales. Effect sizes based on these scales reach a mean effect size of 0.55, 
which is also lower than the effect size of 0.71 that we found for the SCL-90-GSI. In the light 
of these findings it seems reasonable to conclude that the effect size found in the present study 
is comparable with the mean effect sizes found in the meta-analyses. 
Given the large sample size and the number of therapists and institutes involved, it also seems 
justified to conclude that exposure combined with cognitive intervention can be transported to 
the treatment of patients with social phobia in natural settings, without reducing its 
effectiveness. Additionally, we found therapist experience to be unrelated to outcome, which 
is in line with other findings summarized by Bickman (1999), who pointed out the necessity 
of conducting such studies in a natural environment. 
One shortcoming of the present study is the amount of patients (11%) who could not be 
motivated to complete the follow-up questionnaires at post assessment. We found a tendency 
for them to occupy an intermediate position between the completers and the dropouts, who 
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differed significantly from one another on some of the measures. Thus, the question can be 
raised whether this group of patients differs from the sample of completers concerning the 
effectiveness of the treatment. On the other hand, 9 of the 24 patients with missing follow-ups 
agreed to give a rating of improvement, with 7 (77%) rating themselves as better or much 
better (compared to 52% of the completers), which suggests that they improved at least 
equally. The amount of missing follow-ups can be explained by the fact that in three of the 
outpatient clinics, there was no financed personnel to organize the follow-ups. Only 8% 
actually dropped out of treatment, which is low compared to the outcome studies. Reasons for 
this can be suspected in the cognitive preparation phase, after which some patients with major 
concerns about the treatment concept decided not to participate and in the higher binding 
commitment because of the intensive format and the trouble taken for reimbursement of 
treatment costs. If the rate of missing follow-ups is added to the rate of dropout it sums up to 
19%, which is still in the range of the 29 comparison studies, with a mean dropout-rate of 
16% (SD = 7.6). The higher depression scores and comorbidity found for patients who drop 
out of therapy underline the necessity of giving further attention to this group of patients.  
Unfortunately, questionnaires defined specifically for the assessment of social phobia (like the 
SPS and SIAS) as well as the regular assessment of Axis II comorbidity were not part of the 
diagnostic assessment from the beginning, because of different priorities at the beginning of 
data collection. Clearly, the Interpersonal Sensitivity scale of the SCl-90-R is not an optimal 
measure of social phobia as it has not been explicitly validated with social phobic individuals. 
However, it tends to correlate highly with SPS and SIAS, both in this study (r = .65) as well 
as in a large validation study for SPS and SIAS including 357 patients (Heinrichs et al., 
2002). Another limitation of the study is that it is based entirely on self report measures. 
Independent blind assessor ratings are missing – and should be included from a 
methodological point of view. In the current setting as well as in other clinical settings with 
no extramural funding and depending on the insurance companies, it is impractical and too 
expensive to provide such ratings with hired experienced raters. Finally, it must also be 
pointed out that recent data from randomised controlled trials suggest a high placebo response 
rate in social phobia (Fedoroff & Taylor, 2001; Taylor, 1996) and thus the use of pre-
treatment expectancy measures might have provided helpful information. 
Nevertheless, the present study provides convincing evidence that empirically validated 
treatment for social phobia, the combination of exposure and cognitive restructuring, can be 
transported into natural field settings. The results were achieved using a large number of 
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patients and therapists, which underscores the generalization of the results to other settings 
and can be added to the list of cumulative evidence for the generalization of research therapy 
to clinical settings. However, it is most likely that these results require not only a thorough 
diagnostic procedure to assess social phobia as the primary problem but also frequent and 
intensive supervision of the therapists.  
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Table 4.1. 
Pretreatment Means of Dropouts During Treatment (DT), Patients with Missing Follow-ups 
(MF) and Treatment Completers (TC). 
 DT  
n = 18 
  M  
n = 24 
 TC  
n = 175 
   
 M SD  M SD  M SD  F df p 
Age  28.9 9.4  31.6 9.0  34.5 10.4  2.95 2, 214 .06 
Duration  8.5 5.3  13.1 11.9  14.2 11.3  2.09 2, 201 .13  
Severity 6.4 1.1  6.5 1.1  5.8 1.3  3.04 2, 157 .05* 
SCL-GSI 1.31 0.65  1.14 0.53  0.93 0.60  4.18 2, 210 .02*a 
IS, SCL-90-R 1.90 0.90  1.76 1.00  1.51 0.93  2.12 2, 210 .10 
SPS 44.7 21.3  44.7 17.5  37.1 16.7  1.90 2, 114 .16 
SIAS 42.4 16.0  44.0 12.5  39.6 16.1  0.61 2, 113 .54 
BDI 22.7 11.7  18.3 11.6  14.8 10.1  5.32 2, 207 .01*b 
* p ≤ .05; a = significant differences between DT and TC (p ≤ .05) in post hoc Tukey-HSD test or Games-
Howell-Test, b = significant differences between DT and TC (p ≤ .01); Age = age of patients in years, Duration 
= duration of disorder in years, Severity = severity of disorder in DIPS 1-8 rating; SCL-GSI = Symptom 
Checklist-90-Revised; Global Severity Index; IS, SCL-90-R = Interpersonal Sensitivity subscale on the SCL-90-
R; SPS = Social Phobia Scale; SIAS = Social Interaction Anxiety Scale; BDI = Beck Depression Inventory 
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Table 4.2. 
Means, Standard Deviations and paired t Tests for Clinical Outcome Measures  
 Pre  Post    
 M SD  M SD  df t p 
Analysis for sample with completed post-assessment (n = 175) 
SCL-GSI 0.94 0.61  0.51 0.49  157 11.83 .000** 
FLZ-GA 25.7 33.0  38.6 33.5  64 -4.12 .000** 
FLZ-GG 26.5 31.0  54.4 42.7  72 -6.60 .000** 
SCL-IS 1.52 0.95  0.85 0.81  159 11.42 .000** 
SPS 37.7 17.1  22.2 16.7  84 10.30 .000** 
SIAS 40.0 16.5  25.9 15.6  83 10.60 .000** 
BSQ 2.20 0.69  1.70 0.56  148 10.32 .000** 
ACQ-KV 2.50 0.76  1.91 0.72  146 10.22 .000** 
SCL-A 1.23 0.84  0.64 0.67  157 10.60 .000** 
BDI 14.8 10.3  7.8 8.3  154 10.88 .000** 
SCL-D 1.19 0.89  0.67 0.72  160 9.58 .000** 
Intent-to-treat-analysis (n = 217) 
SCL-IS 1.57 0.94  1.07 0.92  213 10.41 .000** 
SPS 38.6 17.2  27.3 18.8  116 8.89 .000** 
SIAS 40.4 15.6  30.2 16.5  115 9.01 .000** 
BDI 15.9 10.7  10.7 10.35  209 9.94 .000** 
** = p ≤ .004; SCL-GSI = Symptom Checklist-90-Revised, Global Severity Index; FLZ-GA = Questions on 
Life Satisfaction, general life satisfaction; FLZ-GG = Questions on Life Satisfaction, satisfaction with health; 
SCL-IS = Symptom Checklist-90-Revised, Interpersonal Sensitivity; SPS = Social Phobia Scale; SIAS = Social 
Interaction Anxiety Scale; BSQ = Body Sensation Questionnaire; ACQ-KV = Agoraphobic Cognition 
Questionnaire, Loss of Control; SCL-A = Symptom Checklist-90-Revised, Anxiety; BDI = Beck Depression 
Inventory; SCL-D = Symptom Checklist-90-Revised, Depression. 
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Table 4.3. 
Intragroup Effect Sizes (IGES), Percentage of Patients with Reliable Change (RC), 
Deterioration (D), Improvement (I) or Maintenance (M) and Clinical Significance Cut-off-
Score (CS) with Percentage of Patients in Healthy Population for Clinical Variables 
SCL-GSI = Symptom Checklist-90-Revised, Global Severity Index; FLZ-GA = Questions on Life Satisfaction, 
general life satisfaction; FLZ-GG = Questions on Life Satisfaction, satisfaction with health; SCL-IS = Symptom 
Checklist-90-Revised, Interpersonal Sensitivity; SPS = Social Phobia Scale; SIAS = Social Interaction Anxiety 
Scale; BSQ = Body Sensation Questionnaire; ACQ-KV = Agoraphobic Cognition Questionnaire, Loss of 
Control; SCL-A = Symptom Checklist-90-Revised, Anxiety; BDI = Beck Depression Inventory; SCL-D = 
Symptom Checklist-90-Revised, Depression.  
 
   RC-POST  Healthy Population 
   M in % D in % I in %  CS % pre % post 
SCL-GSI 0.71  31.6 5.7 62.7  0.51 31 62 
FLZ-GA 0.39  66.2 4.6 29.2  43 30 42 
FLZ-GG 0.89  41.1 6.8 52.1  48 19 58 
SCL-IS 0.71  55.6 1.3 43.1  0.73 24 56 
SPS 0.88  28.2 3.5 68.2  20 17 55 
SIAS 0.86  42.9 0.0 57.1  26 26 59 
BSQ 0.73  73.2 0.7 26.2  2.0 46 74 
ACQ - KV 0.78  39.7 6.2 54.1  2.0 34 55 
SCL-A 0.70  55.6 1.3 43.1  0.84 41 62 
BDI 0.68  51.6 3.2 45.2  9.3 35 69 
SCL-D 0.58  57.8 5.0 37.3  0.64 35 62 
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Table 4.4. 
Mean Pre – Post Effect Sizes for Subsamples with Different Exclusion Criteria or Sample 
Characteristics 
 Criteria applied  Remaining 
sample 
      Difference 
 Mean ES n  Mean ES n  df t p 
Exclusion of:          
(a) BDI ≥  18  0.76 (0.72) 103  1.28 (1.01) 53  79.8 3.29 .00 
(b) prior treatment 0.70 (0.70) 51  0.84 (0.75) 105  154 1.11 .27 
(c) low severity (DIPS 1-3) 0.92 (0.80) 101  0.66 (0.68) 19  118 1.33 .19 
(d) age >20 or < 50 years 0.77 (0.73) 142  0.85 (0.62) 19  159 .47 .64 
     Combined a, b, c, d 0.65 (0.67) 30  0.83 (0.73) 131  159 1.27 .21 
(e) further Axis I disorders  0.77 (0.68) 97  0.89 (0.80) 64  159 1.07 .29 
Sample consists of:          
(f) only students 0.74 (0.74) 35  0.85 (0.71) 117  150 .82 .41 
(g) only specific subtype 1.07 (1.09) 15  0.76 (0.71) 131  15.4 1.10 .29 
(h) only cognitive reactors 0.76 (0.71) 79  0.74 (0.64) 54  131 0.19 .85 
p = two-tailed significance 
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5. STUDY III 
Who Comes, Who Stays, Who Profits? –  
Predicting Refusal, Dropout, Success, and Relapse in the 
Treatment of Social Phobia5 
5.1. Introduction 
The absence of data addressing characteristics of patients who refuse treatment, who drop out 
or who do not improve from treatment is a major limitation of treatment outcome literature. In 
the area of social phobia a series of meta-analyses has found a high efficacy of cognitive 
behavioural treatments, with mean effect sizes ranging from 0.8 to 1.1 (Gould, Buckminster, 
Pollack, Otto, & Yap, 1997; Fedoroff & Taylor, 2001; Feske & Chambless, 1995; Ruhmland 
& Margraf, 2001; Taylor, 1996). However, not all patients benefit from the tested treatment 
approaches. Turner, Beidel, Wolff, Spaulding, and Jacob (1996) calculated treatment success 
taking into consideration not only patients who completed treatment, but also those who were 
offered treatment, but refused or dropped out of it. This resulted in an alarmingly low rate of 
52% of the patients seeking treatment for social phobia who actually profited from it.  
Knowing about factors that are responsible for attrition as well as for failure to benefit from 
treatment may help to understand the processes underlying treatment and enable the therapist 
to adapt treatment procedures, delivery and planning accordingly to improve a specific 
patient’s prognosis (van Minnen, Arntz, & Keijsers, 2002). Also, knowledge of prognostic 
features can be helpful in indicating treatments of choice, since a variety of effective 
treatment variations are available. Table 1 gives an overview of the findings in 18 studies 
investigating prognostic factors of refusal, dropout, gain or endstate functioning in the 
treatment of social phobia. However, the literature review points to a number of limitations in 
the current state of predictor research for social phobia. 
 It becomes clear that most attention has been directed to the questions of treatment success, 
rather than dropout, refusal or relapse after treatment. In fact, refusal and relapse have been 
                                                 
5 Article submitted for publication. Authors: Lincoln, T.M., Rief, W., Hahlweg, K., Frank, M., von Witzleben, 
I.Schröder, B., & Fiegenbaum, W. 
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thoroughly neglected in prediction research. Research investigating dropout during treatment 
yields some evidence indicating that higher pretreatment severity and impairment might be  
 
causing some patients to drop out of treatment. This hypothesis will have to receive further 
attention, as it has important implications for treatment delivery.  
Refusal. Two studies investigated characteristics of patients who refused to enter the 
treatment protocol, which meant agreeing to random assignment. Turner et al. (1996) found 
patients who refused random assignment (15.5%) in a study testing the effects of atenolol, 
flooding and pill placebo to be less severely impaired, but found no differences on 
sociodemographic variables, comorbidity or subtype. Juster et al. (1995) found patients who 
refused random assignment (33%) more likely to be married, not to live alone and to have 
more income. They found no differences on other socio-demographic variables or in the 
response to cognitive behavioural treatment.  
Dropout. We found four studies that had investigated prediction of dropout, with most of the 
investigated variables showing no predictive value. Participants with a lower  expectancy 
towards treatment were found to drop out more often as well as more impaired patients.   
Relapse. The least attention has been given to the question of relapse or failure to maintain 
treatment gain after termination of treatment. Only one study (Mersch et al., 1991) addressed 
this question and found patients who relapsed after postassessment to be older as well as to 
have had significantly lower SCL-90 scores at pretest. 
Change. Most studies have concentrated on predicting change caused by treatment and 
endstate functioning, focusing on sociodemographic and biographical variables, impairment, 
severity, subtypes, and comorbidity as potential predictors for change or endstate functioning. 
The majority of findings are insignificant and most of the significant effects are low. 
It seems that demographic and biographical variables generally have little to offer in the way 
of predicting treatment outcome. The current research has not fully clarified the prognostic 
value of pretreatment severity and impairment. Studies investigating the impact on treatment 
change, rather than endstate-functioning, provide contradictory results. We found no studies 
considering physical anxiety symptoms as a variable of impairment or severity although these 
might be more resistant to change than cognitions and thus have a negative impact. Studies 
examining the predictive value of subtypes generally found patients with generalized social 
phobia to begin and end treatment with more severe symptoms, but to have a similar rate of 
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improvement to the nongeneralized subtype. One difficulty of testing subtypes as a predictor 
for treatment response is the absence of clear diagnostic criteria. This has led different authors 
to use different criteria to distinguish subtypes, making a comparison of results difficult. 
Some authors point out that the categories are somewhat arbitrarily imposed on a continuum 
of impairment and suggest using degree of impairment as a continuous measure (Chambless 
et al., 1997; Stein, Torgrud, & Walker, 2000). Patients without comorbid axis I or axis II 
disorders have often been found to have lower post-scores on measures of general anxiety and 
clinical severity but the same rate of improvement as patients without a comorbid disorder. 
Research on the impact of avoidant personality disorder on treatment outcome has yielded 
contradicting results which might partly be due to still unsolved conceptional difficulties in 
the distinction between the generalized subtype of social phobia and avoidant personality 
disorder. However, there is convincing evidence in support of the hypothesis that comorbid 
depression is a negative predictor of change. Chambless et al. (1997) found a correlation of r 
= .47 between depression and residual gain by postassessment. Also, in a study with 1027 
respondents, DeWit, Ogborne, Offord, and MacDonald (1999) found the probability of 
recovery without undergoing treatment to be three times as high when participants reported no 
additional depression. The amount of research on health related predictor variables was 
meagre, yielding some evidence for a possible negative impact of chronic health problems 
(De Wit et al., 1999). Also, Mersch et al. (1991) found a tendency for a negative impact of the 
use of alcohol and medication. None of the studies investigated the effect of therapist 
variables such as gender or years of treatment experience or treatment duration on response. 
However, Feske and Chambless (1995) analysed the effect of treatment duration in their 
meta-analysis and found a larger number of exposure sessions to produce more favourable 
outcomes. 
Apart from the absence of a row of promising variables, the available studies are limited by 
the fact that predictors were studied in the context of controlled outcome studies whose 
inclusion criteria are likely to limit the variability of the factors studied as predictors. Steketee 
and Shapiro (1995, pp. 341) point out, that “to better serve our client populations, research on 
predictors should be conducted on naturalistic clinical treatments, as well as on controlled 
trials”. Specifically in the case of treatment refusal the question must be raised whether 
refusal of participating in a study with random assignment can be compared to the refusal to 
take up an (individualized) treatment offer as such.  
5. Who Comes, Who Stays, Who Profits?    68 
The first aim of this study is therefore to search for predictors of treatment acceptance, 
attrition, effectiveness, and relapses after treatment for social phobia in a field treatment 
outcome study in four outpatient clinics and using a large sample of unselected patients. The 
second aim is to compare these predictors with variables identified as predictors in the context 
of controlled efficacy studies.  
5.2. Method 
5.2.1. Setting 
The Christoph-Dornier Foundation for Clinical Psychology (CDS) runs seven outpatient 
clinics in Germany, in which patients with a variety of disorders are treated. Patients were 
referred from different sources, for example, general practitioners, psychotherapists, or 
psychiatric hospitals. Most of the treatments were paid by the patient’s insurance company by 
reimbursement of expenses. This means that invoicement for treatment sessions is directed to 
the patient, who can apply for reimbursement with his or her health insurance company. The 
insurance company is free to decide whether they are prepared to cover the expenses for 
treatment or not. This decision process mostly takes place after diagnostic assessment, as the 
health insurances usually expect a brief report of the disorder and a treatment plan as a basis 
for their decision. Additional treatment-expenses, such as accommodation, tickets, etc. were 
generally not covered by the health insurance. Therapists were 62 diploma psychologists 
(roughly equivalent to a master’s degree; 58% were female, 42% were male) with training in 
behaviour therapy.  
5.2.2. Treatment 
Typically, patients were treated with in vivo exposure combined with cognitive interventions. 
The intensive treatment program is characterized by a short duration, usually lasting about 5-7 
days, during which the patients are expected to confront the feared situations for several hours 
per day. It consists of three main phases: 
Psychological and medical assessment. Psychological assessment (4-6 50-minute sessions) 
consists of conducting a reliable and valid structured clinical interview according to the 
criteria listed in the Diagnostic and Statistic Manual of Mental Disorders (DSM-III-R, 3rd ed., 
revised, American Psychiatric Association, 1987). The “Diagnostisches Interview bei 
Psychischen Störungen” [Diagnostic Interview for Psychological Disorders] (DIPS; Margraf, 
Schneider, & Ehlers, 1991) is the German version of the Anxiety Disorders Interview 
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Schedule – Revised (ADIS-R; DiNardo, Barlow, Cerny, Vermilyea, Vermilyea et al., 1986). 
The ADIS-R/DIPS is a semi-structured interview with well-established psychometric 
properties. A medical check-up is particularly important in the context of exposure since this 
can be physiologically stressful. 
Diagnostic feedback and cognitive preparation. Cognitive preparation for therapy takes place 
about one week after assessment and aims at enhancing the patient’s motivation for treatment. 
The patient’s core assumptions about the aetiology of social phobia are integrated into a 
model that is able to explain the way in which specific patterns engender and maintain social 
anxiety. Implications for therapy are then delineated on the basis of this model and patients 
are encouraged to discontinue medication. The patient is given 5-10 days to decide whether to 
participate in the treatment. The preparation phase is described in detail by Tuschen and 
Fiegenbaum (1997).  
High-density exposure combined with cognitive interventions. When the patient decides to 
participate, exposure and cognitive intervention begin (duration is variable and depends on the 
individual patient’s needs). Exposure to the feared situations plays a central role in the therapy 
as it enables the patient to experience a certain degree of habituation and helps the therapist to 
detect and correct core amplifying cognitions, safety behaviours and failure-focused attention. 
Exposure is combined with restructuring interventions in which the patient is taught to 
identify and challenge specific negative thoughts, general cognitive errors and perfectionist 
thinking. At the end of the intensive treatment-phase patients are instructed to continue 
exposing themselves to the feared situations in their everyday life and are offered further 
support if necessary. A more detailed description of the treatment concept is given in a former 
article (Lincoln, Rief, Hahlweg, Frank, von Witzleben, Schroeder et al., 2002). 
5.2.3. Participants 
Participants were 287 patients who were diagnosed with social phobia as the primary disorder 
according to the criteria listed in DSM-III-R (American Psychiatric Association, 1987), 
meaning that social phobia was judged by the patients to be the most severe disorder and the 
one for which they wished treatment. Fifty-six percent of the patients were male. The average 
age was 33.9 years (SD = 10.5) and the average duration of disorder was 13.8 years (SD = 
11.7). Eighty-one percent had already undergone some form of psychotherapy or medical 
treatment, 24% had been hospitalised due to mental problems. Thirty-nine percent were 
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married or living with a partner, 33% had completed secondary school, 33% had a high school 
degree and 34% a university degree.  
Of these 287 patients, 241 came to the cognitive preparation session and 217 decided to begin 
treatment, of which 199 completed it. Treatment effectiveness has been described in detail in 
a former study (Lincoln et al., 2002). A total of 175 patients completed the post assessment 
and 101 completed a one-year follow-up. Figure 1 displays this attrition process. The high 
number of missing follow-ups is due to financial restrictions. In three of the institutes there 
was no financed personal to organize follow-ups and patients could not be paid to complete 
the questionnaires.  
5.2.4. Measures 
5.2.4.1. Predictors 
Demographic and biographical variables. Age, age at onset, duration of disorder, prior 
treatment experience, gender, marital status (0 = married, 1 = living with partner, 2 = 
partnership, 3 = single), and educational level (0 = no school degree, 1 = secondary modern 
school, 2 = advanced secondary school, 3 = A-level, 4 = university degree) were collected 
with the aid of an application questionnaire, which was completed by all patients. 
Severity and Impairment. Patients rated their subjective feeling of impairment on a five-point 
rating scale (0 = not at all, 1 = a little, 2 = moderately, 3 = severely, 4 = extremely). The 
intensity of the perceived distress was measured with the SCL-90-R, Global Severity Index 
(SCL-GSI; Derogatis, 1994; German version: Franke, 1995), which is based on all 90 items of 
the SCL-90-R assessing nine primary symptom dimensions. Internal consistency for the 
German version of the SCL-90 is .97. The therapists rated the severity of the disorder on a 
scale from 0-8 as a result of the diagnostic interview (DIPS). Subjective symptom severity 
was assessed with the Social Phobia Scale and the Social Interaction Anxiety Scale 
(SPS/SIAS, Mattick & Clarke, 1998; German Version: Stangier, Heidenreich, Bernardi, 
Golbs, & Hoyer, 1999). The SPS/SIAS is a 40-item self-report questionnaire, consisting of 
two scales assessing the fear of being observed and evaluated by others as well as interaction 
anxiety. Internal consistency for the German version is .94 for the SIAS and .94 for the SPS. 
As the SPS/SIAS was not given to patients from the beginning of the study, calculations can 
only be made for a smaller sample of n = 85 (SPS) and n = 84 (SIAS). Physical symptoms a 
patient generally experienced during a social situation were assessed in the DIPS, the Body 
Sensation Questionnaire (BSQ; Chambless, Caputo, Bright, & Gallagher, 1984; German 
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version: Ehlers, Margraf, & Chambless, 1993) and the Beck Anxiety Inventory (BAI; Beck & 
Steer, 1993; German Version: Ehlers & Margraf, in press). The BSQ is a 17-item 
questionnaire to measure anxiety with regard to bodily symptoms, with an internal 
consistency of 0.85 for the German version. The BAI was used to assess physical arousal 
symptoms. Although originally developed to measure symptoms of anxiety in general, recent 
research supports the view that the BAI is more sensitive to panic related symptoms than to 
other aspects of anxiety, such as worry and tension (Antony, Purdon, Swinson, & Downie, 
1997).  
Subtypes. Subtypes were considered on a continuum of the amount of 13 social situations in 
the DIPS, in which the patient had described anxiety as being at least moderate (0 = no 
anxiety, 1 = slight anxiety, 2 = moderate anxiety, 3 = severe anxiety, 4 = extremely severe 
anxiety) as well as the total score of anxiety for all these situations.  
Comorbidity. Comorbid disorders were diagnosed based on the information in the DIPS. 
Additionally, patients completed disorder specific questionnaires. Symptoms and severity of 
depression were measured with the Beck Depression Inventory (BDI, Beck & Steer, 1987; 
German version: Hautzinger, Bailer, Worall, & Keller, 1995), a 21-item self-report 
questionnaire. Obsessive-compulsive symptoms were assessed with a short version of the 
Hamburg Obsessive-Compulsive Inventory (HZI; Zaworka, Hand, Jauernig, & Lünenschloß, 
1983), which includes items on obsessive behaviour as well as ruminations prior to acting. 
Agoraphobic cognitions were measured with the Agoraphobic Cognition Questionnaire 
(ACQ; Chambless et al., 1984; German version: Ehlers et al., 1993). Avoidance with regard 
to common agoraphobic situations was assessed by the Mobility Inventory, subscale Alone 
(MI-A; Chambless, Caputo, Jasin, Gracely, & Williams, 1985; German version: Ehlers et al., 
1993). Hypochondrias was measured with the Whiteley-Index (WI; Pilowsky, 1967; German 
Version: Rief, Hiller, Geissner, & Fichter, 1994), which assesses disease phobia, bodily 
preoccupation, and disease conviction.  
Health related variables. Chronic health problems were assessed by the application 
questionnaire and the medical report of the examination before treatment. Satisfaction with 
health was measured by the “Satisfaction with Health” subscale of Questions on Life 
Satisfaction (FLZ-GG; Henrich & Herschbach, 2000; German Version: Henrich & 
Herschbach, 1996). Internal consistency for the German version is .89. As the FLZ-GG was 
not given to patients from the beginning, calculations can only be made for a smaller sample 
of n = 65. Alcohol use was assessed by the self-evaluation scale of the Münchner 
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Alkoholismus-Test [Munich alcoholism test] (MALT-S, Feuerlein, Küfner, Ringer, & 
Antons-Volmerg, 1999). The MALT-S scale contains 24 items that assess three relevant 
aspects of alcoholism: drinking and attitude towards drinking, alcohol related psychological 
and social impairment, and somatic complaints. It has a split-half reliability of 0.94. The use 
of benzodiazepines was assessed by the application questionnaire and the DIPS. 
Treatment and therapist variables. The experience of the therapists was coded on a 6-point 
scale, according to the number of patients with any disorder treated so far (1 = 1-10 patients 
treated with any disorder, 2 = 11-20 patients etc.). 
5.2.4.2. Treatment outcome 
Symptom Checklist-90-Revised – Interpersonal Sensitivity (SCL-IS; Derogatis, 1983; German 
version: Franke, 1995). This subscale assesses feelings of social uncertainty and fears of being 
observed or judged negatively. Internal consistency for the German version of the SCL-IS is 
.86. 
Rating of global improvement (RGI). A 7-point rating scale (1 = very much better, 2 = much 
better, 3 = better, 4 = no change, 5 = worse, 6 = much worse, and 7 = very much worse) was 
used to assess the subjective perception of improvement. The RGI can be considered as a 
global consumer satisfaction measure. 
5.2.5. Analysis 
Analysis was conducted in a series of steps. In a preliminary analysis of treatment attrition, 
reasons for patient discontinuation and dropout were investigated and patients were classified 
as refusers, dropouts and treatment completers. Second, in order to find pre-treatment 
differences between patients who refused treatment and those who completed it ANOVA or 
chi-square tests were computed. 
Third, for prediction of treatment change, the first step was to compute bivariate correlations 
between potential predictors and SCL-90-Interpersonal Sensitivity “Residual Gain Scores” 
(RGS) as well as the ratings of global improvement (RGI) at post treatment and one-year-
follow-up (F1) for the completers. To compute residual gain, raw scores from pre, post, and 
F1 assessment are first converted into Z scores. Change is calculated by subtracting the Time 
1 score, multiplied by the correlation between scores at time 1 and 2 from the time 2 score 
(RGS = Zpost – Zpre rprepost). Thus, residual gain rescales an individual’s score relative to 
typical gains made by others at the same initial level. We then regressed each factor on the 
predictors (method stepwise) to take into account the shared variance of the individual 
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predictors. To safeguard adequate predictive power, we selected only those predictors that 
related (p < .05) to RGS or RGI and entered them into the equations. 
Finally, for the prediction of relapse in the 90 patients that had completed the SCL-IS at post 
as well as F1, we calculated “Reliable Change Indexes” (RCI) using the formula by Jacobson, 
Follette, and Revenstorf (1984), with RCI = (MPOSTTEST – MF1)/SE, and SE = SDPOSTTEST 
'1 rxx− , where 'rxx  is the reliability of the measure. Following the authors’ suggestions, we 
categorized a patient as deteriorated if the RCI was lower than - 1.96. Then we calculated 
differences in pre-treatment and post-treatment variables between those who had improved 
further or remained stable from post to F1 and those who had deteriorated. Finally, variables 
that significantly differentiated the two groups were entered into logistic regression. 
5.3. Results 
5.3.1. Preliminary Analyses 
Thirty percent of the group of treatment refusers after diagnostic assessment gave a reason for 
discontinuation of treatment. Of these, 60% stated that they discontinued because the health 
insurance refused to cover the costs, another 20% had began treatment elsewhere, 13% had 
doubts concerning the treatment concept, and 7% reported organizational difficulties. Thus it 
can be assumed that many of these patients either completed treatment elsewhere or will 
eventually return to treatment when other problems have been resolved or treatment can be 
more easily afforded. The group of dropouts after cognitive preparation, who had received an 
individualized treatment offer presented a different pattern of reasons. Seventy-five percent of 
this group provided us with a reason for discontinuation. Of these, a far lower percentage of 
patients discontinued for financial reasons (28%), but many felt that treatment was too 
difficult to endure (22%) or were sceptical about the treatment rational (17%). Similarly, for 
the group of dropouts during treatment, of which 63% gave us the reason, 17% felt the 
treatment to difficult to endure, 8% were sceptical of the rational and 42% marked the rubric 
“other reasons”, which may have included problems in the therapeutic relationship. As a 
consequence, refusers after diagnostic procedure must be regarded separately from refusers 
after cognitive preparation and interpretation of results in this group must be treated with 
caution. On the basis of this analysis, we decided to categorize the sample as follows: refusers 
after diagnostic procedure (RD = 16%), refusers after cognitive preparation (RC = 8%), 
treatment dropouts (TD = 6%) and treatment completers (TC = 69%). 
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5.3.2. Predictors of Treatment Refusal and Dropout  
Table 5.2. shows the pretreatment variables for refusers after diagnostic procedure (RD), 
refusers after the cognitive preparation phase (RC), dropouts during therapy (TD) and 
treatment completers (TC). Because of the high number of comparisons we applied 
Bonferoni-adjustment for each comparison separately (p = .05/32 =.002). On this basis, the 
groups only differed significantly in their number of comorbid diagnoses and their mean value 
on the MI-A. TD reached higher scores on the MI-A than any of the other groups.  
An additional analysis of group differences, in which all patients giving a financial reason for 
discontinuing were excluded from the calculation produced the same results, apart from one 
difference: patients, who refused treatment after diagnostic assessment were using medication 
significantly less often (23%), than patients who refused after cognitive preparation (56%), 
dropped out during treatment (75%) or completed treatment (57%), (Chi2 = 16.4, df = 3, p 
=.001).  
5.3.3. Predictors of Treatment Outcome  
The results of the two-tailed bivariate correlations between predictors and RGS as well as 
RGI6 are shown in table 3. With regard to the RGS at post, the WI was the only significant 
predictor. Patients revealing more symptoms of hypochondriasis revealed less treatment 
change at post.  
Predictors for RGI at post were the SPS, BSQ, BAI, the number of feared situations as well as 
the perceived anxiety in these situations, the BDI and the FLZ-GG. Patients who experienced 
more impairment before treatment on these measures rated themselves as having improved 
less at post. These seven variables were entered to predict RGI at post. Only the FLZ-GG 
made a significant contribution with a regression coefficient of B = -0.01 ( β = -.40; p < .01) 
and explained 16% of the total variance. Due to missing data in one or more of the predictor 
variables, only 60 patients were entered into the analysis. 
By the 1-year follow-up (F1), patients with a higher level of education revealed less change. 
Also, the number of feared social situations as well as the amount of anxiety in these 
situations were negatively related to RGS at F1. These three variables were entered into the 
                                                 
6 Patient ratings of global improvement were highly correlated with therapist ratings of global improvement for 
post (r = .68, p < .01) and for F1 (r = .81, p < .01). 
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linear regression analysis with the RGS at F1 as dependent variable. The amount of fear in 
social situations (B = .03; β  = .32; p < .01) and the level of education (B = .21; β  = .25; p < 
.05) both made a significant contribution to predicting treatment change and accounted for 
13% of the total variance for N = 89 patients. 
Predictors for the RGI at F1 were gender, marital status, SCL-GSI, SPS, BAI, the number of 
feared situations as well as the perceived anxiety in these situations, BDI, ACQ, FLZ-GG and 
number of treatment sessions. Female as well as married patients tended to rate themselves 
more improved. On the questionnaires, the severity or impairment before treatment was a 
negative predictor for perceived improvement. Patients who received a higher number of 
treatment sessions rated themselves as less improved at F1. Two of the eleven variables 
entered into linear regression to predict RGI at F1 made a significant contribution. The marital 
status had a regression coefficient of B = 0.24 ( β = .36; p < .05) and the FLZ-GG had a 
regression coefficient of B = -0.01 ( β = -.35; p < .05) for N = 31 patients. Together these two 
variables explained 28% of the total variance. 
5.3.4. Predictors of Deterioration after Treatment 
The results of the calculation of differences in pretreatment as well as in posttreatment 
variables between those who had improved further from post to F1 and patients who had 
deteriorated are depicted in table 4. Patients who could not maintain their treatment gain were 
shown to be significantly younger, to have higher pre-treatment-scores on the SPS, higher 
pretreatment and posttreatment scores on the SIAS, a larger number of feared social situations 
as well as higher levels of anxiety in these situations. These variables were entered into 
logistic regression (forwards, wald). Only the pretreatment score of the SPS reached statistic 
significance as a predictor, with a coefficient of B = -.12 (wald = 5.4; p < .05; N = 39) and 
accounted for 24% of the total variance.  
5.4. Discussion 
The calculation by Turner et al. (1996), in which they estimated 52% of the patients seeking 
treatment as actually profiting from it, is underlined by our data from the clinical field. If we 
consider not only patients who refused after cognitive preparation, but also those who 
discontinued after diagnostic procedure and did not justify refusal with financial difficulties 
and add the rate of patients who dropped out during treatment, we are left with 80% of the 
patients who completed treatment. For these, we can consider a rate of 56% reliably improved 
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patients at post, which was calculated in a former study (Lincoln et al., 2002) and 
optimistically assume that patients who did not send back the follow-up questionnaires 
equally improved, and we are left with a rate of 43%. Our study was to our knowledge the 
first field study investigating predictors of refusal, dropout and treatment response for social 
phobia treatment. In the next section, some of the findings will be discussed in detail. 
First, it seems important to point out that treatment refusers are not a less severely impaired 
group of patients that we do not have to be overly concerned about. Twenty-five percent even 
of this group have already been hospitalised for mental problems, and they achieve results 
comparable to treatment completers on all pretreatment questionnaires.  
Patients who dropped out during treatment revealed more avoidance behaviour than any of the 
other groups as indicated by the higher scores on the MI-A. In line with this finding is the 
significant difference between the groups in the number of comorbid diagnoses. Possibly, the 
higher comorbidity causes these patients to feel more uncertain about whether the treatment is 
going to be sufficient. Additionally, dropout might be explained by the tendency for these 
patients to be characterized by higher rates of depression. A depressive attribution style will 
tend to be more global and stable (e.g. I will always be a total loser) and lead patients to give 
up more readily, when treatment success does not become visible quickly enough. Thus, in 
the case of intensive treatment with a large amount of exposure elements it seems to be more 
important to make sure a depressed patient completes treatment than to worry about treatment 
response. In spite of slightly contradictory results about the exact way in which depression 
interferes with treatment, some authors come to the conclusion that it may be wise to spend 
more time tracing and dealing with pretreatment hampering cognitions or argue for concurrent 
treatment of anxiety and depression for the more depressed patients (Scholing & Emmelkamp, 
1999; Chambless et al., 1997; Rief, Auer, Wambach, & Fichter, in press; Heinrichs et al., 
2001).  
Although there were a number of significant, but low correlations between pre-treatment 
variables and change or subjective improvement, there were not many significant predictors 
once variables were entered into linear regression. The “satisfaction with health” subscale of 
the FLZ was the most significant predictor in the regression analysis of subjective 
improvement at post and 1-year follow-up, without, however, predicting actual change. Also, 
more objective data, such as the presence of chronic disease, as reported in the medical report 
or stated by patients in the application questionnaire did not show any relationship to 
improvement. High scores on the FLZ-GG might reflect a positive thinking bias. Patients who 
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reveal less discrepancy between importance of health aspects and satisfaction with these 
aspects might generally tend to be less sensitive to negative discrepancies in their life.  
More generalized social phobia (indicated by a higher amount of fear in social situations) was 
a negative predictor of change at 1-year-follow up, which stands in contrast to the results of 
former studies finding no effect of subtype on change (Brown et al., 1995; Hope et al., 1995; 
Turner et al., 1996). However, most of these studies did not predict change by 1-year follow-
up and all used a dichotomic subtyping scheme. Chambless et al. (1997), using a similar 
approach (continuum of impairment instead of dichotomised subtypes) found no correlation 
with change at post symptoms, but a weak correlation after six months. Hope et al. (1995) did 
not find subtypes to improve unequally by one-year follow-up, but they only had a small 
sample (N = 16) for their follow-up assessment and the effect is not a very large one. Our 
finding seems plausible because patients with more generalized social phobia still suffer more 
from symptoms and avoidance after treatment, possibly leading to fewer positive new 
experiences in social situations and thus making it harder to maintain treatment gain over a 
longer period of time.  
We also found a higher level of education to be a negative predictor of change at 1-year-
follow up. This finding is new as the available studies did not investigate the effect of 
education on change or endstate functioning. However, the effect is small and definitely needs 
to be replicated before giving it further attention. Finally, patients, who were married rated 
themselves as more improved after one year. This finding also stands in contrast to the results 
in other studies, finding no impact of marital status for social phobic patients (Salabería & 
Echeburúa,1996), but is in line with findings by Heinrichs, Hahlweg, Fiegenbaum, Frank, & 
Schroeder (2001) for patients with panic and agoraphobia. It seems, that future research 
should give more attention to the impact of marriage and partnership. 
Although depression added no significant contribution in the regression analyses we would 
like to point out, that symptoms of depression were related to subjective improvement ratings 
at post and F1, but not to symptom change. Possibly, the global improvement ratings are 
vulnerable to depression, because depressed patients tend to evaluate success less 
optimistically. This explanation also fits in well with the finding of Chambless et al. (1997), 
who found depressed patients to reveal less change in the self-report measures, but to be rated 
more positively by observers.  
For prediction of deterioration after treatment, only the pretreatment score on the SPS added a 
significant contribution to the regression analysis. Patients with higher pretreatment social 
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phobia scores were more likely to relapse. This contradicts the finding by Mersch et al. 
(1991), who found patients who relapsed to have had lower pretreatment severity scores. 
However, their method of categorization was different, including patients who made no 
further progress in the category of relapse. Also, our finding is supported by the other 
significant correlations, indicating that patients with a more generalized form of social phobia 
deteriorated more often after treatment as well as by the negative predictors of long-term 
treatment change. In sum, our data indicate that less severely disordered patients tend to find 
it easier to keep up a stable treatment gain over a longer period of time. 
Limitations and Considerations. One limitation of the study is that the Personal Sensitivity 
subscale of the SCL-90-R was the only outcome variable available for the entire sample. 
Observer rated outcome as well as more specific measures of social fear and avoidance would 
have been a better indicator of treatment success. Also, the high percentage of missing follow-
ups after one year makes the generalisation of the predictors of long-term change contestable. 
On the other hand, this high rate of missing data might reflect the reality of field treatment, in 
which patients are under no obligation to send back follow-ups. A further limitation is that not 
all variables of interest (e.g. Axis II comorbidity, motivation and expectancy) were assessed, 
which complicates the search for important predictors, as regression coefficients change with 
every change in the predicting variables. This limitation is due to a long period of data 
collection and the fact, that at the beginning some variables were considered to be less 
important.  
One problem of long-term follow-up assessments is that it is difficult to control for all the 
important variables that may influence outcome. For example, Chambless et al. (1997) found 
medication use and additional treatment between posttest and follow-up to predict outcome 
and thus controlled for these factors in her study. Although approximately one third of our 
sample received some form of additional treatment after postassessment, ranging from brief 
counselling or relaxation to another attempt at cognitive behaviour therapy this revealed no 
significant relationship to residual gain or reliable change at one-year follow up.  
Generally, research on treatment predictors has not led to a great insight in the sense that a 
particular factor can be seen as mainly responsible for treatment failures. Even if larger effects 
were found, it is always possible that an unknown third variable moderates the relationship. 
But, as in the experimental settings, the effect sizes in this study are generally small, 
suggesting that specific pretreatment variables are of limited value, and that it is more helpful 
to interpret patterns of predictors. However, some important clinical implications should be 
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emphasised: (1) The group of treatment refusers is as severely impaired by social phobic 
symptoms as patients who undergo treatment. Additional efforts are needed to motivate these 
patients to take up treatment. (2) Cognitive preparation and the beginning of treatment should 
be even more adapted to depression or other comorbid disorders, by restructuring hampering 
cognitions or conducting disorder-specific additional treatment. (3) It seems important to 
arrange for additional sessions over a specific period of time when patients are more severely 
impaired or suffer from more generalized social phobia, to enable them to integrate the 
treatment effects into their everyday life. 
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Table 5.1.  
Overwiew of Predictors for Treatment Refusal, Dropout, Treatment Change, Endstate 
Functioning and Relapse after Treatment for Social Phobia 
Predictors  Refusal  Dropout  Change   Endstate  Relapse 
           
Older Age  0 9, 18   0 15, 18  0 15, 3  + 12 +12 
Gender  0 9, 18  0 15, 18  0 15  0 13 0 12 
Marital Status  +9 0 18  0 15, 18  0 15    
Education  0 9, 18  0 18      
Occupation  0 9  0 15  015    
older Age at onset  0 18  0 18   _ 4  _ 4  
Duration of Disorder  0 9    0 3    
More family members      _ 4  _ 4  
Medication use      _ 5    
Earlier treatment trials        _ 12  
Severity/Impairment   0 9 _ 18  _ 18  _ 16 03, 5  _ 12, 13, 15 _ 12 
Behavioural impairment  018  +15    _12  
Comorbid Axis I   0 9, 18  0 18, 11  0 18, 11  _ 18 011, 13  
Depression      _ 5, 16  0 13  
Generalized Subtype  0 18  0 18   0 2, 8, 18  _ 2, 8, 18  
Comorbid Axis II   0 9, 18  0 18  _ 2, 5, 7, 17, 18  
0
 1, 3, 16, 18,  8 
 _ 18, 7, 8  
High Expectancy    014 _15  + 5, 14  + 15  
Locus of Control        0 10  
Homework Compliance        + 6, 10 
 
 
_ = negative predictor, + = positive predictor; 0 = no significant effect found, 1 =  Alden & Capreol (1993), n = 
76; 2 = Brown, Heimberg, & Juster (1995), n = 104 ; 3 = Butler, Cullington, Munby, Amies, & Gelder (1984), n 
= 49; 4 = Cameron, Thyer, Feckner, Nesse, & Curtis (1986), n = 41 (including specific phobia and agoraphobia); 
5 = Chambless, Tran, & Glass (1997), n = 62; 6 = Edelman & Chambless (1995), n = 52; 7 = Feske, Perry, 
Chambless, Renneberg, & Goldstein (1996), n = 60; 8 = Hope, Herbert, & White (1995), n = 28; 9 = Juster, 
Heimberg, & Engelberg (1995), n = 70; 10 = Leung & Heimberg (1996), n = 104; 11 = Mennin, Heimberg, & 
MacAndrew (2000), n = 122; 12 = Mersch, Emmelkamp, & Lips (1991), n = 47; 13 = Otto, Pollack, Gould, 
Worthington, McArdle, et al. (2000), n = 15; 14 = Safren, Heimberg, & Juster (1997), n =  113;15 = Salabería & 
Echeburúa (1996), n = 48; 16 = Scholing & Emmelkamp (1999), n = 50; 17 = Turner (1987), n = 13; 18 = 
Turner, Beidel, Wolff, Spaulding, & Jacob (1996), n = 84.  
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Table 5.2.  
Mean (SD) and Percentages of Variables at Pre-treatment for Refusers after First Session 
and Diagnostic Procedure (RD), Refusers after Cognitive Preparation (RC), Treatment 
Dropouts (TD) and Completers (TC). 
 RD = 46 RC = 24 TD = 18 TC =199 df Test-Value p 
Demographic and biographical variables 
Age 33.8 (10.4) 35.4 (10.4) 29.4 (9.4) 34.1 (10.2) 280 F =1.4 .241 
Male 63% 50% 42% 58% 3 Chi2 = 2.3 .512 
Marital Status 
Married 
Partner 
No partner  
 
34%  
14%  
46% 
 
33%  
21%  
46%  
 
18%  
6%  
77%  
 
32% 
25%  
43%  
6 Chi2 = 7.6 .266 
Education 
Sec. School 
High School 
University 
 
27%  
38%  
36%  
 
33%  
25%  
42%  
 
47% 
26% 
32%  
 
36%  
32%  
32%  
6 
 
Chi2 = 3.7 .712 
Age at onset 20.1 (10.6) 20.4 (9.6) 19.3 (10.7) 19.8 (9.5) 263 F =0.48 .986 
Duration 13.4 (14.2) 15.2 (12.7) 9.8 (7.8) 14.1 (11.4) 260 F = 0.84 .474 
Pre-treatment 
None 
Outpatient 
Inpatient 
 
21% 
52%  
26%  
 
9% 
57%  
35%  
 
6% 
50%  
44%  
 
22% 
57%  
21%  
6 
 
Chi2 = 8.8 .187 
Medication 37%  48% 71% 57% 3 Chi2 = 8.1 .045  
Severity and Impairment 
General 
Impairment 
3.4 (.73) 3.8 (.52)  3.8 (.43)  3.4 (.67) 207 F = 3.32 .021 
SCL-GSI 1.09 (0.59) 1.15 (0.48) 1.32 (0.65) 0.96 (0.59) 264 F = 2.68 .047 
SPS 34.9 (15.4) 40.4 (12.8) 44.7 (21.3) 38.2 (16.9) 149 F = 0.73 .538 
SIAS 41.1 (13.4) 42.5 (15.1) 42.4 (16.0) 40.3 (15.6) 148 F = 0.13 .941 
DIPS  5.7 (1.6) 6.2 (1.5) 6.4 (1.2) 5.9 (1.3) 197 F = 1.02 .386 
SCL-IS 1.73 (0.94) 1.98 (1.15) 1.96 (0.90) 1.54 (0.94) 265 F = 2.38 .047 
Subtypes 
Situations 6.4 (2.7) 6.3 (2.9) 7.4 (3.0) 6.7 (3.0) 254 F = 0.50 .683 
Anxiety 21.5 (9.0) 22.8 (10.1) 25.8 (10.6) 21.8 (9.3) 255 F = 1.09 .353 
Comorbidity 
Diagnoses  0.5 (0.7)  1.0 (0.9) 1.3 (1.3) 0.5 (0.7) 283 F = 8.52 .000 
BDI 18.6 (8.6) 17.1 (8.5) 22.7 (11.7)  15.3 (10.4) 259 F = 3.64 .013 
HZI-G 2.5 (2.5) 2.1 (1.3) 3.9 (2.5) 2.4 (2.1) 213 F = 1.86 .137 
HZI-H 2.6 (2.3) 2.6 (2.0) 3.3 (1.7) 3.0 (1.9) 213 F = 0.59 .625 
ACQ 1.9 (0.6) 2.2 (0.5) 2.3 (0.9) 1.9 (0.5) 260 F = 3.78 .011 
MI-A 1.8 (0.7) 1.9 (0.8) 2.6 (1.0) a  1.8 (0.7) 229 F = 6.37 .000 
WI 3.9 (3.6) 4.2 (3.2) 4.5 (3.2) 2.8 (2.7) 226 F = 3.29 .022 
Physical symptoms 
Symptoms 14.7 (7.8) 19.5 (8.3) 18.9 (12.5) 17.3 (8.5) 250 F = 1.70 .168 
BSQ 2.2 (0.6) 2.4 (0.8) 2.4 (0.7) 2.2 (0.7) 254 F = 0.92 .431 
BAI 19.9 (11.6) 25.6 (11.8) 24.5 (12.2) 21.1 (12.1) 253 F = 1.42 .236 
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Health related variables 
FLZGG 5.4 (28.8) 14.1 (34.8) 15.0 (23.5) 23.8 (31.4) 137 F = 2.03 .112 
Chronic 
illness  
16% 0% 7% 15% 3 Chi2 = 4.5 .213 
MALT 3.3 (4.5) 2.9 (4.3) 1.8 (1.6) 2.9 (3.3) 219 F = 0.57 .638 
Benzo-
diazepine 
5% 17% 12% 19% 3 Chi2 = 5.3 .153 
Therapist Variables 
Experience 2.6 2.5  2.3  2.2 275 F = 1.83 .142 
Male 54% 30% 32% 44% 3 Chi2 = 4.4 .218 
a = differences between TD and TC in post hoc Tukey-HSD, Games-Howell or Chi 2 Test (p ≤ .01); SCL-GSI = 
Symptom Checklist-90-Revised, Global Severity Index; SPS = Social Phobia Scale; SIAS = Social Interaction 
Anxiety Scale; DIPS = Diagnostic Interview for Psychological Disorders; SCL-IS = Symptom Checklist-90-
Revised, Interpersonal Sensitivity; BDI = Beck Depression Inventory; HZI–G, Hamburg Obsessive Compulsive 
Inventory – Ruminations; HZI-H; Hamburg Obsessive Compulsive Inventory – Obsessive Behaviour; ACQ = 
Agoraphobic Cognition Questionnaire; MI-A = Mobility Inventory, Alone; WI = Whiteley Index; BSQ = Body 
Sensation Questionnaire; BAI = Beck Anxiety Inventory; FLZ-GG = Questions on Life Satisfaction, satisfaction 
with health; MALT = Munich Alcoholism Test. 
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Table 5.3. 
Bivariate Correlations Between Potential Predictors and Residual Gain Scores (RGS) of 
Social Phobic Symptoms and Subjective Rating of Global Improvement (RGI) of Completers 
at Posttreatment (post) and One-year follow-up (F1)  
 Post F1 
 SCL-IS (N) SCL-IS (N) 
 RGS RGI RGS RGI 
Demographic and biographical variables 
Age -.00 (160) .10 (166) -.10 (100) -.10 (118) 
Gender .05 (160) .05 (167) .02 (100) .28 (119)** 
Education -.02 (157) -.07 (164) .20 (99)* .12 (117) 
Marital status .02 (157) -.10 (165) -.03 (99) .20 (118)* 
Age at onset .04 (149) .04 (156) -.00 (97) -.04 (114) 
Duration -.03 (149) .05 (155) -.10 (97) -.04 (113) 
Prior treatment .06 (155) .11 (162) .07 (98) .17 (117) 
Medication .08 (156) .05 (163) -.05 (99) -.06 (118) 
Severity & Impairment 
Impairment  .02 (112) -.03 (115) .10 (73) -.20 (81) 
SCL-GSI .03 (159) .13 (164) .04 (100) .27  (117)** 
DIPS  -.03 (120) .15 (129) .06 (81) .19 (95) 
SPS .05 (84) .26 (82)* .23 (48) .29 (52)* 
SIAS .07 (83) .18 (81) .14 (48) .23 (52) 
Physical 
symptoms 
.01 (143) -.04 (150) .02 (90) .16 (109) 
BSQ .14 (154) .20 (158)* .01 (95) .16 (111) 
BAI .10 (152) .16 (157)* .03 (95) .23 (111)* 
Subtypes 
Situations .06 (145) .17 (152)* .26 (91)* .27 (110)** 
Anxiety .11 (145) .22 (152)** .27 (91)** .30 (110)** 
Comorbidity 
Diagnoses -.08 (160) .03 (167) -.05 (100) .09 (119) 
BDI .09 (155) .23 (160)** .09 (97) .23 (113)* 
HZI-G -.01 (139) -.08 (141) .08 (86) .02 (102) 
HZI-H .02 (139) .02 (141) -.10 (86) .08 (102) 
ACQ .13 (157) .11 (161) .04 (98) .24  (114)** 
MI-A -.08 (141) .03 (147) .04 (86) .14 (101) 
WI .19 (139)* .15 (139) -.02 (87) .19 (96) 
Health related variables 
FLZ-GG -.11 (77) -.34 (74)** -.04 (45) -.37 (48)** 
Chronic disease -.06 (82) .01 (86) -.05 (52) -.12 (60) 
MALT .12 (133) -.06 (138) .01 (88) .19 (100) 
Benzodiazepines .10 (156) .15 (163) .03 (99) .02 (118) 
Treatment and therapist variables 
Gender .11 (156) .02 (163) .05 (98) -.05 (117) 
Experience .03 (155) -.04 (162) .13 (97) -.10 (116) 
No. Sessions .09 (121) .08 (125) .10 (77) .27 (93)** 
5. Who Comes, Who Stays, Who Profits?    84 
Sample numbers for correlations are additionally reduced by missing data in the assessment measures. * = p 
≤ .05, ** = p ≤ .01 for significant correlations; SCL-GSI = Symptom Checklist-90-Revised, Global Severity 
Index; DIPS = Diagnostic Interview for Psychological Disorders; SPS = Social Phobia Scale; SIAS = Social 
Interaction Anxiety Scale; BSQ = Body Sensation Questionnaire; BAI = Beck Anxiety Inventory; BDI = Beck 
Depression Inventory, HZI-G = Hamburg Obsessive Compulsive Inventory – Ruminations; HZI-H = Hamburg 
Obsessive Compulsive Inventory – Obsessive Behaviour; ACQ = Agoraphobic Cognition Questionnaire; MI-A 
= Mobility Inventory, Alone; WI = Whiteley Index; FLZ-GG = Questions on Life Satisfaction, Satisfaction with 
Health; MALT = Munich Alcoholism Test. 
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Table 5.4.  
Means and Standard Deviations or Percentages of Variables at Pre- and Postassessment for 
Patients who Deteriorated (DET) or Remained Stable (STAB) between Post- and 1-year  
Follow-up 
 DET 
N = 12 
STAB 
N = 78 
Test-Value df p 
Demographic and biographical variables 
Age 29.8 (5.4) 34.1 (10.0) t = -2.2 24.7 .037* 
Male 75% 53% Chi2 = 2.1 1 .145 
Marital status 17% married 
25% partner 
58% solo 
32% married 
26% partner 
42% solo 
Chi2 = 1.4 2 .491 
Educational level 0% none 
25% sec. school 
33% high school 
42% university 
2% none 
37% sec. school 
33% high school 
28% university 
Chi2 = 1.8 3 .621 
Age at onset 19.4 (3.3) 20.8 (9.9) t = -0.9 49.6 .353 
Duration 10.4 (3.9) 13.3 (10.7) t = -1.7 44.8 .095 
Prior treatment 83% Outpatient 
25% Inpatient 
67% Medication 
59% Outpatient 
12 % Inpatient 
37% Medication 
Chi2 = 2.6 
Chi2 = 1.5 
Chi2 = 3.8 
1 
1 
1 
.109 
.217 
.051 
Severity and Impairment 
SPS pre1 
SPS post 
56.4 (10.4) 
29.4 (19.7) 
30.4 (16.8) 
16.5 (13.8) 
t = 3.4 
t = 1.9 
40 
45 
.002** 
.067 
SIAS pre1 
SIAS post 
58.6 (13.1) 
36.6 (17.9) 
36.5 (15.7) 
21.9 (13.8) 
t = 3.0 
t = 2.2 
40 
45 
.005** 
.034* 
DIPS  6.4 (1.1) 5.9 (1.1) t = 1.3 73 .214 
Impairment  3.5 (0.8) 3.3 (0.8) t = 0.8 64 .441 
SCL-GSI pre 
SCL-GSI post 
1.1 (0.5) 
0.5 (0.4) 
0.9 (0.6) 
0.5 (0.5) 
t = 1.5 
t = -0.6 
88 
87 
.146 
.951 
No. Physical 
symptoms 
18.1 (9.6) 16.9 (8.0) t = 0.5 78 .655 
BAI pre 
BAI post 
20.3 (7.5) 
8.4 (4.5) 
19.8 (11.8) 
11.8 (10.4) 
t = 0.2 
t = -1.9 
83 
37.7 
.875 
.060 
BSQ pre 
BSQ post 
2.1 (0.5) 
1.7 (0.5) 
2.2 (0.7) 
1.6 (0.6) 
t = -0.6 
t = 0.3 
83 
84 
.577 
.735 
Subtypes 
Situations 8.4 (2.2) 6.3 (3.0) t = 2.2 79 .030* 
Anxiety 26.4 (6.1) 20.5 (8.8) t = 2.1 79 .037* 
Comorbidity 
Diagnoses  0.6 (0.8) 0.51 (0.7) t = 0.2 88 .831 
BDI pre 
BDI post 
18.4 (12.8) 
6.6 (6.9) 
13.6 (9.6) 
6.7 (7.1) 
t = 1.5 
t = 0.0 
85 
14.8 
.129 
.969 
HZI-G pre 
HZI-G post 
3.5 (2.8) 
1.8 (2.3) 
2.6 (2.1) 
1.4 (1.5) 
t = 1.3 
t = 0.6 
75 
74 
.200 
.548 
HZI-H pre 
HZI-H post 
2.9 (1.3) 
2.5 (1.7) 
3.2 (1.9) 
2.7 (1.8) 
t = -0.4 
t = -0.4 
75 
73 
.716 
.710 
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ACQ pre 
ACQ post 
1.9 (0.4) 
1.5 (0.3) 
1.9 (0.5) 
1.5 (0.5) 
t = 0.4 
t = 0.1 
86 
85 
.710 
.935 
MI-A pre 
MI-A post 
1.9 (0.6) 
1.3 (0.5) 
1.8 (0.7) 
1.3 (3.6) 
t = 0.4 
t = 0.0 
76 
79 
.690 
.998 
WI pre 
WI post 
2.4 (3.0) 
2.3 (2.9) 
3.1 (2.9) 
2.0 (2.5) 
t = -0.8 
t = 0.3 
77 
77 
.405 
.738 
Health related variables 
FLZ-GG pre 
FLZ-GG post 
21.0 (17.0) 
77.5 (30.7) 
32.1 (37.4) 
59.2 (41.2) 
t = -0.6 
t = 0.9 
37 
42 
.565 
.395 
Chronic Disease 0% 15% Chi2 = 0.5 1 .470 
Benzodiazepine 8.3% 15.6% Chi2 = 0.4 1 .508 
MALT pre 
MALT post 
3.5 (2.6) 
1.3 (1.6) 
2.6 (3.0) 
2.1 (3.0) 
t = 0.8 
t = -0.8 
76 
76 
.424 
.440 
Therapist Variables 
Experience 2.1 (1.0) 2.1 (1.0) t =  0.1 85 .922 
Male therapists 58% 36% Chi2 = 2.3 1 .132 
No. of sessions 30.7 (12.6) 35.4 (13.6) t = -0.9 67 .355 
* = p ≤ .05, ** = p ≤ .01 for significant differences in t-test or Chi Square Test; 1 = SPS = Social Phobia Scale; 
SIAS = Social Interaction Anxiety Scale. 1Calculations for SPS and SIAS were based on smaller samples: for 
pre: n = 5 deteriorated and n = 37 stable, for post: n = 5 and n = 42 respectively; DIPS = Diagnostic Interview for 
Psychological Disorders; SCL-GSI = Symptom Checklist-90-Revised, Global Severity Index; BAI = Beck 
Anxiety Inventory; BSQ = Body Sensation Questionnaire; BDI = Beck Depression Inventory; HZI-G = 
Hamburg Obsessive Compulsive Inventory – Ruminations; HZI-H = Hamburg Obsessive Compulsive Inventory 
– Obsessive Behaviour; ACQ = Agoraphobic Cognition Questionnaire; MI-A = Mobility Inventory, Alone; WI = 
Whiteley Index; FLZ-GG = Questions on Life Satisfaction, Satisfaction with Health.  
2Calculations for FLZ-GG were based on smaller samples: for pre: n = 4 deteriorated and n = 35 stable, for post: 
n = 4 and n = 40 respectively; MALT = Munich Alcoholism Test. 
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6.1. Summary 
In spite of the success of cognitive behavioural therapy for social phobia found in research, it 
remains unclear whether interventions will remain successful in the routine of clinical 
practice, where patients and treatment conditions might differ from those in research samples. 
Also, response rates make clear that not all patients benefit from the investigated treatment 
approaches. Almost half of the patients either refuse to undergo treatment after it has been 
offered, drop out during treatment or do not profit from completing it. In order to adapt 
treatment conditions better to individual needs, knowledge about variables predicting 
treatment success or failure is necessary. Studies investigating such predictors have so far 
yielded some contradictory results, have neglected prediction of refusal and relapse after 
treatment and have been carried out in typical research conditions, with samples not 
necessarily representative of clinical practice. 
As a consequence, the studies address three basic questions: (1) Do typical research 
conditions have an affect on the effect sizes achieved? (2) Can the results found in 
randomised controlled trials be generalized to clinical practice? (3) Which variables can 
predict treatment attrition and response in clinical practice?  
Several approaches were taken in order to answer these questions. First, thirty studies testing 
treatment effects for social phobia were re-examined by categorizing them according to the 
quality and amount of applied sample restriction and laboratory study characteristics and 
comparing their mean effect sizes. Second, 217 unselected patients with a primary diagnosis 
of social phobia according to DSM-III-R who began treatment in one of four outpatient 
clinics of the Christoph-Dornier Foundation of Clinical Psychology in Germany (CDS) were 
assessed before and six weeks after treatment, using an extensive assessment battery. 
Treatment outcome as well as clinical significance were calculated. Both the sample and the 
treatment outcome were compared to samples and outcome in the 30 efficacy studies and to 
outcome reported in meta-analyses. Thirdly, it was tested whether a restriction of the sample 
according to typical exclusion criteria would result in a larger effect size. Finally, the sample 
was completed by another 70 social phobic patients who were seeking treatment in the CDS 
but discontinued before treatment started. The 287 patients were then classified as refusers 
after diagnostic assessment (16%), refusers after cognitive preparation (8%), dropouts (6%), 
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and completers (69%). Outcome was assessed by calculating relative change via residual gain 
scores and by patient improvement ratings six weeks and one year after the end of treatment. 
Patients who completed the one-year follow-up (n = 101) were categorized as stable (87%) or 
deteriorated (13%). Demographic and disorder-related as well as therapist and treatment 
variables were analysed  as predictors for each classification. 
The results of the analysis of outcome studies indicate that even the accumulation of sample 
restriction, such as excluding patients with comorbid disorders or outside a certain age-range 
does not have any predictive value for treatment effect. However, there was a significant 
tendency for studies applying several “laboratory treatment conditions”, such as recruiting 
patients by adverts, applying treatment in university settings, using specifically trained 
therapists, and following a treatment manual to achieve higher effect sizes.  
The sample of patients in the study in clinical practice did not differ considerably from the 
samples in the comparison studies. The results six weeks after the end of therapy showed 
significant reductions in social phobic fears and avoidance as well as in general anxiety and 
symptoms of depression. The effect sizes are comparable with the average effect-sizes 
reported by meta-analytic studies of controlled efficacy research using selected patients. 
Restricting the sample according to the selection criteria often applied in research settings did 
not result in higher effect sizes. Fifty-six percent of the sample changed significantly with 
regard to social phobic symptoms.  
The analysis of response in the sample of 287 patients seeking treatment for social phobia 
revealed a much lower response rate: only 43% of the patients originally seeking treatment 
completed and benefited from it in the end. The only significant predictor for treatment 
attrition was comorbidity. Treatment gain was best predicted by satisfaction with health (FLZ-
GG). Also, patients characterized by more generalized social phobia improved less by 1-year-
follow-up. Pretreatment depression had no effect on change as assessed by the self report 
measures, but more depressed patients reported having improved less. Finally, patients who 
were more severely impaired at pretreatment (as assessed by the SPS) found it harder to 
maintain treatment gain.  
Taken together, it can be concluded that sample selection does not seem to enhance the effects 
of treatment and that individual cognitive behaviour therapy for social phobia can be 
transported from research settings to the field of mental health. However, although similar 
success rates can be achieved in clinical practice, practitioners are well advised to maintain 
supervision and keep up regular training. Finally, there is hope to further improve the 
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effectiveness of treatment by giving more attention to severely impaired patients or patients 
with comorbid disorders, who are more prone to dropout or relapse after treatment. 
6.2. Zusammenfassung 
Trotz der durch eine Vielzahl von Forschungsarbeiten bestätigten Erfolge von kognitiver 
Verhaltenstherapie für Soziale Phobie bleibt fraglich, ob die untersuchten Interventionen auch 
im klinischen Alltag, in dem sich Patienten und Behandlungsbedingungen möglicherweise 
von denen in der Forschung unterscheiden, erfolgreich sind. Die bisherigen Befunde 
verdeutlichen zudem, dass bei Weitem nicht alle Patienten von den Behandlungsangeboten 
profitieren. Fast die Hälfte derer, die Behandlung aufsuchen, treten entweder vor Beginn der 
Behandlung zurück oder erreichen keine nennenswerte Verbesserung. Um Behandlungs-
angebote besser an die individuellen Bedürfnisse anzupassen, ist Wissen über Prädiktoren zur 
Vorhersage von Therapieerfolg unabdingbar. Trotz einer Reihe von Studien, die Therapie-
prädiktoren bei der Behandlung von Sozialer Phobie untersuchten, gibt es bisher nur wenige 
eindeutige Ergebnisse. Außerdem ist zu bemängeln, dass die Vorhersage von Rücktritten und 
Rückfällen vernachlässigt wurde, und dass die Studien unter kontrollierten 
Forschungsbedingungen stattfanden, in denen die Bandbreite potentieller Prädiktoren 
möglicherweise eingeschränkt ist.  
Aus diesen Überlegungen leiten sich drei wesentliche Fragestellungen ab: (1) Haben typische 
Forschungsbedingungen und selegierte Stichproben Einfluss auf die Effektgröße? (2) Ist es 
möglich, die Ergebnisse aus randomisierten und kontrollierten Studien auf die klinische 
Praxis zu übertragen? (3) Durch welche Variablen können Rücktritte, Dropout und 
Behandlungserfolg in der klinischen Praxis vorhergesagt werden?  
Verschiedene Herangehensweisen dienten der Beantwortung der Fragestellungen. Zunächst 
wurden 30 Studien, die die Wirksamkeit kognitiver Verhaltenstherapie für Soziale Phobie 
untersuchten, re-analysiert, indem sie anhand der Qualität und Quantität von 
Stichprobenselegierung und Laborcharakteristika eingestuft und ihre mittleren Effekte 
verglichen wurden. Weiterhin wurde eine unselegierte Gruppe von 217 Patienten mit der 
Primärdiagnose Soziale Phobie nach DSM-III-R, die in einem von vier Instituten der 
Christoph-Dornier Stiftung für Klinische Psychologie (CDS) eine Behandlung aufsuchten, vor 
und sechs Wochen nach der Behandlung einer ausführlichen Diagnostik anhand einer 
klinischen Fragebogenbatterie unterzogen. Der Behandlungserfolg und die klinische 
Signifikanz wurden errechnet. Die Stichprobe und die Ergebnisse wurden mit Stichproben 
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und Ergebnissen der 30 Wirksamkeitsstudien sowie mit den in Metaanalysen berichteten 
durchschnittlichen Effekten verglichen. Zusätzlich wurde untersucht, ob eine Selegierung der 
Stichproben anhand forschungsüblicher Kriterien in einer größeren Effektstärke resultieren 
würde. Schließlich wurde die Stichprobe um weitere 70 Patienten mit Sozialer Phobie 
ergänzt, die zwar Behandlung aufsuchten, aber vor Beginn der Behandlung zurücktraten. Die 
Gesamtstichprobe von 287 Patienten wurde in 4 Gruppen unterteilt: Rücktritte nach der 
Diagnostik (16%), Rücktritte nach Kognitiver Vorbereitung (8%), Abbrüche während der 
Therapie (6%) und Patienten, die die Therapie abschlossen (69%). Für die behandelten 
Patienten wurde der Therapieerfolg als das relative Ausmaß der durch die Behandlung 
erzielten Veränderung („residual gain scores”) sowie durch die subjektive Therapieerfolgsein-
schätzung erfasst.  Patienten, die an der 1-Jahres Katamnese teilnahmen (n = 101) wurden als 
stabil (87%) oder verschlechtert (13%) eingestuft. Demographische und störungsbezogene, 
sowie Therapeuten- und Behandlungsvariablen wurden als Prädiktoren für jede Klassifikation 
analysiert.  
Die Ergebnisse der Analyse der Therapiestudien deuten darauf hin, dass sogar eine 
Akkumulation von angewendeten Selektionskriterien, wie z.B. der Ausschluss komorbider 
Depression oder von Patienten außerhalb einer bestimmten Altersspanne keinen Einfluss auf 
die Größe der Effekte hat. Andererseits fand sich ein Zusammenhang zwischen der Menge 
zutreffender „Laborcharakteristika“, wie z.B. Werbung der Patienten über Anzeigen, 
Durchführung der Behandlung in universitärem Setting, speziell trainierte Therapeuten oder 
genaues Befolgen eines Therapiemanuals, und der Größe des Effektes. Studien, auf die 
mehrere Laborkriterien zutrafen, erzielten etwas höhere Effekte.  
Es zeigten sich keine wesentlichen Unterschiede zwischen unserer Stichprobe in der 
klinischen Praxis und Stichproben in Vergleichsstudien. Die Ergebnisse sechs Wochen nach 
Beendigung der Therapie zeigten eine deutliche Verringerung sozialphobischer Ängste und 
Vermeidungsverhaltens, wie auch allgemeiner Ängstlichkeit und Depressivität. Die erreichten 
Effekte entsprechen den mittleren Effektstärken aus Metaanalysen, die überwiegend 
kontrollierte Studien mit selegierten Patientengruppen auswerteten. Eine Einschränkung 
unserer Behandlungsgruppe anhand typischer Selektionskriterien führte nicht zu höheren 
Effektstärken. Eine klinisch relevante Verbesserung sozialphobischer Symptome wurde von 
56% der Patientenstichprobe erreicht. Die Analyse der Gesamtstichprobe von 287 Patienten, 
die ursprünglich Behandlung aufsuchten, ergab eine deutlich geringere Erfolgsrate: Lediglich 
43% der Patienten vollendeten die Behandlung und profitierten von dieser.  
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Im Hinblick auf Prädiktoren für Therapieabbrüche erwies sich eine höhere Komorbidität als 
positiver Prädiktor. Die durch die Behandlung erzielte Veränderung konnte am besten durch 
die subjektive Zufriedenheit mit gesundheitlichen Lebensaspekten (FLZ-GG) vorhergesagt 
werden. Patienten, die durch eine generalisiertere Sozialphobie gekennzeichnet waren, zeigten 
weniger Veränderung zur 1-Jahres Katamnese. Komorbide Depression zu Beginn der 
Behandlung hatte zwar keinen Einfluss auf die Veränderung durch die Behandlung, aber 
depressivere Patienten hatten den subjektiven Eindruck, weniger profitiert zu haben als nicht 
depressive. Schließlich gelang es Patienten, die bereits vor der Therapie einen höheren 
Schweregrad der Sozialen Phobie (in der SPS) aufwiesen, schlechter, den erreichten 
Behandlungserfolg aufrechtzuerhalten.  
Zusammenfassend kann gefolgert werden, dass Stichprobenselegierung die Behandlungs-
effekte nicht begünstigt, und dass individuelle kognitive Verhaltenstherapie für Soziale 
Phobie von der Forschung in die klinische Praxis übertragen werden kann. Obwohl 
vergleichbare Erfolge erreicht werden können, sind Praktiker gut beraten, eine ausführliche 
Supervision in Anspruch zu nehmen und regelmäßige Fortbildungen aufzusuchen. Schließlich 
bleibt zu hoffen, dass die Effektivität der Behandlung weiter verbessert werden kann, indem 
zusätzliche therapeutische Interventionen stärkere Berücksichtigung finden, die der 
besonderen Belastung von komorbid oder in höherem Ausmaß gestörten Patienten gerecht 
werden.   
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Appendix A. Categorization of Studies 
Table A.1. Categorization of Studies According to Restriction and Laboratory Characteristics 
Study N ES a b c d e f g k l m n o p 
1 19 1.76 1 1 1 0 0 0 0 1 1 1 1 1 1 
2 15 0.35 0 0 0 1 1 1 * 0 0 1 0 1 1 
3 7 0.5 1 1 1 0 1 0 0 1 1 0 * 1 0 
4 25 0.63 * * * * 0 0 * 0 0 0 0 1 0 
5 7 4.75 * * * * 0 0 0 0 0 0 0 1 0 
6 17 1.18 1 1 0 0 1 0 1 0 1 1 1 1 1 
7 29 0.73 1 1 0 0 0 0 * 0 1 0 1 1 1 
8 7 1.25 1 1 0 0 1 0 1 0 0 1 0 1 0 
9 20 0.98 1 1 1 0 0 0 1 0 0 0 1 1 1 
10 28 0.30 1 1 0 0 0 1 1 0 1 1 * 1 0 
11a 8 1.10 0 0 0 0 1 0 * 1 1 1 1 1 1 
11b 7 0.75 0 0 0 1 1 0 * 0 1 1 1 1 1 
12 20 0.86 1 1 1 1 1 0 1 0 0 1 1 1 1 
13a 12 1.39 1 0 0 0 0 0 1 1 1 1 1 1 1 
13b 8 0.86 1 0 0 1 0 0 1 0 1 1 1 1 1 
14a 5 1.04 1 1 1 0 0 0 * 1 0 0 0 1 0 
14b 5 0.84 1 1 1 0 0 0 * 1 0 0 0 1 0 
15 36 1.33 * * * * 0 0 0 0 1 1 1 1 0 
16 175 0.82 0 0 0 0 0 0 0 0 0 0 0 0 0 
17 44 0.65 1 1 1 1 0 0 * 0 1 0 1 1 1 
18 20 1.10 1 1 1 1 1 0 * 0 1 0 1 1 1 
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19 30 0.82 1 0 0 0 1 0 1 0 1 1 1 1 0 
20 16 0.94 1 1 0 0 1 0 * 0 1 1 1 1 1 
21 15 0.60 1 0 0 0 0 1 * 0 1 0 0 1 0 
22 15 1.85 * * * * 1 * 1 0 1 1 0 1 0 
23 20 0.478 1 0 0 0 0 1 * 1 0 1 1 1 1 
24 59 1.33 1 0 0 0 1 1 * 1 1 1 1 1 1 
25 40 0.86 1 0 0 0 0 0 0 0 1 1 1 1 0 
26 11 1.25 1 1 0 0 0 0 * 1 0 0 0 1 0 
27 44 1.38 1 0 0 0 0 0 1 1 1 0 1 1 1 
28 12 0.87 1 1 1 0 0 0 1 0 0 0 * 1 0 
29 21 0.94 1 1 1 0 0 0 * 0 0 0 1 1 0 
30 42 0.73 1 1 1 0 0 1 0 0 0 0 0 0 0 
Study = included study or study sample (see references). Separate samples within one study 
are marked with a and b.; N = Number of participants of the sample; ES = effect size; (a) 
exclusion of comorbid psychosis; substance misuse or bipolar disorder; (b) exclusion of 
comorbid depression; (c) exclusion of comorbid axis I disorders; (d) exclusion of comorbid 
avoidant personality disorder; (e) exclusion of low severity; (f) exclusion of prior treatment; 
(g) majority of sample are students; (k) qualitative sample restrictions; (l) patients recruited by 
adverts; (m) carried out in a university setting; (n) using specially trained therapists; (o) 
following a treatment manual; (p) monitoring treatment manual 
1 = applies; 0 = does not apply; * = missing value 
Appendix                                     4 
 
 
 
Appendix B. Timing of Assessment 
Table B.1. Timing of Assessments 
 Pretreatment  Assessment  
Posttreatment  
Assessment  
1-year-Follow-
Up (F1) 
 Before first session 
During diagnostic 
procedure 
6 – 8 weeks after 
treatment  
1 year after 
treatment  
Application  X    
Medical Check-up  X   
Socio-demographic 
Questionnaire 
 X   
Diagnostic Interview 
(DIPS) 
 X  X 
SPS  X X X 
SIAS   X X X 
SCL-90-R  X X X 
BDI  X X X 
BAI  X X X 
BSQ  X X X 
ACQ  X X X 
MI  X X X 
HZI  X X X 
WI  X X X 
FLZ  X X X 
MALT-S  X X X 
FU-Questionnaire    X 
Rating of Global 
Improvement 
  X X 
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Appendix C. Description of the Sample (N = 
287) 
C.1. Sociodemographic Variables  
Age 
 
≤  20 years: 6% 
21-30 years: 40% 
31-40 years: 32% 
41-50 years: 16% 
≥  50 years: 7% 
N = 284 
Gender 
 
Male: 56%  
Female: 44 %  
N = 288 
Marital status 
 
Married: 33% 
Living with a partner: 13% 
Partnership (non-committal): 10% 
Single: 44% 
N = 280 
Educational level  
 
No school degree: 3% 
Lower school [Hauptschule]: 11% 
Secondary school [Realschule]: 21% 
A-levels [Abitur]: 32% 
University degree: 33% 
N = 284 
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Occupational status 
 
Employed: 46% 
Self-employed: 14% 
Unemployed: 7% 
Student in Training: 27% 
Housewife: 3% 
In Retirement: 3% 
N = 274 
C.2. Disorder Related Variables 
Age at onset of social phobia M = 19.9 (SD = 9.7, range 4 - 56) N = 267 
Duration of social phobia M = 13.8 (SD = 11.7, range 0-68) N = 267 
Feeling of general impairment 
  
Extreme impairment: 56.1% 
Strong impairment: 34.9% 
Medium impairment: 8.5% 
Low impairment: 0.5% 
N = 212 
Areas of extreme impairment Family life: 34.4% 
Partnership: 35.7% 
Work: 89.6% 
N = 244 
N = 213 
N = 240 
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Social situations causing strong or 
extreme fear  
Speaking in front of a group: 82%  
Meetings: 62.8% 
Parties: 52% 
Speaking with authorities: 51% 
Eating in public: 46% 
Dates/Rendez-Vous: 43% 
Requesting a behavioural change: 39% 
Starting a conversation: 38% 
Repudiating unduly claims: 32% 
Writing in front of others: 31% 
Keeping up a conversation: 29%  
Using public toilets: 10% 
N = 256 
N = 258 
N = 258 
N = 257 
N = 258 
N = 255 
N = 255 
N = 257 
N = 254 
N = 256 
N = 252 
N = 257 
Physical symptoms causing strong 
or extreme impairment 
Stronger heartbeat: 66%  
Transpiration:62% 
Trembling: 55% 
Hot flushes: 41% 
Derealisation: 26% 
Dizziness: 24% 
Shortness of breath: 22%  
Nausea: 20% 
Chestpain: 17% 
Feelings of suffocation: 12% 
Numbness: 6 % 
N = 251 
N = 252 
N = 252 
N = 251 
N = 252 
N = 251 
N = 251 
N = 251 
N = 252 
N = 251 
N = 253 
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C.3. Comorbid Diagnoses According to DSM-III-R 
Any Comorbid Diagnosis   
Major Depressive Disorder 22.2% 
Agoraphobia Without History  
of Panic Disorder 1.4% 
Specific Phobia 7.4% Obsessive-Compulsive  
Panic Disorder With Agoraphobia 7.3% Personality Disorder 1.2% 
Dysthymic Disorder 5.3% Posttraumatic Stress Disorder 1.1% 
Generalized Anxiety Disorder 3.5% Primary Insomnia 0.8% 
Avoidant Personality Disorder 3.3% Dependent Personality  
 Disorder 0.7% Panic Disorder Without  
Agoraphobia 2.8%  
Hypochondriasis 2.5% 
Obsessive Compulsive 
Disorder 0.4% 
Bulimia Nervosa 2.5% Cyclothymic Disorder 0.3% 
Somatization Disorder 1.9% Separation Anxiety   
Alcohol Abuse 1.5% Disorder 0.3% 
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C.4. Previous Treatment Attempts 
Psychological Treatment 69% N = 276 
Hospitalisation 24% N = 276 
Medical Treatment Any medicine: 54% 
Benzodiazepines: 16% 
Antidepressants: 16%  
Neuroleptics: 5%  
ß-blocker: 8% 
Other: 26% 
N = 276 
N = 276 
N = 276 
N = 276 
N = 276 
N = 276 
Other Treatment 6% N = 273 
No Treatment 20% N = 272 
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Appendix D. Description of Treatment 
D.1. Formal Treatment Conditions 
During the one or two weeks of intensive treatment patients are normally accommodated in a 
hotel or a guesthouse situated in close proximity to the Christoph-Dornier-Foundation. At the 
time of the therapy described in the studies (1990-1999) the cost of treatment was paid for in 
most cases by the health insurance as "Kostenerstattungsverfahren” [reimbursement of 
expenses]. This means that invoices for treatment sessions are directed to the patient, who has 
to apply for reimbursement with his or her health insurance company. The insurance company 
is free to decide whether or not they are prepared to cover the expenses for treatment. This 
decision process mostly took place after diagnostic assessment, and the rejection of the 
application to cover the costs was the most frequent reason for treatment attrition at this stage 
of treatment. Additional treatment-expenses, such as accommodation, tickets, etc. were not 
covered by the health insurance.  
D.2. First Session 
After receiving the application questionnaire, the therapist contacts the patient and arranges a 
date for a first session. The first session is usually conducted in the rooms of the institute of 
the Christoph-Dornier-Foundation, but therapists are willing to conduct it in the house of the 
patient if problems are so disabling they prevent a patient from coming.  
The most important aspects of the first session have been described by Frank and Frank 
(2000). The first contact offers the patient an opportunity for a first impression of the therapist 
and the institute, a first description of the problem for which he or she is seeking treatment 
and clarification of organisational questions. 
The therapist tries to gain all necessary information needed for the planning of the diagnostic 
procedure as to clarify whether he will be able to offer the patient adequate treatment or 
whether he must refer to another institution. Additionally, the therapist informs about the 
disorder, offers explanations for symptoms, and gives information on the further procedure of 
treatment and other organisational questions. At the same time he concentrates on building up 
a good emotional relationship by assuring that he understands the patient’s suffering, as well 
as taking the problem seriously and refraining from evaluating or accusing.  
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D.3. Medical Check-up and Diagnostic Assessment 
A medical check-up is carried out by general practitioners or specialists in cooperation, who 
are well informed about symptoms of social phobia. The doctors complete a medical report, 
which has been specifically developed for patients with an anxiety disorder. The medical 
check-up is particularly important in the context of exposure since this can be physiologically 
stressful and may be contraindicative (e.g. for patients with coronary heart disease). Further, a 
detailed attempt to clarify the source of specific, particularly impairing symptoms (e.g. 
extreme trembling) can be of importance with regard to cognitive restructuring interventions 
as well as for setting realistic goals. 
Diagnostic assessment takes place in approximately four to six treatment sessions, usually 
completed in one day. It consists of several components. One basic component is the 
diagnostic interview [Diagnostisches Interview für Psychische Störungen] (DIPS, Margraf, 
Schneider, & Ehlers, 1991). Apart from gaining a reliable diagnosis the therapist aims at 
receiving a clear picture of all anxiety provoking situations as well as the amount of fear they 
provoke. He will also try to gain as much information about avoidance behaviour and safety 
behaviours, needed for an adequate planning of treatment. The therapist also tries to gather 
the information required for the model of explanation, the factors that engender and maintain 
the problem in the past or at present. Finally the patient is asked to complete a series of 
questionnaires which are depicted in Appendix E.  
D.4. Cognitive Preparation 
Cognitive preparation for therapy takes place about one week later and is necessary to 
enhance the patient’s motivation for treatment. The concept of cognitive preparation is based 
on the explanations given by Bartling, Fiegenbaum, and Krause (1980) for the treatment of 
panic disorder and agoraphobia, but has been adapted to the treatment of social phobia. The 
length of the cognitive preparation session is variable and depends on the individual problem 
of a patient, his or her expectations concerning therapy, the motivation for change and the 
relationship between patient and therapist. The cognitive preparation has four basic goals.  
D.4.1. Explanation of cause and maintenance of social phobic 
behaviour and experiences 
According to intellectual abilities, previous experience and own attempts of explaining the 
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problem, different cognitive-behavioural theories can be used. The phobic behaviour is 
portrayed as normal, learnt behaviour that has developed because of inconvenient learning 
conditions. A basic aim is to relieve the patient from concerns about being different or 
something being „fundamentally wrong“ with him or her, as such assumptions lead to 
devaluations of the self. Instead it is underlined that avoidance and safety behaviour carry the 
main responsibility for maintenance and intensification of anxiety. The influence of further 
important factors, as far as they turned out to be of importance in the diagnostic assessment 
(perfectionism, self-focused attention, one-sided interpretations) is explained. The therapist 
develops an individualized model with the patient, for example following the model of Clark 
und Wells (1995), and sketches it for the patient on paper. An example for such a model can 
be seen in Figure D.1. 
Figure D.1. Simplified Example of an Explanation Model used in Therapy 
 
D.4.2. Deriving the treatment 
The sketched model is used as a basis from which the treatment is derived stringently and the 
treatment procedure is explained in a transparent way. The necessity of a detailed analysis of 
dysfunctional cognitive schemes responsible for the specific interpretation in the situation as 
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well as the importance of exposure to the feared situations is derived in a way that that is 
plausible for the patient. The understanding on behalf of the patient is enhanced by using 
metaphors and encouraging patients to imagine what would happen if they do not avoid the 
feared situations, using so called “thought-experiments”. Furthermore, information on the 
duration and course of treatment is given. The therapist points out, that he will not get 
involved in discussions or distractions during exposure tasks, but will try to prevent 
avoidance-behaviour whenever possible. The patient is requested to refrain from all 
precautions that normally serve to reduce fear (sedatives, lucky charms, or not drinking coffee 
beforehand in order to avoid trembling).  
D.4.3. Emphasising the patient’s responsibility 
The personal responsibility of the patient is underlined by explicitly giving the patient about a 
week time to come to their own decision for or against participation in the therapy. The 
therapist makes absolutely no attempt to persuade the patient to participate. In this time 
purposely no further interventions take place in order to not disturb the decision process. 
However, the patient is offered the possibility of consultation if needed.  
D.4.4. Development of a trusting relationship 
The aim is to build up the relationship between patient and therapist in way that encourages 
the patient to trust the therapist and perceive him as competent. The therapist makes clear that 
he takes the patient’s fears seriously and understands how difficult and stressful it must be for 
the patient to have to confront him- or herself with the feared situations.  
D.5. Therapy 
When the patient decides to participate, exposure and cognitive intervention begin (duration is 
variable and depends on the individual patient’s needs). The therapist is in close contact with 
the patient during the first days, during which it is not unusual for treatment to last for six to 
eight hours. Exposure to the feared situations plays a central role in the therapy as it serves 
several purposes, with varying importance in the course of treatment. First, it is used to 
experience a certain degree of habituation to the situation. Secondly, it helps to assess further 
anxiety-provoking and maintaining cognitions, safety-behaviour, selective attention as well as 
self-focused attention. Thirdly, confrontation with the feared situations offers the patient the 
possibility of testing negative beliefs concerning his or her behaviour or the behaviour of 
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others, by evaluating video-recordings of the exposure situation. If possible, an audience used 
for the exposure situation can also function as giving feedback in order to correct 
dysfunctional self-perception. Fourthly, for patients with deficits in social skills the situations 
can also be used for training.  
Exposure always takes place with cognitive restructuring interventions, in which the analysis 
of fear-relevant cognitive concepts and schemes play a central role. Only after these concepts 
have been clearly defined the actual restructuring can take place. The basic strategy then 
consists of “system-immanent” dialoguing, which increases a patient’s motivation to drop and 
replace dysfunctional concepts. Thus, finally, after restructuring interventions have taken 
place, the exposure situations give the patient an opportunity to test out alternative concepts 
(e.g. “It is okay to make a mistake sometimes”), by changing his or her behaviour in the 
situation (e.g. allowing mistakes to happen or even making a mistake on purpose).  
Generally, exposure situations are chosen depending on the patients’ individual fears and 
starting with those in the top half of an anxiety hierarchy. Examples for exposure situations 
are giving a short speech in front of an audience, eating soup in a restaurant, serving drinks, 
chatting with a member of the opposite sex, or keeping eye-contact with other passengers in 
public transport. The therapist aims at providing the patient with situations that are as natural 
as possible and contain the specific fear provoking elements.  
Further elements of the therapy, that are used when it seems appropriate consist of 
behavioural experiments, such as experimenting with the effect of safety behaviours using 
video-feedback or conducting an opinion poll on a theme that is relevant to the patient (e.g. 
“What goes through people’s mind when someone blushes?”). Apart from being a basis for 
cognitive restructuring, these interventions also contain exposure elements.  
Therapists are free to vary the amount of exposure and cognitive therapy as well as the length 
of the intervention according to the needs of the individual patient. They are also free to use 
additional specific interventions for the treatment of co-morbid disorders. 
In order to gain a clearer and less abstract picture of the treatment a brief case description will 
be given. A 25-year old man called Max was one of our patients who was diagnosed with 
social phobia. Max’s main fear was that other people would see that his hands were shaky and 
he would be rejected because of this. One of his most feared items was having to serve drinks 
to his guests, especially while being observed by several people. Thus, one of the first 
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exposure interventions consisted of the therapist inviting an audience and preparing drinks to 
be served. The therapist made sure that coffee was served in fine china cups, which had to be 
held by the handle, as mugs would have made it easier to conceal jittering. Also, as Max had 
reported being particularly concerned about being rejected by men of his age, the therapist 
made sure that the audience consisted mainly of men in the range of 20 - 30 years of age. The 
exposure was extensively prepared with Max, noting expectations about the way he felt he 
was going to be perceived and defining criteria for success. Max feared that at least one 
person in the audience would be laughing, or that there would always be an awkward silence 
while he was serving. He defined a successful situation as one in which he did not actually 
spill any coffee and managed to stay until everybody had been served. For Max it was 
particularly important to hear from the audience whether and how much they actually 
perceived him to be trembling and what they had been thinking, when they noticed this. 
During the exposure situation a co-therapist videotaped the exercise and the therapist 
occasionally interrupted the performance to assess the amount of perceived anxiety, rated on a 
scale from 0 (no fear) to 10 (maximum fear). As fear remained high while serving drinks, the 
therapist instructed Max to serve another round of coffee. The situation was terminated when 
Max reported the fear to be at the level of about four. The audience was then asked to give the 
specific feedback defined before the exposure. The feedback was also videotaped because 
Max feared that people would not be honest enough to his face. Finally, the therapist 
discussed the exposure situation and the feedback with Max, using it as a natural segue into 
restructuring interventions in which Max was taught to identify and challenge specific 
negative thoughts and general cognitive errors (e.g. “Because I feel uncertain, I must be 
performing badly and trembling extremely.”) and perfectionist thinking (e.g. “A less-than-
perfect performance is a failed performance.”). The video feedback was used as an objective 
feedback and also helped to detect safety behaviours. For example it could be seen that Max 
sometimes used both hands when offering the cup to someone.  
D.6. Self-Control Phase 
In the days after the intensive treatment phase the patient is encouraged to continue exposing 
himself to the identified situations for several hours each day. During this period further 
contacts with the therapist (e.g. in form of a telephone contact at the end of the day or a short 
treatment session) are scheduled. The patient plans the self-control phase in close cooperation 
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with the therapist. Together, they clearly define which situations are to be practiced, how long 
the patient should remain in the situations and when and how often the patient is to expose 
him- or herself to feared situations. At the end of the self-control phase patient and therapist 
analyse the experiences the patient made and derive a supporting program for the next weeks, 
during which the exposure tasks are integrated more and more into the patient’s every-day life 
and do not require so much additional time.  
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Appendix E. Specific Assessment Measures 
and Formulas  
(the diagnostic interview and all other questionnaires are not added because 
for reasons of copy-right)  
E.1. Application Questionnaire 
E.2. Socio-demographic Questionnaire 
E.3. Medical Report 
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PAT: 
 
 
Eingangsfragebogen 
 
Stand: 1.7.2000 
 
Der folgende Fragebogen enthält eine Reihe von Fragen zu Ihrem Therapiewunsch. Diese 
Informationen helfen uns, das Erstgespräch sowie die nachfolgende diagnostische 
Untersuchung entsprechend Ihrer individuellen Situation zu planen und durchzuführen. 
 
Bitte beantworten Sie jede Frage bzw. kreuzen Sie die jeweils zutreffende der vorgegebenen 
Antwortmöglichkeiten an. Falls Sie möchten, können Sie weitere Bemerkungen am Rand 
hinzufügen. 
 
Sämtliche Angaben werden selbstverständlich streng vertraulich behandelt. Um die 
Lesbarkeit Ihrer Antworten sicherzustellen, schreiben Sie bitte in Druckbuchstaben. Bitte 
senden Sie den Fragebogen vollständig ausgefüllt und unterschrieben an unsere Anschrift 
zurück. Wir danken Ihnen für Ihre Mitarbeit. 
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Ich interessiere mich für eine Behandlung in der Christoph-Dornier-Stiftung für 
Klinische Psychologie und bitte Sie, mich für ein persönliches Erstgespräch 
vorzumerken. 
 
 
 
 
Datum: 
............................................. 
 
 
 
 
 
Unterschrift: 
..................................................................... 
 
 
Institutswunsch 
Die Christoph-Dornier-Stiftung für Klinische Psychologie hat Institute in Berlin, 
Braunschweig, Dresden, Marburg und Münster. Bitte geben Sie nachfolgend Ihren 
Institutswunsch an: 
о Berlin 
 
о Braunschweig 
 
о Dresden  
 
о Marburg  
 
о Münster 
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Teil 1: Angaben zur Person 
 
Bitte tragen Sie die folgenden Informationen ein: 
 
Heutiges Datum: ____________________________________ 
 
Name,Vorname:______________________________________________________________ 
 
Anschrift: ______________________________________________________________ 
 
Telefon privat: _______________________   dienstlich: __________________ 
 
Wann sind Sie am  ______________________________________________________ 
besten telefonisch  
erreichbar?  _________________________________________________________ 
 
Fax privat: _______________________   dienstlich: __________________ 
Planen Sie, in о nein  о ja  
nächster Zeit 
umzuziehen? 
Wenn ja: wann?________________________________ 
neue Anschrift: _____ _________________________________________________________ 
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Geschlecht: о weiblich  о männlich 
 
Geburtsdatum:  __________________________ 
Familienstand: о ledig  о unverheiratet mit Partner/in 
zusammenlebend 
(Mehrfachangaben о verheiratet о feste Partnerbeziehung, aber in getrennten 
 möglich) о zum zweiten Mal oder  Haushalten lebend 
   öfter verheiratet о keine feste Partnerbeziehung, aber sexuelle 
  о getrennt lebend  Kontakte 
  о geschieden о weder feste Partnerschaft noch sexuelle 
  о verwitwet  Kontakte 
 
Haben Sie Kinder? о nein  о ja 
Wenn ja, geben Sie  
bitte Geschlecht ___________________________________________________________ 
und Geburtsdatum 
jedes Kindes an: _________________________________________________________ 
 
 
Ausbildung: о kein Schulabschluss о Fachabitur 
(Mehrfachangaben о Hauptschulabschluss о Abitur 
 möglich) о Realschulabschluss о abgeschlossenes Fachhochschul- oder 
    Hochschulstudium 
  о andere: _______________________________________________ 
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erlernter Beruf:  _______________________________________________________ 
 
derzeitig ausgeübter  _______________________________________________________ 
Beruf:    
 
Arbeitgeber:  _______________________________________________________ 
 
derzeitiger beruflicher о vollzeit о Hausfrau /-mann 
 Status: о teilzeit о in Altersrente / Pension 
 о arbeitslos о erwerbsunfähig (EU-Rente) auf Dauer 
 о in Ausbildung о erwerbsunfähig (EU-Rente) auf Zeit 
о sonstiges:  _____________________________________________ 
 
Sind Sie zur Zeit о nein о ja 
 krankgeschrieben / 
 dienstunfähig? 
 
Krankenkasse/ bitte nachfolgend ankreuzen: bitte ggf. zusätzlich angeben: 
 -versicherung: о AOK Allgemeine Ortskrankenkasse..........Ort: ................................ 
  о BKK Betriebskrankenkasse.......................Betrieb: ........................... 
  о IKK Innungskrankenkasse.........................Innung: ........................... 
  о BEK Barmer Ersatzkasse.................................................................... 
  о  DAK Dt. Angestellten-Krankenkasse................................................ 
  о  andere Ersatzkasse...................................welche: ............................ 
о  KKH Kaufm. Krankenkasse Halle.................................................... 
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  о  TK Techniker Krankenkasse............................................................ 
  о  Private Krankenversicherung.....................bei: ................................ 
о  Beihilfe.......................................................bitte Zusatzv. angeben 
(s.u.*) 
о  Post, Bahn, Polizei, Bundeswehr ..............Behörde: ........................ 
о  Sozialamt....................................................welches: ........................ 
о  LVA Landesversicherungsanstalt...............Bundesland: .................. 
о  BfA Bundesvers.anstalt f. Angest. ................................................... 
о Knappschaft........................................................................................ 
о  Berufsgenossenschaft................................welche: ........................... 
о  sonstige.............................................................................................. 
о  nicht versichert.................................................................................. 
 
Name, Anschrift und Telefonnummer der zuständigen Geschäftsstelle bzw. 
Behörde:____________________________________________________ 
 
 
* Zusatzversicherung: о nein   о  ja 
 
Falls ja: Name, Anschrift  
und Telefonnummer ________________________________________________________ 
der zuständigen  
Geschäftsstelle:  _______________________________________________________ 
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Teil 2: Problembeschreibung und bisherige Behandlungen 
 
2.1 Bitte geben Sie nachfolgend Ihr Problem an,  
 wegen dem Sie eine Behandlung wünschen: 
    
 
 
2.2 Seit wann etwa leiden Sie unter diesem  
 Problem?  
 
2.3 Waren Sie wegen diesem Problem schon in medizinischer oder psychologischer 
 Behandlung? (Gemeint sind sowohl ambulante Behandlungen bei einem Arzt oder 
 Psychologen als auch stationäre Behandlungen in einer Klinik.)    о nein       о  ja 
 
  Falls ja, wo und wann waren Sie in 
  Behandlung? 
 Ambulante Psychotherapien: wo? ________________________________ 
 
wann? ______________________________ 
 
 
wo? ________________________________ 
 
wann? ______________________________ 
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wo? ________________________________ 
 
wann? ______________________________ 
 
Stationäre Psychotherapien:  wo? ________________________________ 
 
wann? ______________________________ 
 
 
wo? ________________________________ 
 
wann? ______________________________ 
 
 
wo? ________________________________ 
 
wann? ______________________________ 
 
 
Ambulante medizinische Behandlungen: wo? ________________________________ 
 
wann? ______________________________ 
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wo? ________________________________ 
 
wann? ______________________________ 
 
 
wo? ________________________________ 
 
wann? ______________________________ 
 
 
wo? _______________________________ 
 
wann? ______________________________ 
 
2.4 Wie stark fühlen Sie sich zur Zeit durch Ihr о  sehr stark 
 Problem belastet? о  stark 
 о  mittelmäßig 
 о wenig 
 о  gar nicht 
 
2.5 In welchen Lebensbereichen fühlen Sie sich о Partnerbeziehung 
 durch Ihr Problem besonders beeinträchtigt? о  Familiensituation 
 (Mehrfachangaben möglich) о  Berufsausbildung/-ausübung 
  о Freizeitbereich 
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  о  Finanzielle Situation 
  о  Allgemeiner Bewegungsspielraum 
  о  Körperliche Gesundheit 
  о  Kontakte zu anderen Menschen 
  о  Sonstiges:_____________________ 
 
2.6 Wie und durch wen sind Sie auf die  
 Christoph-Dornier-Stiftung für Klinische 
 Psychologie aufmerksam geworden? ________________________________________ 
 
 
2.7  Sind Sie über die unter Punkt 2.1 genannten о Depression 
 Probleme hinaus schon einmal wegen einem  о  Ängste 
 oder mehreren der folgenden Probleme    о  Essprobleme 
 behandelt worden? о andere psychische Störungen 
    (welcher Art): 
    ___________________________________ 
  о  prämenstruelle Beschwerden 
  о  hormonale Beschwerden im Zusammenhang 
    mit Geburt 
  о  andere hormonelle Beschwerden 
  о Alkohol- und Drogenprobleme 
  о Verdauungsstörungen 
  о  stressbezogene Beschwerden (z.B. Magen 
    geschwür, Bluthochdruck): welcher Art: 
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     _____________________________________ 
  о  Herzprobleme (welcher Art): 
     ______________________________________ 
  о  nervöse Störungen 
  о  Schilddrüsenfunktionsstörungen 
  о Glaukom (erhöhter Augeninnendruck) 
  о  Asthma 
  о  Migräne 
  о  andere Kopfschmerzen 
  о Epilepsie 
  о  neurologische Probleme 
  о  niedriger Blutdruck 
  о  Kalziummangel 
  о  Leberschaden 
  о  Magen- oder Darmprobleme 
  о  Bauchspeicheldrüsenentzündung 
  о  Untergewicht 
  о  Übergewicht 
  о  Sonstiges:___________________________ 
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Teil 3: Angaben zur Gesundheit 
 
3.1 Wann sind Sie das letzte Mal von einem Arzt 
 gründlich untersucht worden?   ______________________________ 
 
3.2 Haben Sie zur Zeit ernsthafte Probleme mit о  nein о  ja 
 Ihrer Gesundheit? 
 
 Wenn ja: Welcher Art sind diese 
 Gesundheitsprobleme? ______________________________ 
 
 
 Seit wann haben Sie diese Probleme? ______________________________ 
 
 
 Haben die Ärzte Schwierigkeiten, eine kör- о  nein о  ja 
 perliche Ursache für Ihre Probleme 
 festzustellen? 
 
3.4 Nur für Frauen: 
 Sind Sie schwanger?  о  nein о  ja 
 
 wenn nein: 
 Planen Sie, in den nächsten sechs 
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 Monaten schwanger zu werden?  о  nein о  ja 
 
Gibt es sonst noch irgend etwas, das Ihnen wichtig erscheint, bisher aber noch nicht erwähnt 
wurde? 
 
___________________________________________________________________________ 
 
 
 
___________________________________________________________________________ 
 
Wir danken Ihnen für Ihre Mühe beim Ausfüllen des Fragebogens. Bitte überprüfen Sie noch 
einmal, ob Sie auch wirklich alle Fragen beantwortet haben. Senden Sie dann den Fragebogen 
an die 
 
 
 
Christoph-Dornier-Stiftung  
für Klinische Psychologie  
Universitätsstr. 27 
35037 Marburg 
 
Wir werden uns nach der Auswertung des Fragebogens bei Ihnen melden und Sie über das 
weitere Vorgehen informieren. 
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PAT.NR.: Version G 
 
DATUM: 
 
 Soziodemographischer Fragebogen 
 
Bitte beantworten Sie die folgenden Fragen, indem Sie das jeweils auf Sie Zutreffende 
ankreuzen. Einige Fragen erfordern Angaben in Ihren eigenen Worten. 
 
1. Geschlecht: weiblich O 
  männlich O 
 
2. Geburtsdatum: _____________________________________ 
 
3. Familienstand (Mehrfachangaben sind möglich): 
  ledig     O 
  verheiratet     O 
  zum 2. Mal oder öfter verheiratet   O 
  getrennt lebend    O 
  geschieden     O 
  verwitwet     O 
  unverheiratet mit Partner/in zusammenlebend  O 
  feste Partnerbeziehung, aber   O 
  in getrennten Haushalten lebend 
  keine feste Partnerbeziehung, aber   O 
  sexuelle Kontakte 
  weder feste Partnerschaft noch    O 
  sexuelle Kontakte 
 
4. Dauer der jetzigen Partnerschaft in Jahren und/oder Monaten: 
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5. Ausbildungsstatus: 
  kein Schulabschluß   O 
  Hauptschulabschluß   O 
  Realschulabschluß   O 
  Fachabitur     O 
  Abitur    O 
  Abgeschlossenes Fachhochschul-  O 
  oder Hochschulstudium 
 
6. Erlernter Beruf: __________________________________________________________ 
 
 
7. Gegenwärtig ausgeübter Beruf:_____________________________________________ 
 
 
8. Berufsgruppe des erlernten Berufs: 
 
 Wenn Sie nicht ganz sicher sind, in welche Berufsgruppe Sie sich einordnen sollen, 
wählen Sie bitte die Kategorie, die am ehesten auf Sie zutrifft. 
 
 Arbeiter/in     O 
 Facharbeiter/in / Handwerker/in   O 
 Angestellte/r / Beamter/in des einfachen Dienstes  O 
 Angestellte/r / Beamter/in des mittleren Dienstes  O 
 Angestellte/r / Beamter/in des gehobenen Dienstes  O 
 Selbständige/r mit nicht-akademischem Beruf  O 
 (z.B. Landwirt/in ohne akademischen Abschluß,  
 Gastwirt/in, Ladeninhaber/in) 
 Selbständige/r Akademiker/in   O 
 (z.B. Arzt/Ärztin, Notar/in) 
 Firmeninhaber/in (mittelständiges oder   O 
 großes Unternehmen, mehr als 20 Mitarbeiter) 
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 Hausfrau/mann      O 
 Mithilfe im Familienbetrieb    O 
 Auszubildende/r     O 
 Schüler/in / Student/in    O 
 
9.  Berufsgruppe des gegenwärtig ausgeübten Berufs: 
 
 Auch bei dieser Einschätzung beachten Sie bitte: Wenn Sie nicht ganz sicher sind, in 
welche Berufsgruppe Sie sich einordnen sollen, wählen Sie die Kategorie, die am ehesten 
auf Sie zutrifft. 
 
 Arbeiter/in     O 
 Facharbeiter/in / Handwerker/in   O 
 Angestellte/r / Beamter/in des einfachen Dienstes  O 
 Angestellte/r / Beamter/in des mittleren Dienstes  O 
 Angestellte/r / Beamter/in des gehobenen Dienstes  O 
 Selbständige/r mit nicht-akademischem Beruf   O 
 (z.B. Landwirt/in ohne akademischen Abschluß,  
 Gastwirt/in, Ladeninhaber/in) 
 Selbständige/r Akademiker/in   O 
 (z.B. Arzt/Ärztin, Notar/in) 
 Firmeninhaber/in (mittelständiges oder   O 
 großes Unternehmen, mehr als 20 Mitarbeiter) 
 Hausfrau/mann      O 
 Mithilfe im Familienbetrieb    O 
 Auszubildende/r     O 
 Schüler/in / Student/in    O 
 Arbeitslos     O 
 Rentner/in     O 
 
 
 
 
Appendix                                     34 
 
 
 
 
10. Erlernter Beruf des Partners bzw. der Partnerin:____________________________ 
 
 
 
11. Gegenwärtig ausgeübter Beruf des Partners bzw. der Partnerin:_________________ 
 
12. Berufsgruppe des erlernten Berufs des Partners bzw. der Partnerin: 
 Bitte wählen Sie die Kategorie, die am ehesten auf den erlernten Beruf Ihres Partners bzw. 
ihrer Partnerin zutrifft. 
 Arbeiter/in     O 
 Facharbeiter/in / Handwerker/in   O 
 Angestellte/r / Beamter/in des einfachen Dienstes  O 
 Angestellte/r / Beamter/in des mittleren Dienstes  O 
 Angestellte/r / Beamter/in des gehobenen Dienstes  O 
 Selbständige/r mit nicht-akademischem Beruf   O 
 (z.B. Landwirt/in ohne akademischen Abschluß, 
 Gastwirt/in, Ladeninhaber/in) 
 Selbständige/r Akademiker/in   O 
 (z.B. Arzt/Ärztin, Notar/in) 
 Firmeninhaber/in (mittelständiges oder   O 
 großes Unternehmen, mehr als 20 Mitarbeiter) 
 Mithilfe im Familienbetrieb    O 
 Hausfrau/mann     O 
 Auszubildende/r     O 
 Schüler/in / Student/in    O 
 
 
13.  Berufsgruppe des gegenwärtig ausgeübten Berufs des Ehemanns bzw. Partners: 
 Bitte wählen Sie die Kategorie, die am ehesten auf den gegenwärtig ausgeübten Beruf 
Ihres Ehemanns bzw. Partners zutrifft. 
 Arbeiter/in     O 
 Facharbeiter/in / Handwerker/in   O 
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 Angestellte/r / Beamter/in des einfachen Dienstes O 
 Angestellte/r / Beamter/in des mittleren Dienstes O 
 Angestellte/r / Beamter/in des gehobenen Dienstes O 
 Selbständige/r mit nicht-akademischem Beruf  O 
 (z.B. Landwirt/in ohne akademischen Abschluß,  
 Gastwirt/in, Ladeninhaber/in) 
 Selbständige/r Akademiker/in  O 
 (z.B. Arzt/Ärztin, Notar/in) 
 Firmeninhaber/in (mittelständiges oder  O 
 großes Unternehmen, mehr als 20 Mitarbeiter) 
 Mithilfe im Familienbetrieb   O 
 Hausfrau/mann 
 Auszubildende/r    O 
 Schüler / Student    O 
 Arbeitslos    O 
 Rentner    O 
14a. Geschlecht und Geburtsdatum der zur Zeit in Ihrem Haushalt lebenden Kinder: 
  ______________________________________________________ 
  ______________________________________________________ 
 
14b. Geschlecht und Geburtsdatum Ihrer leiblichen Kinder: 
  ______________________________________________________ 
  ______________________________________________________ 
 
15. Leben Ihre Eltern bzw. Schwiegereltern, andere Verwandte oder Bekannte mit im 
Haus? 
  ja O nein O 
 
  Wenn ja, wer? Eltern O 
     Schwiegereltern  O 
     Andere Verwandte  O 
     Bekannte   O 
Appendix                                     36 
 
 
 
 
16. Führen Sie einen gemeinsamen Haushalt mit Ihren Eltern/Schwiegereltern,     
anderen Verwandten oder Bekannten? 
 
  ja   O nein O 
 
  Wenn ja, mit wem? Eltern   O 
     Schwiegereltern  O 
     Andere Verwandte  O 
     Bekannte   O 
 
 
17. Religionszugehörigkeit: 
 
  während der Kindheit: __________________________________ 
 
  derzeit: ______________________________________________ 
 
 
18. Inwiefern fühlen Sie sich derzeit einer Religionsgemeinschaft innerlich verbunden? 
Bitte kreuzen Sie auf der folgenden Skala die für Sie am meisten zutreffende Ziffer 
zwischen 1 und 8 an. 
 
.................1 ........... 2............3 ........... 4............. 5............ 6............7 ........... 8 
 gar nicht       sehr 
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Konsiliarbericht 
vor Aufnahme einer Psychotherapie durch  
Psychologische Psychotherapeuten und  
Kinder- und Jugendlichenpsychotherapeuten für  
 
______________________________________________________ 
 Name und Geburtsdatum des Patienten/der Patientin 
 
Auf Veranlassung der:     Bezugstherapeut: 
Christoph-Dornier-Stiftung     Dipl. 
Psych._____________________ 
für Klinische Psychologie 
Universitätsstr. 27, 35037 Marburg 
Tel. 06421/17696-0, FAX 06421/17696-25 
 
Es sollen ggf. Angaben zu folgenden Inhalten gemacht werden: 
Bestehen aus ärztlicher Sicht Hinweise auf Kontraindikationen zur geplanten Verhaltenstherapie der 
_________________________________________________________________________________? 
Werden Parallelbehandlungen durchgeführt (z.B. laufende Medikation) und kann 
diese für die Zeit der Therapie ausgesetzt werden? 
 
Psychiatrische bzw. kinder- und 
jugendpsychiatrische Abklärung ist   erforderlich  nicht erforderlich 
       erfolgt   ist veranlasst 
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Sind ärztliche/ärztlich veranlasste Maßnahmen bzw. Untersuchungen notwendig bzw. 
veranlasst und ggf.  welche?____________________________________________ 
_____________________________________________________________________
_____________________________________________________________________ 
 Aufgrund somatischer/psychiatrischer Befunde bestehen derzeit Kontraindikationen 
 Aufgrund somatischer/psychiatrischer Befunde bestehen derzeit keine 
Kontraindikationen 
 Ärztliche Mitbehandlung ist erforderlich 
 Art der Maßnahme:_________________________________________________ 
_____________________________________________________________________ 
 
 
 
 
 
 
___________________ 
Ausstellungsdatum 
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